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ABSTRACT  
 
That ‘Children are not small adults’ is a commonly quoted adage: nowhere is 
this more true than in pharmaceutics. When trying to make an “age-
appropriate” oral dosage form, a number of patient needs must be met 
including swallowability, dose-adaptability and acceptability. Acceptability 
may be enhanced by better tasting, non-gritty medicines: with this in mind 
this research sought to develop a suspension platform for functionalised 
multiparticulates, namely for taste-masking. 
 
The rheology of the suspending media and its effect on the suspendability of 
large (>100 µm) placebo particles was investigated before the influence of 
particle concentration, size and media viscosity of these suspensions on 
grittiness and acceptability was assessed in two sensory trials containing 
young adults. It was found that higher concentrations of 
hydoxypropylmethycellulose were not well tolerated due to their inherent 
taste and that their acceptability was improved through the addition of 
flavouring/sweetening agents. Statistical analysis of the results on the refined 
media and sensory trial showed that particle size and media viscosity had an 
effect on grittiness, unlike particle concentration. 
 
Microparticles of Eudragit® E (a reverse-enteric polymer marketed for taste-
masking) containing quinine hydrochloride as a bitter drug were prepared by 
spray-drying without using organic solvents. Initial experiments resulted in 
many blockages of the spray dryer which were eventually rectified by 
increased homogenization and a fractional factorial experimental design 
employed to screen the influence of different levels of excipients. However, 
even the optimised process suffered from problems with a low feed solids 
concentration, low spray rate and low yield. Most particles had an aggregated 
morphology and the formulations which showed the lowest release in salivary 
pH were the most aggregated with particle sizes >1 mm. These large 
particles were not easy to uniformly suspend and would have required a 
large mass to be administered due to low drug loading which made them 
unsuitable for use as a uniform platform.  
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1. INTRODUCTION 
1.1. Overview of Multiparticulate Dosage Forms 
 
Multiparticulates or multiparticulate dosage forms can be defined as when 
“the dosage of the drug is divided among several discrete delivery entities, in 
contrast to a classical single-unit dosage form” (Colorcon, n.d.). The typical 
size range of multiparticulates can be seen in Figure 1-1. 
 
 
 
 
 
 
 
Figure 1-1: Size Range of Multiparticulates (Images from left to right from 
Thomasson, 2006, Chem List, PharmaTrans Sanaq AG Pharmaceuticals, Thomson 
et al., 2009b) 
 
Multi-particulates cover a range of different forms and are produced by a 
number of different methods as discussed in Section 1.4. Different 
multiparticulates are used to provide a number of different functionalities 
including: 
 
 Modified Release (Roberts et al., 2012, Shavi et al., 2011) 
 pH dependent Release (Alhnan et al., 2010, Nilkumhang et al., 2009, 
Raffin et al., 2006) 
 Bioavailability Enhancement   (Jha et al., 2011, Li et al., 2010) 
 Taste Masking  (Hu et al., 2009, Shah and Mashru, 2008a, Vaassen et 
al., 2012) 
Nanometer Micrometer Millimeter 
> 2mm 
Minitablets 
 
0.2-2mm 
Pellets, 
Granules 
2-20µm 
Microspheres 
Microencapsulates 
 
10-100nm 
Nanoparticles 
Nanoencapsulates 
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Multiparticulates are often used  in adults due to the ability to blend different 
multiparticulates of different release rates (e.g. immediate release and 
modified release) to provide tailored release profiles with multiparticulates 
transiting more reproducibly through the GI tract than tablet formulations and 
often associated with less local gastrointestinal irritation (Davis et al., 1986, 
Newton, 2010, Varum et al., 2010, Zeeshan and Bukhari, 2010).   
 
In the context of this project, multiparticulates were thought to be of interest 
for use in children to overcome some of the issues discussed throughout this 
chapter.  
 
 
1.2. Medicines for children: what are the requirements and hurdles? 
 
The term “children” covers a large and heterogeneous population who can be 
loosely grouped based on their biological development stages as shown in 
Table 1-1.  This demonstrates that the term “children” can include the very 
preterm infant weighing less than a kilogram, all the way through to morbidly 
obese teenagers. As well as differences in body weight, volume and surface 
area, this disparate group also covers a wide range of physiological 
development and in particular enzymatic and liver functions  
 
Table 1-1: International Conference on Harmonisation (ICH) Definitions of Different 
Periods of Childhood (European Medicines Agency, 2001) 
Definitions  Age Range  Biological Stage 
Preterm newborn 
infants  
< 37 weeks’ gestation  Normal gestation 
Term newborn infants  0 – 27 days  Postnatal Changes 
Infants and toddlers  28 days to 23 months  Rapid Development Spurt 
Children  2 – 11 years  Slower Growth period 
Adolescents  12 – 16 or 18 years  Hormonal Changes 
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Historically, children have been given medicines many of which have not 
been tested on them due to the ethical considerations of testing medicines in 
this age group along with the cost and practicalities associated with 
additional research in paediatrics. This meant that medicines legally used in 
paediatrics were often either completely unlicensed for this age group or not 
licensed for the particular condition being treated (e.g. used “off-label”) 
(Conroy, 2011). The proportions of children receiving unlicensed or off-label 
medication differ depending on where the child is being treated and age of 
the child, with the youngest and sickest patients, such as those on a neonatal 
intensive care department, often receiving the most (Whittaker et al., 2009b). 
As a result of receiving medicines not tested on them, the consequences 
shown in Figure 1-2 may occur. Children may suffer from adverse events and 
medication errors may be increased due to the lack of age appropriate 
dosage forms requiring manipulations of adult dosage forms. Manipulations 
such as crushing tablets and opening capsules before dispersing the 
contents and administering a proportion have been shown to be less than 
reproducible at giving the required dose (Best et al., 2011, Nissen et al., 
2009, Richey et al., 2012).  Manipulated dosage forms are often poorly 
accepted resulting in a reduction in concordance (Milani et al., 2010). 
 
Figure 1-2: Graphical representation of potential negative outcomes caused by 1. 
Side effects despite correct dosing and 2. Medication error/non compliance with the 
arrow highlighting that these outcomes can be interlinked (Florence and Lee, 2011) 
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Since 2007, the advent of the Paediatric Regulation (Regulation (EC) No 
1901/ 2006) has meant that companies must consider the need for data from 
paediatric studies to support a marketing authorization for a new chemical 
entity. If required, these paediatric studies must be undertaken in accordance 
with a paediatric investigation plan (PIP) which must be approved by the 
European Medicines Agency (EMA) Paediatric Committee. The PIP shall 
specify the timing and the measures proposed to access the quality, safety 
and efficacy of the medicinal product in all subsets of the paediatric 
population concerned. As part of the PIP, an age appropriate formulation 
must be developed meaning that companies now have a legal requirement to 
develop these which has further increased discussion and research into this 
area. If there is no therapeutic need for the drug in children, this requirement 
for data will be waived: The requirement can be deferred if, for example, 
research is required in adults first to ensure the trials done on children are 
both safe and ethical. Companies can also benefit from use of the Paediatric 
Use Marketing Authorisation (PUMA) to undertake research on off-patent 
medicines with the reward of a ten year period of market exclusivity. 
 
Around 26% of the world’s population are under 15 years old, with higher 
proportions of young people found in developing countries (Population 
Reference Bureau, 2012). Despite this large patient group their particular 
formulation requirements are often not recognized nor catered for, many 
children still lack age-appropriate formulations to meet their specific needs 
which are discussed throughout Section 1.3.  
 
The production of any dosage form is always a balance between what the 
pharmaceutical industry require and what the patient needs from a medicine,  
Figure 1-3 summarises the general requirements which need to be met for 
any medicine to satisfy all parties and that these requirements are interlinked. 
It is worth remembering that in paediatrics this will generally involve a third 
party as a caregiver as well. It can be seen from this figure that there is the 
potential for all of these requirements to be addressed through the use of 
multiparticulate dosage forms as will be highlighted throughout this thesis. 
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Figure 1-3: General Requirements for Medicines showing the Key Requirements for 
each Stakeholder with the areas of colour crossover highlighting the importance of 
considering all three stakeholders  adapted from  European Medicines Agency, 
2005 and Krause & Breitkreutz 2008 
 
 
1.3. Challenges associated with Paediatric Formulations 
 
1.3.1. Adherence 
Medicine compliance is a problem in paediatric therapy with compliance rates 
ranging anywhere from 11-93% depending on many factors including 
frequency of therapy and taste (Matsui, 2007). When 88 US paediatricians 
were asked about barriers to treatment completion: frequency of dosing 
96%/91% and unpleasant taste 91%/84% were reported as the top two 
barriers in children with acute/chronic illnesses respectively (American 
Academy of Pediatrics, 2000). These reasons for the lack of compliance are 
important since they may be overcome through the use of age appropriate 
taste-masked or modified release formulations such as functionalised 
multiparticulates.  
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1.3.1.1 Swallowability and Saliva pH 
 
In general, children can swallow semi-solid foods from around six months so 
may be able to include multiparticulates in their favourite food, yet they 
cannot swallow conventional tablets until much older (Delaney and Arvedson, 
2008, Rogers and Arvedson, 2005, European Medicines Agency, 2011). 
There is no clear evidence based answer as to at which age children can 
swallow monolithic dosage forms but is it is often considered to be around six 
years (Meltzer et al., 2006, Yeung and Wong, 2005). Paediatric patients with 
chronic conditions may be trained in order to swallow tablets by using 
sweets, a flavoured lubricant spray or head positioning techniques (Diamond 
and Lavallee, 2010). 
 
Children aged between six months and two years of age can swallow 
minitablets (2 and 3 mm) which are a form of multi-particulate but only single 
minitablet administration has been tested (Thomson et al., 2009a, Spomer et 
al., 2012). Dysphagia (the inability to swallow) additionally affects many old 
people, who report difficulty in swallowing solid dose medication at some time 
so the geriatric population would benefit from multiparticulates as would 
many patients who require tube feeding (Stegemann et al., 2012, Stegemann 
et al., 2010). Predominantly, medicines are designed for oral administration 
and this will be the only route focused on in this thesis. 
 
Chewable tablets exist which are most commonly available for children in the 
form of chewable vitamins bought over-the-counter by parents which may be 
“candy-like” with fears of potential overdoses (Lam et al., 2006). Chewable 
dosage forms have not been extensively used for prescription medicines and 
as many of them are both a chewable and dispersible form, the age range of 
which chewable tablets are accepted from is unclear (Strickley et al., 2008). 
There have been safety concerns over using chewable tablets in younger 
patients however, these tablets have not been seen be a major contributor to 
aspiration injuries (Michele et al., 2002) . Due to the mechanical nature of 
chewing increasing the surface area of the tablet, it would be difficult to 
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control drug release from the tablets in terms of modified release or taste 
masking. 
 
The pH of the saliva is an important part of dosage form design, especially in 
the development of taste masked formulations. If a drug is coated with a 
polymer to prevent the bitter taste of the drug being detected by the taste 
buds, the polymer must not be soluble at the pH values found within the 
mouth – otherwise the drug will be released and the taste masking capacity 
of the polymer will be lost.  Unstimulated salivary pH values have been seen 
to range between 7-7.5 in children aged between 3 and 13.years which is 
similar to that of adults (Sanchez and Fernandez De Preliasco, 2003, Wu et 
al., 2008). Unstimulated pH values were seen to be slightly lower in infants 
aged from 3 days to 12 months ranging from 6 – 6.74 (Ben-Aryeh et al., 
1984).  When the saliva is stimulated, for example by drinking soft drinks, the 
pH values of saliva from healthy children/adults was not seen to drop below 
pH which is likely to be due to the buffering capacity of saliva (Sanchez and 
Fernandez De Preliasco, 2003, O'Sullivan and Curzon, 2000, Meurman et 
al., 1987). 
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1.3.1.2. Tolerance of Poor Taste/Acceptability 
 
Taste can be defined as “the sensation of flavour perceived in the mouth and 
throat on contact with a substance” (Oxford Dictionary, 2012). It can be seen 
from Figure 1-4 that the tongue contains three types of gustatory papillae 
(circumvallate, foliate and fungiform) which are largely on the upper surface 
of the tongue (Jacob, n.d.). On these papillae are taste buds which contain 
taste receptor cells (shown by sensory cells in Figure 1-4), supporting cells, 
basal cells which are developing into taste cells and the gustatory afferent 
axon (nerve). The taste receptors have projections into the lumen of the taste 
buds which detect dissolved compounds. Taste signals are relayed from the 
receptor cell synapse at the base of the sensory cell to the brain via the 
cranial nerves IX and VII (in addition to X with signals from the extraoral 
receptors) to the nucleus tract solitarius in the medulla oblongata. From here, 
the signal is further relayed to the somatosensory cortex which is responsible 
for taste perception and the hypothalamus, amygdale and insula which 
cause, for example, aversions. 
 
 
Figure 1-4: Representation of the Types and Location of Papillae on the Tongue 
with the Location and Structure of Taste Buds (Jacob, n.d.) 
 
Different types of molecule illicit different taste responses and there are five 
primary taste sensations of sweet, sour, salty, bitter and unami (known as a 
savoury taste or the taste of certain amino acids) although overall taste is 
likely to be a blend of these. Signal transduction of taste stimuli is still not 
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fully understood but sweet, bitter and unami tastes are thought to be 
mediated largely via g-protein coupled receptors whereas salt is via sodium 
channel and sour by acid sensing channels, all causing depolarisation. 
Different types of g-protein coupled receptor exist where sweet substances 
binding to receptors known as T1R2 and T1R3 receptors, bitter substances 
bind to T2Rs and unami substances to T1R1 and T1R3 receptors. Bitter 
receptors known as T2Rs have more subtypes than other taste sensations 
which may be due to the large variety of different chemical structures that are 
detected as bitter.  
 
There are around 25 members of the bitter receptor family known as TAS2R 
with one subtype, TAS2R38, having two different genetic forms where those 
with an inactive form are insensitive to the bitter taste of propylthiouracil. 
When children (range 3.1-10.9 years, n=448) were assessed for these forms, 
it was found that those who were sensitive to the taste were more likely to 
have tried solid dosage forms (52% vs. 36%) which are less in contact with 
the taste buds than liquid forms and those who were bitter sensitive preferred 
higher concentrations of sucrose (Lipchock et al., 2012).  Similarly in young 
patients with HIV (median 2.9 years, Interquartile range: 2.5-3.26), where 
many of the medicines are known to be bitter, taste issues and vomiting were 
reported more often with syrup than tablets. By 8 weeks of therapy, tablets 
were preferred by the majority of patients and caregivers, despite the low age 
of patients (Nahirya-Ntege et al., 2012). 
 
While often reported taste thresholds are shown in Table 1-2, taste 
perception differs depending on the individual’s genetics and where they live 
- therefore not everyone is equally sensitive to tastes and these thresholds 
have not been validated in all the paediatric spectrum (Mennella et al., 2005). 
When 8-9 year boys and girls were compared to adult male and females, it 
was seen that the boys had a poorer ability to detect sucrose, sodium 
chloride, and citric acid than adults (e.g. higher concentrations were required 
before the chemicals were detected) along with a poorer ability than female 
adults to detect caffeine.  However the responses of 8-9 year old girls to the 
chemicals were similar to those of adults suggesting that their gustatory 
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response was fully mature (James et al., 1997). In contrast, when 8-9 year 
old children were compared with adults looking at the sweetness of sucrose, 
similar responses were seen between adults and children for simple stimuli 
such as sucrose alone but not for complex stimuli like orange juice 
suggesting that taste perception was still developing (James et al., 2003). 
 
Table 1-2: Thresholds for Common Tastes (Cardello, 1998) 
 Substance Threshold for Detection (M) 
Salt Sodium Chloride 0.01 
Sweet Sucrose 0.01 
Sour Hydrochloric acid 0.0009 
Bitter Quinine 0.000008 
Unami Glutamate 0.0007 
 
The taste system of an infant develops throughout pregnancy and postnatally 
with taste cells first appearing in the foetus at 8-9 weeks of gestation and 
appearing mature by 13-15 weeks of gestation while the tongue continues to 
grow until it reaches adult dimensions at 15-16 years. Within a few hours of 
birth, infants prefer sweet/unami tastes and reject bitter substances – this 
trend of taste preference continues until adolescence (Mennella and 
Beauchamp, 2008). Children were seen to have higher optimal preferred 
sucrose concentrations than both adolescents and adults (De Graaf and 
Zandstra, 1999).  
 
Many medicines by virtue of being external noxious substances to our body 
taste bitter in a physiological attempt to prevent administration which may be 
harmful and evoke a gustatory response e.g. vomiting (Shi et al., 2003). This 
is obviously problematic for children when they prefer sweet tastes and have 
a poor tolerance for bitterness. 
 
Most medicines for adults are available as solid oral dosage forms such as 
capsules and coated tablets. They have fewer issues with any bitter tasting 
drugs as the dosage form stays intact within the mouth and hence the drug 
does not become in contact in solution with the taste receptor and therefore 
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no adverse taste is recognised. Even if taste is recognised as an issue in a 
dosage form, the medicine can be encapsulated or coated and adults are 
able to logically determine that they need to take their medicine for the 
desired therapeutic outcome, even if they do not like the taste of it and 
anecdotally may even believe that a worse tasting medicine is stronger! 
 
There are two main formulation methods of overcoming the problem of 
objectionable taste: either to obscure it by the addition of various additives or 
to prevent/reduce the concentration of  the drug coming into contact with the 
taste buds (Ayenew et al., 2009). Even where approach of 
preventing/reducing the contact of the drug with the taste buds is used, it 
formulation will still probably need a degree of flavouring/sweetening to aid 
acceptability. 
 
Historically, medicines were made to taste better “with a spoonful of sugar to 
make the medicine go down”. The problem of administration of unpleasant 
tasting medicines has been around for centuries with advice from the 1800s 
recommending the use of sweeteners such as sugar or jam to make 
medicines palatable (Churchill, 1883). This attempt to obscure the taste of 
the medicine was used with commonly used suspensions such as Calpol® 
(containing the bitter drug paracetamol) containing sugar, sweeteners and 
flavouring agents. In the United Kingdom, this was known to be very much 
liked in children and anecdotally evokes fond memories amongst adults when 
remembered. Over the years, this product has been reformulated into a 
sugar-free and subsequently a sugar-/colour-free suspension as there 
becomes increased awareness of the lack of inertness of excipients yet there 
is a lack of evidence showing improved safety from the removal of these 
excipients (Fabiano et al., 2011).  
 
There are a variety of “additives” to be used in taste masking such as 
sweetening agents, flavouring agents, salts and viscosity enhancers which 
have been employed with varying degrees of success 
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The sweeteners used can either be ‘natural’ chemicals such sucrose, which 
has fallen out of favour due to its impact on dental caries, or artificial 
sweeteners, which despite having enhanced sweetness intensity can have a 
metallic/bitter aftertaste and increased toxicity concerns (Feigal et al., 1981). 
High concentrations of sweeteners may be required to try to taste mask 
which may be associated with adverse effects and many sweetening agents 
are short acting so do not cover the after taste associated with a medicine. 
As an example, epinephrine was unable to be taste masked through the 
addition of aspartame or acesulfame potassium but the acidic nature of 
added citric acid imparted an acceptable “lemon like” flavor (Rachid et al., 
2010). 
 
Flavouring agents such as fruit flavours can suffer from poor stability due to 
the volatile components of the essential oils used in them and can show 
limited acceptability dependent upon cultural and individual tastes (e.g. 
cherry and bubble gum flavour are common in the United States whereas 
less common in the United Kingdom). A flavouring agent cannot cover the 
taste of all drugs and must be determined on a case-by-case basis which 
may require time consuming sensory trials though these may now be 
supported through the use of an electronic tongue. An undisclosed drug had 
its taste improved by the addition of a cherry or lemon flavour whereas grape 
and vanilla flavours were found to make the taste worse (Campbell et al., 
2012)! The addition of sodium chloride and glutamate were seen to improve 
the taste of a range of drugs including pseudoephedrine and quinine but the 
effect of the salt on the overall dosage form must also be considered 
(Campbell et al., 2012, Rachid et al., 2010). 
 
The taste of a drug can be masked through the addition of a chemical that 
interacts with the taste buds so that it is not able to combine and be tasted: 
an example of this is of enterodiol (25 mg/L) which interacted with the protein 
model of the bitterness receptor hTas2R10 to reduced the caffeine (500 
mg/L) bitterness intensity by 30% in an adult sensory trial (n=22) but so far 
has been of limited pharmaceutical use (Ley et al., 2012, Ley, 2008).  
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Not having the drug in an aqueous solution is a way to reduce the bitter taste 
of a drug, this can be achieved by preparing the drug e.g. in a lipid vehicle 
such as medium chain triglycerides or by preparing the drug in a suspension 
(which may be beneficial if the drug already has low solubility) (Bahal et al., 
2003). However, even in a non-solution dosage form, the concentration of 
drug in solution, even if low, might reach the taste threshold (Lorenz et al., 
2009). Drug modification to reduce solubility such as adding a prodrug moiety 
works by a similar effect but would be labour intensive and may modify the 
release/therapeutic nature of the compound (Hejaz et al., 2012).  
 
An additional way to reduce the bitter taste is by either molecular or inclusion 
complexation of the drug so that it is unable to interact with the taste buds. 
This approach is very drug specific since it is dependent upon the interaction 
between the drug and the complexing agent so would need to be individually 
assessed. Common agents used in this type of complexation include 
modified cyclodextrins and a cationic polymer, Eudragit® E as described later 
in Section 1.4 and Chapter 4 (Orlu-Gul et al., 2012, Szejtli and Szente, 2005, 
Randale et al., 2010, Khan et al., 2007). Ion Exchange Resins work on this 
principle and are discussed in Section 1.5. 
 
A final approach to reducing the problem of bitter taste is to apply a barrier 
between the drug and the taste bud. In adults this would be achieved by 
coating a tablet, coating the dosage form is still an option but difficult with 
smaller dosage forms that may be desired for children for ease of 
swallowability. Encapsulation of the drug within a barrier/polymer is a way to 
produce particles which are taste masked as has been achieved by extrusion 
of lipid components or through microencapsulation (Krause et al., 2009).  
 
The most commonly used forms of microencapsulation (particle size <100 
µm) used for taste masking are: 
 
 Emulsification/solvent evaporation (Gao et al., 2006, Hashimoto et al., 
2002, Chiappetta et al., 2009) 
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 Spray drying (Xu et al., 2008a, Sollohub et al., 2011, Bora et al., 2008) 
 Co-acervation (Shah et al., 2008, Yoshida et al., 2009) 
 
Commonly used polymers include the poly (meth) acrylates and cellulosic 
derivatives as discussed in Section 1.4. and Chapter 4.  
 
The approach of encapsulating a drug to prevent release is desirable 
because it can be used as a drug independent platform for taste masking 
rather than other types which depend on individual research. This 
encapsulation depends upon the drug not releasing an appreciable drug 
concentration at the near neutral pH in the mouth or for the time it is being 
administered as is discussed in Section 1.5. Moreover, the particles 
produced must not be gritty otherwise this can adversely affect acceptability 
of the dosage form as discussed in Chapter 3. 
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1.3.1.3. Need for Medicines at School 
 
The vast majority of oral medicines on the market are available as 
immediate-release capsules and tablets (British Medical Association and the 
Royal Pharmaceutical Society of Great Britain, 2008a).  Although these 
monolithic, solid dosage forms are successfully used in the pharmacological 
management of a variety of conditions, drug delivery systems which are able 
to offer modified drug release may offer a number of benefits over immediate 
release preparations. One of the most notable is increased patient 
compliance due to a decreased dosing frequency down to once daily dosing 
in an ideal situation as illustrated in Figure 1-5. Once daily dosing would be 
especially desirable for groups such as school children who are often unable 
to receive medicines whilst at school, or elderly patients who may have 
difficulty in remembering to take medicines more frequently or at different 
times of the day (Wong et al., 2004). Modified release preparations can also 
offer reduced adverse drug effects associated with high plasma 
concentrations and maintaining stable concentrations is of benefit in many 
chronic conditions or where constant drug levels are required (National 
Prescribing Centre, 2000). 
 .  
Figure 1-5: Schematic Representation comparing Conventional and Modified 
Release Drug Profiles 
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It can therefore be seen that taste masking by preventing the release of the 
drug in the mouth may be classed as delayed or modified drug release but 
may also be classed as immediate release if 80% of the drug is released 
within 45 minutes in the gastric contents. This will depend on the intent of the 
formulator and the target product profile desired. 
 
The terms delayed or modified release includes the pH dependent release of 
drugs, either to: 
 
 Target the dosage form to a specific area of the gastro-intestinal tract 
(GIT) for example budesonide to the colon in ulcerative colitis 
(Varshosaz et al., 2011) 
 Prevent release in certain areas e.g. enteric coating of non-steroidal 
anti-inflammatory drugs (NSAIDs) such as diclofenac to protect the 
gastric mucosa (Rattes and Oliveira, 2007) 
 Protect the drug from releasing in the stomach if it is acid-labile (e.g. 
omeprazole) (Ponrouch et al., 2010) 
  
There are a number of solid oral dosage forms that provide controlled drug 
release on the market (95 individual drugs contained within 218 formulations 
in the British National Formulary 2008 when the terms sustained, delayed, 
repeat prolonged, controlled, modified and enteric were searched) (British 
Medical Association and the Royal Pharmaceutical Society of Great Britain, 
2008a). Modified release dosage forms contain a larger dose of drug to allow 
for less frequent dosing and additional excipients to control release when 
compared to immediate release tablets. Due to this increased drug and 
excipient load in modified release tablets, they are often of a larger size than 
those tablets designed for immediate drug release. These large, modified 
release formulations may be difficult to swallow, especially for paediatric and 
geriatric patients but also other patients with dysphagia. Tablets have an 
additional drawback for these patient groups in that, they are unable to 
provide the range of doses required in heterogeneous population. Dosing 
needs based on age, weight, surface area or adapted to hepatic or renal 
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function cannot be met as it is recommended that controlled release 
formulations are not split or crushed. Using a small in sized dosage form 
such as a functionalised multiparticulate would allow the benefits of modified 
release dosage forms to be experienced by those patients who struggle to or 
are unable to swallow larger dosage forms such as tablets and capsules. 
 
 
1.3.1.4. Industrial Need for a Universal Platform Approach 
 
As the Paediatric Rule discussed in Section 1.2. only came into existence 
within the past ten years, companies still have limited experience of 
formulating for children. This combined with the consequence of the 
increasing cost of drug development makes it of benefit for industry to use 
formulations known as “platform formulations” which are base formulations 
without drug into which a variety of drugs can be added without needing to 
develop a formulation from scratch for each individual drug. There is clinical, 
scientific and commercial value of a platform formulation including quicker 
access of the paediatric patients to an effective treatment, better scientific 
understanding of formulation to tailor release to requirements and reduced 
formulation cost allowing better patient access with the potential for industry 
collaboration. 
 
This need for a universal platform includes the requirement that dosage 
forms researched can potentially be scaled up and made available for clinical 
practice. In terms of manufacturing multiparticulates, the pharmaceutical 
industry already use and have products on the market produced by large 
scale granulation, pelletization and spray drying whereas other laboratory 
scale techniques such as emulsification/solvent evaporation would be more 
difficult to try to scale up.  
 
In terms of considering cost and developability from the industrial 
prospective, organic solvents should be avoided as discussed in Chapter 4 
and the minimum required levels/numbers of excipients used which comes in 
line with excipients not being inert from the patient perspective.   
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1.3.2. Possible Approaches to Meet Paediatric Medicine Requirements 
 
1.3.2.1 Liquids 
 
Liquid dosage forms are still considered the “gold standard” by many for 
children largely due to the ease with which they can be swallowed and the 
ability to give a range of different doses as the child matures and dose 
weight/volume increases. However despite these key advantages, liquids 
have a number of disadvantages. 
 
Liquids can be difficult to administer in the range of different implements used 
shown in Figure 1-6: it can be seen from these that the potential for spilling 
the medicine if trying to administer to a reluctant child is high and volume 
errors, which may be as high as a factor of 10 may occur due to high drug 
concentrations (Yin et al., 2010, McMahon et al., 1997, Madlon-Kay and 
Mosch, 2000). 
 
 
Figure 1-6: A Selection of Administration Devices for Liquid Medications 
 
It is difficult to achieve functionalised capacity in a liquid in terms of taste 
masking or controlled release. Few controlled release liquid forms exist that 
are based on ion exchange resins or multiparticulates as described in 
Section 1.6. In situ gelling systems seem an interesting approach to 
controlled release liquids but due to the intricacies of gelation, must be 
formulated on a drug-by-drug basis (Itoh et al., 2011, Itoh et al., 2010). 
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Often the need for excipients in liquid is higher in quantity than those in solid 
dosage forms (e.g. in mg/ml compared with a few mg in a tablet) and in a 
larger variety to address the additional taste & stability challenges as 
discussed in Section 1.3.2.1. and Chapter 2 respectively. 
 
Many of the excipients currently in use in products designed for paediatric 
use are deemed to be acceptable due to their long standing use in children. 
However some excipients are known to cause problems in specific subsets of 
the paediatric population such as preservatives, co-solvents, and 
sweeteners. Some examples of problematic excipients are shown in Table 
1-3 (Breitkreutz and Boos, 2007b, Whittaker et al., 2009a).  
 
Adverse events are even more common in younger children due to the 
immaturity of their renal and hepatic clearance as well as physiological 
differences such as altered body composition and a higher likelihood of 
allergies due to their developing immune system.(Whittaker et al., 2009a, 
Alcorn and McNamara, 2003) 
 
Table 1-3: Examples of Excipients and their Adverse Effects in Children from Ernest 
et al., 2007 
Excipient Use Adverse Effect 
Aspartame Sweetener Potential issues in 
phenylketonurics 
Polyols Bulking agent/ vehicle GI disturbances 
Benzyl alcohol  Antimicrobial 
preservative  
Gasping syndrome which 
can cause fatalities  
Carrageenan  Suspending agent  Induces inflammatory 
responses in animals  
Diethylene glycol  Co-solvent/Vehicle  Poisoning  
Docusate sodium  Wetting agent  Diarrhoea  
Ethanol  Co-solvent  Neurotoxicity  
Propylene glycol  Co-Solvent/Anti-
microbial Preservative  
CNS adverse events  
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Due to the limited evidence base surrounding the use of many excipients in 
children, a risk vs. benefit analysis must underlie the decision to give any 
excipient to a child (Salunke et al., 2012). The excipient used, in order to 
minimise risk, should be technically necessary, those that we know the most 
about (which may be in relation to patient metabolic activity) and in the lowest 
dose/exposure possible as “the only difference between a cure and a poison 
is the dose” Paracelsus (1493-1541). Nevertheless the advantages of a liquid 
dosage form means that many formulations for paediatrics are liquids 
containing a myriad of technically necessary excipients. 
 
 
1.3.2.2. Solid Oral Dosage Forms 
 
It terms of multiparticulates it can be seen from Table 1-4 that powders or 
multiparticulates are accepted by most age groups except preterm newborn 
infants for whom the oral route is not usually used. While this table from the 
EMA is used to define acceptability of various dosage forms in different aged 
children, it is important to recognize that the table was developed after asking 
only around 40 patients, health care professionals and parents and these 
mainly German, which dosage forms they thought each age range would be 
able to accept. This highlights the importance of the need for more research 
into the acceptability of dosage forms in children as discussed further in 
Chapter 3. 
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Table 1-4: Acceptability of Dosage Forms for Different Ages of Children (European 
Medicines Agency, 2005) 
Oral Dosage 
Form 
Preterm 
newborn 
infants  
Term 
newborn 
infants 
(0d-28d)  
Infants 
and 
Toddlers 
(1m-2y)  
Children 
(pre 
school) 
(2-5y)  
Children 
(school 
age) 
(6-11y)  
Adolescent  
(12-
16/18y)  
Solution/ Drops 
  
2  4  5  5  4  4  
Emulsion/ 
Suspension  
2  3  4  5  4  4  
Effervescent 
Dosage Forms  
2  4  5  5  4  4  
Powders/Multi-
particulates  
1  2  2  4  4  5  
Tablets  1  1  1  3  4  5  
Capsules  1  1  1  2  4  5  
Orodispersable 
Dosage Forms  
1  2  3  4  5  5  
Chewable 
tablets  
1  1  1  3  5  5  
Key: 1 = not accepted, 2 = accepted under reserve/reluctantly, 3 = acceptable,  
4 = preferred acceptability, 5 = dosage form of choice  
 
In addition, an expert panel found that there was a “general acceptance of 
the benefits of flexible solid dosage forms over liquid dosage forms for 
stability, dosing and administration issues” with less excipients in quantity 
(dependent upon dose volume), especially when used in developing 
countries - these forms include multiparticulates with benefits such as: (World 
Health Organisation, 2008) 
 
 Ease of Swallowing 
 Stability 
 Dose Flexibility  
 Dose Uniformity 
 Ease of Administration 
 Range of Types Available  
 Taste masking 
 Modified Release 
 Excipients 
 Price 
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These flexible oral dosage forms are recommended as most suitable for 
developing countries due to the difficulty and high cost of transporting liquids, 
difficulty in obtaining clean water and for those medicines where precise dose 
measurement or titration are required to allow production of 'tailored’ doses 
and strengths. Flexible oral dosage forms allow for the preparation of a range 
of dosage form e.g. by using one multiparticulate formulation in a variety of 
ways such as granules to be compressed into tablets for adults and 
administered as a sprinkle on food for children. Multiparticulates offer 
benefits over liquids for substances that are not stable or cannot be taste 
masked in liquid preparations or to provide controlled release although the 
high surface area to volume ratio may mean make it difficult to control 
release using multiparticulates (European Medicines Agency, 2005). 
 
There are some potential disadvantages to using multiparticulates with one 
being the risk of choking/aspiration of dosage forms however no literature 
was found on this and multiparticulates are often used in food on children 
who are already weaned. It is not known what size of multiparticulate would 
be assessed as gritty and there may also have to be considerations as to 
what dose can be administered in this way as investigated in Chapter 3. 
Lastly the method of administration needs to be decided – often this is as a 
sprinkle on food where issues of uniformity and compatability may arise – 
different method of administering multiparticulates are examined in Section 
1.5. 
 
In summary, multiparticulates provide an excellent formulation for children 
due to their small size for swallowability, dose adaptability and ability to 
provide taste masking/controlled release functionalities (they provide many of 
the advantages of tablets without the disadvantages). However for ease of 
administration/compatability and to provide a dosage form for pre-weaning 
children, multiparticulates could be suspended in a liquid.  
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1.4. Preparation of Multiparticulate Dosage Forms 
 
The most common ways to prepare commercial multi-particulate dosage 
forms are to prepare granules or produce pellets by extrusion/spheronisation, 
or coat drug onto ready prepared spheres which could them be functionalized 
by coating. Lately minitablets (tablets usually smaller than 5 mm) have been 
proposed as a multiparticulate dosage form of interest for children since the 
small mass of drug which can be contained within each minitablet would 
necessitate the dosing of multiple minitablets for all those but the most potent 
drugs (Thomson et al., 2009b, Tissen et al., 2011).  
 
As the suspension of multiparticulates in a suspending vehicle would be 
desirable for administration, it is thought given the size range of granules, 
pellets and minitablets are often in the hundreds of microns to millimeters in 
size that all of these approaches will make particles too large to suspend. 
Hence the production of microparticles by solvent evaporation, coacervation 
and spray drying which can produce small (<100 µm particles) are 
considered. 
 
1.4.1. Controlling Drug Release 
 
Multiparticulates are typically used to control drug release to achieve an 
appropriate pharmacokinetic profile. Controlling drug release depends on the 
matrix the drug is entrapped in and the physicochemical properties of both 
the drug and polymer as shown for Eudragit® L or S particles containing 
dipyridamole, cinnarizine, amprenavir, bendroflumethiazide, budesonide and 
prednisolone (Alhnan et al., 2010). Polymer molecular weight/blending and 
crystallinity are important in controlling drug release profiles (Alhnan and 
Basit, 2011). Drug release can be triggered by a range of variables  as well 
covered in a review by Freiberg and Zhu, 2004 including pH (Rattes and 
Oliveria, 2007, Xu et al., 2008b), ionic strength (Asare-Addo et al., 2013, Qiu 
and Park, 2012) and enzymes (Hu et al., 2012, Thornton et al., 2007). Once 
the polymer/matrix reaches the appropriate conditions for drug release the 
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drug may diffuse through pores or be released by degradation/erosion of the 
polymer or by osmosis (Rizi et al., 2011). 
 
There is often an initial burst release of drug from the surface (presumably 
due to drug that has not been successfully captured by the control 
mechanism) followed by a more constant release phase as seen for 
ibuprofen microparticles coated with ethylene vinyl acetate, ethyl cellulose, 
ethyl cellulose aqueous dispersion, polyethacrylate or Eudragit® NE 30D or 
carnauba (Sriamornsak et al., 2011). Drug release can be modified by the 
location of drug in the multiparticulate – if it is uniformly dispersed it may 
have a larger initial burst than if most of the drug is encompassed in the core 
of the microsphere; if it is encompassed mainly in the core, release will be 
retarded. In microspheres where the drug is variably and unpredictably 
dispersed, the release will be variable and difficult to control – the location of 
drug can be assessed by confocal laser scanning microscopy as in the case 
of Eudragit® L containing riboflavin, dipyridamole and acridine orange  
(Nilkumhang et al., 2009). 
 
In light of this, microspheres can be further modified by the addition of an 
outer layer or shell to enhance controlled release and reduce the initial burst 
effect. For example by coating highly porous particles or in pH-dependent 
delivery where the shell will degrade at a specific pH value and leave the 
core to provide prolonged release as in the case of erodible microcapsules of 
diclofenac coated with CAP and EC, or to encompass two different drugs 
such as codeine and chlorpheniramine (Biju et al., 2004, Zeng et al., 2007). 
However as coated microspheres will be larger than uncoated microspheres, 
it may be that the larger size of coated microspheres are more difficult to 
suspend if they are desired to be administered in a suspension formulation. 
Washing the microspheres to remove surface drug or curing the 
microspheres may further modify drug release after manufacture as in the 
case of ibuprofen loaded poly(D,L-lactic acid) microspheres washed with 
sodium carbonate solution (Leo et al., 2000). 
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Many of the microparticles prepared by various methods have the 
disadvantage of a low mass of drug relative to that of polymer with drug to 
polymer ratios of 1:10 not uncommon (Al-Zoubi et al., 2008b). This high mass 
of polymer is less acceptable in paediatrics as it may result in a proportionally 
higher dose-volume which is more difficult to give a child. It also means more 
polymers which may not necessarily have much relevant toxicity information 
in the younger age groups e.g. phtalates. 
 
The use of lower ratios of polymer to drug has found incomplete microparticle 
formation with drug crystals not only on the microparticles but also existing as 
discrete crystals. This may be due to how the particles are prepared e.g. from 
the solution or solid drug dispersion: As a result of crystal growth, an uneven, 
aggregated product can be formed as seen for Eudragit® RS or Kollicoat SR 
microparticles containing buspirone or paracetamol containing particles 
produced using various cellulose derivatives (Al-Zoubi et ail., 2008a, Billon et 
al., 1999). This impacts on drug release rates as well as make the 
microparticles more difficult to handle due to their impaired flow properties. 
 
 
1.4.2. Polymers 
 
Polymers can be water soluble or insoluble. They can also exhibit pH 
dependent or independent solubility. In the course of trying to make a 
functionalised suspension from multi-particulates, insoluble polymers or pH 
sensitive polymers are likely to have increased release retardation in liquid 
compared with hydrophilic polymers. Two of the larger classes of polymers 
are those of the cellulose derivatives and methacrylates with the former 
summarised in Table 1-5 . 
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Table 1-5: Summary of Commonly Used Cellulose Derivatives and their Solubility 
Water Soluble Water Insoluble pH Sensitive 
Hydroxypropylmethylcellulose 
Hydroxypropylcellulose 
Hydroxyethylcellulose 
Sodium 
Carboxymethylcellulose 
Ethylcellulose 
Cellulose 
acetate 
Cellulose acetate 
phthalate 
HPMC acetate succinate 
Cellulose acetate 
trimellitate 
Hydroxypropylcellulose 
phthalate 
 
Eudragit® polymers are methyacrylic acid copolymers available in a variety 
of different grades for different purposes. The different grades can be used to 
provide enteric-coating, immediate release or sustained release. Varying the 
ratios of the different polymers and the film thickness can customize drug 
release profiles. The different polymers are described in Table 1-6 
 
Other polymers such as chitosans, alginates and gelatin along with lipid 
components such as wax have also been used for multiparticulate 
preparation. There was insufficient time to explore the utility of all of these 
polymers in the course of this thesis work.  There may be value in exploring 
these polymers in a blend with the Eudragit® E since the polymer used did 
not achieve the required robust encapsulation of the trial drugs used but this 
may be aided by polymers of possessing difference characteristics such as 
different glass transition temperatures (discussed in Chapter 4). 
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Table 1-6: Description of the Composition and Functionalities of Different Eudragit® 
Polymers (Evonik Industries, n.d.) 
Polymer Description Formulation Dissolution 
Properties  
Use 
L 100-55 
L 30 D-55 
Methacrylic Acid - 
Ethyl Acrylate 
Copolymer (1:1) 
Powder 
Aqueous 
dispersion 30 % 
Dissolves at < 
pH 5.5 
E
n
te
ric
 C
o
a
tin
g
 
L 100 
L 12.5 
Methacrylic Acid - 
Methyl Methacrylate 
Copolymer (1:1)“ 
Powder 
Organic solution 
12.5 % 
Dissolves at < 
pH 6 
S 100 
S 12.5 
Methacrylic Acid - 
Methyl Methacrylate 
Copolymer (1:2) 
Powder 
Organic solution 
12.5 % 
Dissolves at < 
pH 7 
FS 30D Anionic copolymer 
based on methyl 
acrylate, methyl 
methacrylate and 
methacrylic acid 
Aqueous 
dispersion 30 % 
Dissolves at < 
pH 7 
RL 30D 
RL PO 
RL 100 
RL 12.5 
Ammonio 
Methacrylate 
Copolymer Type A 
 
Aqueous 
dispersion 30 % 
Powder, Granules 
Organic solution 
12.5 % 
Insoluble 
High 
permeability 
PH independent 
swelling 
S
u
s
ta
in
e
d
 R
e
le
a
s
e
 
RS 30D 
RS PO 
RS 100 
RS 12.5 
Ammonio 
Methacrylate 
Copolymer Type B 
Aqueous 
dispersion 30 % 
Powder ,Granules 
Organic solution 
12.5 % 
Insoluble  
Low permeability  
pH independent 
swelling 
 
NE 30D 
NE 40D 
 
Polyacrylate (ethyl 
acrylate and methyl 
methacrylate) 
Dispersion 30 % 
Aqueous 
dispersion 30% 
40 %  
Insoluble  
Low permeability  
pH independent 
swelling 
E 100 
E PO 
E 12.5 
Basic butylated 
methacrylate 
copolymer 
Granules 
Powder  
Dispersion  
Soluble in 
gastric fluid up 
to pH 5, 
swellable and 
permeable 
above Ph5 
P
ro
te
c
tio
n
/ 
T
a
s
te
 M
a
s
k
in
g
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1.4.2. Production Methods 
 
The three ways most commonly used to produce multiparticulates of a 
particle size <100 µm are emulsification/solvent evaporation, co-acervation 
and spray drying as detailed below. 
 
 
1.4.3.1. Emulsification and Solvent Evaporation 
 
The technique of emulsification/solvent evaporation depends upon the 
aqueous solubility of the drug to be entrapped. If the drug in question is 
hydrophobic then it can be combined with the polymer in an organic solvent 
(known as the disperse phase), this is then emulsified by the addition of an 
aqueous continuous phase. Following the formation of this oil-in-water 
emulsion (o/w), the solvent in the disperse phase diffuses into the continuous 
phase so that the disperse phase forms solid particles which can be removed 
and undergo further drying to remove the residual organic solvent as 
summarised in Figure 1-7 
 
Figure 1-7: Overview of a Simple Emulsification/Solvent Evaporation Process 
 
The situation is not as straight forward for hydrophilic drugs since if the o/w 
emulsification method is used then the hydrophilic drug would leech out into 
the aqueous continuous phase and hence the drug would be lost. This 
Aqueous Phase Organic Phase
Emulsification
Solvent
Evaporation
Washing/Drying
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means that there are four different ways in which to entrap hydrophilic drugs: 
by preparing a water-in-oil-in-water (w/o/w) double emulsion, using a co-
solvent to dissolve the drug in an organic disperse phase, dispersing the drug 
as a powder in a polymer/organic solvent solution or making an oil-in-oil (o/o) 
emulsion. 
 
Co-solvents can be added to help the drug dissolve in the disperse phase 
(ethanol is a common choice due to its miscibility with water) or porosity 
generators such as hexane can be used to produce pores in the 
microspheres to increase drug release rate in the case of aspirin 
microcapsules containing aspirin (Yang et al., 2000). However increasing the 
porosity of the microspheres may also decrease encapsulation efficiency so 
this must be balanced with the requirements of the product. Porosity 
generators can also reduce diameter and lead to an irregular surface 
morphology (Yang et al., 2000). Reducing the water content of the first 
emulsion can also decrease the porosity as can using a more volatile solvent 
as can increasing the water content of the second emulsion (due to 
increased polymer precipitation) – up to a certain rate where the increased 
solvent removal will form pores as was seen in the case of somatostatin 
(Herrmann and Bodmeier, 1998). 
 
Surfactants (amphiphilic molecules that consist of a hydrophobic and 
hydrophilic section) may be added to the continuous phase to ensure uniform 
sized microspheres with a small size distribution and predictable drug 
release. These may be anionic (-ve charge) like SDS, cationic, amphoteric 
(anionic in alkaline pH and cationic in acidic pH) or non-ionic like partially 
hydrolysed PVA: increasing concentrations create smaller microparticles by 
lowering the surface tension of the continuous phase until the CMC is met 
(Yang et al., 2001) 
 
A number of particle parameters can be modified to achieve the size, 
morphology and drug encapsulation desired. The polymer concentration or 
molecular weight can be increased which will increase the viscosity of the 
disperse phase: this leads to a larger, smoother microsphere with increased 
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encapsulation efficiency and slower drug release (Alhnan et al., 2010). The 
volume of disperse phase relative to continuous phase can be increased 
which may decrease diameter or may have no impact. Increasing the 
quantity of drug in the dispersed phase can make the microsphere become 
more porous and have a more irregular shape; it may also reduce 
encapsulation efficiency due to the formation of pores if the quantity of drug 
contained is too high (Witschi and Doelker, 1998). 
 
Operating conditions can be modified such as increasing the agitation rate to 
decrease the average size of microspheres (Freitas et al., 2005). The rate of 
solvent evaporation can be increased by either increasing the temperature or 
by reducing the pressure - However increasing the temperature also 
increases the particle size formed and makes the particles less uniform, 
decreases encapsulation and reduces particle recovery (Witschi and Doelker, 
1998). The boiling point of the solvent and thermal stability of the drug must 
also be considered. Hence reducing the system pressure may be more 
beneficial especially since it can also improve the drug encapsulation 
efficiency and smooth surface/smaller surface area (thought to be due to the 
solvent removal being too rapid for the polymer to crystallise) (Alhnan and 
Basit, 2011). Care must be taken not to reduce the pressure too far as once it 
becomes lower than the saturated vapour pressure of the solvent, the solvent 
will start to boil and the bubbles produced will destroy any potential 
microspheres. Low temperatures have also been shown to increase the 
particle size due to an increased viscosity.  
 
Particles have been produced by emulsification/solvent evaporation for use in 
suspensions as detailed in Section 1.4. with Eudragit® polymers and 
cellulose derivatives proving popular. In terms of taste masking, a range of 
drugs have been successively masked by this method (Gao et al., 2006, 
Hashimoto et al., 2002, Chiappetta et al., 2009).  
 
Despite the promise of this emulsification approach for microparticle 
production, this technique was not chosen as to date there is a lack of 
information on performing this technique on an industrial scale, so does not 
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fit the industry requirement for a manufacturable platform formulation 
approach. In addition the need for specific solvents for each drug does not 
suit this methodology to providing a platform approach for multiple drugs. 
 
1.4.3.2. Coacervation 
 
Particles can be formed by precipitation which is where an insoluble solid is 
formed from a solution such as in a coacervation approach. There are three 
types of coacervation: simple, complex and salt. Simple coacervation is when 
a water-miscible non-solvent for example ethanol is added to an aqueous 
polymer solution which causes the formation of a polymer rich phase to form 
microparticles around a drug that may either remain in solution in the polymer 
or form insoluble particle. Complex coacervation depends on mutual 
neutralisation between two oppositely charged colloids (usually positively 
charged gelatin with a negatively charged component).  Salt coacervation is 
where an electrolyte is added to an aqueous solution which results in the 
polymer separating from the aqueous solution.   
 
Microcapsules of indomethacin were produced using gelatin-cellulose 
acetate phthalate by complex coacervation or cellulose acetate phthalate by 
simple coacervation prior to incorporation into slurry to make sustained-
release tablets.  The morphology was found to be temperature-dependent. 
For both polymers, the majority of the microcapsules were in the size range 
15 to 60 µm. Although cellulose acetate phthalate appears to encompass the 
drug more effectively, the higher drug loadings of the complex gelatin-
cellulose acetate phthalate may be a consequence of a higher proportion of 
drug being used in the preparation so may be a result of incomplete 
coacervation. Tablets prepared from these were physically and chemically 
stable with both showing sustained release and reducing stomach irritation in 
rats.  However as the gelatin containing microsphere tablets were linked with 
formaldehyde and the other microspheres with the less toxic, acetic acid, and 
there is no significant difference in activity between the two it would make 
sense to choose the cellulose phthalate microsphere tablets (Lu et al., 2007). 
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Previously a number of approaches to make pH sensitive microparticles for 
site-specific delivery to the gastro-intestinal tract using Eudragit®  polymers 
were investigated (Kendall, 2007). It was found that a simple, non-aqueous 
coacervation technique was successfully able to produce microparticles but it 
was not possible to harvest these due to agglomeration of the particles and 
phase-separation on removal of the solvent phase. It was also found that 
aqueous spray drying was unsuccessful, as collapsed microparticles were 
produced which were unable to control drug release over acidic pH values. 
The problems of these above techniques were overcome by producing 
microparticles through an emulsification/solvent evaporation process. 
 
Co-acervation had also been used to make taste masked particles of 
mefloquine with Eudragit® E and clarithromycin with gelatin/various 
Eudragit® polymer coatings (Shah et al., 2008, Friend, 1992).  
 
Again, coacervation was not considered a suitable approach for this project 
as; coacervation can be difficult to control in terms of size and agglomeration; 
the multiple steps and use of organic solvents render it difficult to scale up 
above lab scale and the requirement for specific solvent/antisolvent pairs for 
different drugs mean that these cannot be adapted into a platform approach 
for multiple drugs.  
 
 
1.4.3.3. Spray Drying 
 
Due to its adaptability and industrial scale applicability spray drying suggests 
itself as the most likely approach to producing microparticles that could be of 
benefit in this application. Spray Drying is a process whereby a liquid feed is 
transformed into a dry particle by spraying the feed into hot gas. It can be 
seen to consist of 4 main steps: 
1. Atomisation of the Feed Spray 
2. Air-Fluid Contacts 
3. Particle Drying 
4. Separation of Spray Dried Particles from the Drying Air 
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The progress of spray drying of the solution or suspension feed can be seen 
visually in Figure 1-8 where the feed is pumped through the spray dryer until 
it is atomised at the nozzle and reaches the drying chamber before the 
particles are separated as they reach the collection container after passing 
through the cyclone.  
 
 
Figure 1-8: Diagram of Spray Drying Product Flow (CHEC Research Centre, 2007) 
 
Spray Drying has been commonly used by the food, agricultural and 
pharmaceutical industries for a number of years. Spray drying is a frequently 
used technique as it is a one-stage technique to dry and embed the drug into 
a polymer network that can be relatively easily scaled up to an industrial 
scale. Its advantages include short duration, reproducible results, cost-
effectiveness, good flow properties and with a good yield of production and 
encapsulating efficiency (Masters, 1991).  
 
The properties of the spray-dried powders can be controlled by the polymer 
used, operating conditions and properties of the feed to be spray dried (Al-
Zoubi et al., 2008a). Modifiable parameters include inlet and outlet 
temperatures, spray-rate and drug-polymer ratio of the feed as are shown in 
Table 1-7. 
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Table 1-7: Effect of Different Spray Drying Parameters on Product (Xu et al., 2008a, 
Rattes and Oliveira, 2007, Wan et al., 1992) 
Parameter Effect on Particle Characteristics 
Solid 
concentration 
of feed 
Increased solid concentration leads to increased particle 
size and density 
Solvent Choice of solvent affects the particle morphology and size 
Atomising 
Pressure 
Increased pressure leads to a smaller particle size 
Feed Rate Increased feed rate leads to larger particles with a higher 
residual moisture 
Air Flow Increased flow rate leads to decreased drying 
Inlet 
Temperature 
Increased temperature may reduce particle seize or make a 
porous product whereas too low a temperature may allow 
crystallisation due to slow evaporation of solvent 
Outlet 
Temperature 
A low outlet temperature can lead to increased particle 
wetness and crystallization (outlet temperature not directly 
controlled but is linked to many parameters including inlet 
temperature, spray rates and solvent) 
 
In terms of spray drying, the use of no organic solvents would be desirable for 
reasons as detailed in Chapter 4 although the vast majority of research still 
involves organic solvents. Particles formed from various cellulose derivatives 
with different additives containing paracetamol produced by aqueous spray 
drying in drug to polymer ratios of 1:1 or 10:1 (Billon et al., 1999). The highest 
production yields were achieved with aqueous suspensions containing 
microcrystalline cellulose (MCC) or ethylcellulose (EC), both optimal at 1%, 
followed (in order) by hydroxyethylcellulose (HEC), sodium 
carboxymethylcellulose (NaCMC), hydroxypropyl methylcellulose (HPMC) and 
hydroxypropylcellulose (HPC) which were all optimal at 0.1 %. The availability of 
drug from multiparticulate systems depends on the hydrophilicity of the polymer. 
Hydrophilic polymers such as NaCMC and HEC gelled faster than the other 
polymers examined resulting in the fast formation of a viscous gel barrier and 
hence prolongation of drug release, with increasing polymer concentration 
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increasing the thickness of the layer and hence further slowing paracetamol 
release.  Faster drug release was seen with higher drug: polymer ratios due to 
the lack of/too thin continuous gel layer.  
 
Sustained release and enteric-coated tablets of theophylline have been 
prepared by compressing spray dried microspheres prepared by organic-
solvent free spray-drying using Eudragit® L30D or L100-55 for enteric-
coating and Eudragit® E30D for sustained release.  Colloidal silica and talc 
were added to all three feeds to prevent adhering of the particles to the spray 
drier chamber walls with polyethylene glycol (PEG) 6000 as a plasticiser.  
Eudragit® L30D and E30D are aqueous dispersions so the drug is in a 
solution feed whilst the theophylline was suspended in the Eudragit®  L100-
55 feed.  Ammonia 2% w/w (aq) was used as a solvent.  Eudragit® L100-55 
at a drug to polymer ratio of 1:1 or 1:3 formed particles in the range of 10-
30µm with smooth surfaces with the larger particles due to agglomerated 
crystals in those particles with less polymer.  The crystallinity of the drug in 
the particles decreased by increasing polymer concentration and was absent 
in those particles above drug to polymer ratios of 1:3. A similar decrease was 
seen with Eudragit® L30D but there are still some crystals due to drug 
undissolved in the fluid and also with Eudragit® E30D. Enteric behaviour was 
seen in tabletted microparticles of L100-55 and L30D at a drug to polymer 
ratio of 1:3. and sustained, pH independent theophylline release was seen 
with the tabletted Eudragit® E30D microspheres (Takeuchi et al.). Whether 
the microspheres would produce modified release whilst as discrete particles 
is unknown. Aqueous spray drying is discussed further in Section 4. 
 
One of the newer options for taste-masking formulations for patients with 
swallowing difficulties is to produce particles coated with the polymer 
Eudragit® E PO. Eudragit® E PO has been used to produce famotidine 
microspheres by aqueous spray drying which were formed into an orally 
disintegrating tablet which disintegrates rapidly in the saliva without the need 
for water (Xu et al., 2008a). The polymer may also be extruded. Eudragit® E 
PO is a cationic copolymer of dimethylaminoethyl methacrylate and neutral 
methacrylic esters. This co-polymer dissolves below pH 5 so is soluble in the 
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stomach so that the bioavailability of this medicine which is designed to act 
on the stomach is not effected. At the higher pH of the buccal cavity the 
particles remain intact. The tablets formed from microspheres were found to 
disintegrate within 30 s in the buccal cavity and were rated as having an 
acceptable taste by a human taste panel. Spray drying for taste masking is 
discussed further in Chapter 4. 
 
In summary, spray drying was chosen as it is a microencapsulation method 
which can be performed without organic solvents which is able to be scaled-
up to industrial scales. Due to the pH dependency of Eudragit® E retarding 
release in at salivary pH (and hence potentially being able to be administered 
in a pH controlled suspending vehicle) along with the ability to be aqueously 
spray dried. This polymer was chosen to try to produce a taste masked 
multiparticulate form as detailed in Chapter 4. 
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1.5. Administration of Multiparticulates 
 
1.5.1. Multiparticulates Commercially Available in the British National 
Formulary for Children 
The British National Formulary for Children was first produced in 2005 and is 
updated annually. It is different to the British National Formulary in that it 
contains advice for patients up to 18 years of age – however it does not only 
list licensed medicines, merely those with paediatric use and hence some 
formulations are unlicenced completely in children with the associated risk of  
adverse effects. The Children’s British National Formulary (2008) was 
searched and reported over 400 dosage forms of which a large percentage 
were monolithic dosage forms. The search terms used for finding 
commercially available multiparticulates: granules, bead, pellets and 
minitablets (beads are likely to be pellets). The resulting entries found were 
assessed for drug, therapeutic group, functionality, age licensed from and 
pharmaceutical form/administration with the aid of the Summary of Product 
Characteristics for each product with Figure 1-9 showing the types of 
multiparticulates and functionalisation retrieved.  
 
 40 multiparticulate formulations were available 
 Granules were the most common type of multiparticulates (as shown 
in Figure 1-9) 
 Most formulations were functionalised such as modified release or 
enteric coated (as shown in Figure 1-9) 
 Over half (22 out of 40 formulations) were for delivery to the 
gastrointestinal tract e.g. by enteric coating  
 Pancreatin was the drug with the most formulations (8 Multiparticulate 
Products) 
• Most multiparticulates were available in capsules (which may have to 
be opened for younger children and not all manufacturers provide 
advice as to the feasibility of this) 
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• Three formulations were unlicensed in all ages of children (Cacit® D3 
calcium carbonate/colecalciferol, Motifene® diclofenac sodium and 
Coracten SR® nifedipine ) 
 
  
Figure 1-9: Multiparticulate Dosage Forms Available in the British National 
Formulary for Children 2008 in terms of Type of Multiparticulates and Functionality 
(n=40 for each as all multiparticulate formulations are accounted for in each graph) 
 
When the search was updated in December 2012, five more formulations 
were found of which three are described as “granules for suspension” (with 
one being modified release, one enteric coated and one immediate release), 
one modified release pellet in a sachet and one enteric coated capsule for 
opening showing increased development in this area. Three dosage forms 
are licenced from birth (with the others from one year old and twelve years) 
and two are for gastro-intestinal therapeutic effects. 
 
It can be seen that commercially available multiparticulates are mainly 
supplied for administration in capsules, sachets or multi-use containers. In 
terms of administering multiparticulates, these can be administered wet or 
dry as detailed below.  
 
 
 
 
 
Granules 
Pellets
Minitablets
Beads
Enteric 
Coated
Modified 
Release
Film 
Coated
None
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1.5.2. Dry Administration 
 
By administering the multiparticulates dry, the multiparticulates will be from a 
dry dosage form such as a  capsule, from a sachet/stickpack/bottle, from 
being compressed into tablets or via an administration device (Walsh et al., 
2011). 
 
As seen in Section 1.5.1, commercially marked multiparticulates are 
commonly administered sprinkled into a spoonful of food and the two most 
commonly recommended soft foods are yoghurt and apple sauce which were 
investigated in Chapter 2 but may have issues with food compatibilities and 
chewing.  These dosage forms could also be administered directly into the 
mouth but may have problems with adverse mouth feel or grittiness as 
discussed in Chapter 3. 
 
Multiparticulates can be processed into tablets such as orally disintegrating 
tablets (ODTs) which can help with taste masking due the lower surface area 
exposed to the mouth when compared to uncompressed microspheres and 
are easier to swallow than conventional tablets since they rapidly disintegrate 
and disperse in the saliva. This form is commonly used for the administration 
of taste masked multiparticulates in the literature (Khan et al., 2007, Anand et 
al., 2007a, Randale et al., 2010, Xu et al., 2008a) . While this appears to be a 
valid approach, the integrity of the polymer layer must be ensured so that 
taste masking occurs and younger children will probably still require a liquid 
dosage form. 
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1.5.2. Wet administration 
 
Wet administration of a multiparticulate is being taken to be administering a 
multiparticulate in a suspension. 
 
Based on the BNF for Children, there are five granules for suspension 
multiparticulate formulations available in the UK, namely (British Medical 
Association and the Royal Pharmaceutical Society, 2012, Electronic 
Medicines Compendium, n.d.): 
 
 Klaricid® Clarithromycin (containing carbomers and HPMCP) 
 MST Continus® Morphine (containing Dowex 50WX8 100-200 mesh 
cationic exchange resin) 
 Carbomix® Activated Charcoal (containing only acacia, glycerol and 
citric acid)  
 Modigraf® Tacrolimus (containing HPMC and croscarmellose sodium) 
 Nexium® Esomeprazole (containing HPC, HPMC and Methacrylic acid 
–ethyl acrylate copolymer (1:1) dispersion 30 %) 
 
In addition to those multiparticulates in suspension available in the BNF for 
Children, some modified release suspension dosage forms have been 
patented. LiquiXR® technology from Tris Pharma used various ion exchange 
resins (IER) but predominantly Amberlite IRP 69 to complex the drugs in this 
technology. These drug-IER complexes are then mixed with an aqueous 
polymeric dispersion (most commonly Kollicoat® SR 30D). This slurry is 
dried, milled and passed through a 40 micron mesh. An aqueous polymeric 
dispersion (usually Kollicoat® SR 30D) with triacetin is applied using a fluid 
bed processer to coat the drug-polymer-IER complexes before these are 
placed into a suspending base. The types of IERs, polymers and excipients 
of the suspending base differ depending on the active pharmaceutical 
ingredient as do the quantities of each used; hence the formulation is not a 
"uniform platform." Various drugs are named in the patent including 
cardiovascular drugs, ibuprofen and dextromethorphan. 
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In the literature, there are several papers as described below detailing the 
formulation of multiparticulates within a suspension to allow for functionality.  
These particles are usually formed by the complexation of a drug with an ion 
exchange resin or less commonly through coating or encapsulating the drug 
in a polymer. Where the drug is encompassed in a polymer, a variety of 
methods can be used including solvent evaporation/emulsification and co-
acervation.  However, none of these used an organic solvent free process, 
was scale-upable and or shown to encompass multiple drugs. 
 
Some of the drugs with the most research into their functionalised 
suspensions are ibuprofen, theophylline, codeine, morphine and 
chlorpheniramine.  Most are weak acids with codeine and chlorpheniramine 
being slightly soluble in water and morphine and ibuprofen (weak acid) being 
practically insoluble. Ibuprofen microparticles could be beneficial to provide 
enteric coating to protect the stomach from the gastro-intestinal side effects 
associated with local irritation while the other drugs would benefit from 
modified release to reduce the frequency of dosing. 
 
Ion Exchange Resins 
 
The loss of drug into the suspending medium is mainly due to the solubility of 
the drug in this medium; hence water-insoluble drugs can be suspended in 
aqueous media without significant leeching. One of the ways to overcome the 
leeching of water-soluble drugs into aqueous media is by binding the drug to 
an ion-exchange resin which will prevent the diffusion of drug when in non-
ionic suspension: drug release occurs due to the ions of the GIT on oral 
administration  as covered in the review by Anand et al., 2001. Ion exchange 
resins (IERs) are insoluble polymers that contain acidic or basic functional 
groups with different capacities and can exchange a range of counter ions 
with aqueous solutions. IERs combine with a drug to form a complex: this is 
known as a resinate which retains the drug and prevents dose dumping into 
the suspending media especially in the case of water soluble drugs. 
Resinates can be formed of different sizes and prepared as either a batch or 
continuous process. 
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Terbutaline was loaded onto an ion-exchange resin sulphonic acid cation-
exchange resins in the H+ form (Dowex® 50W-x4, 200–400 mesh) in 
Eudragit® RS/RL microparticles which were suspended in 
hydroxypropylmethylcellulose (HPMC) 0.75 % solution to achieve controlled 
release (Cuna et al., 2000). Those microcapsules made by an oil-in-water 
solvent evaporation showed good stability for 6 months whereas those made 
by an oil-in-oil method were not stable even after one week. This was thought 
to be due to rupture of the polymer coating due to swelling on contact with 
the aqueous suspending medium.   
 
Codeine and chlorpheniramine (both soluble cationic drugs with short half 
lives) were also successfully loaded onto AMBERLITE® IRP 69 (45–125 μm) 
which is a cation exchange resin prepared as the sodium form of the 
sulfonated styrene divinylbenzene copolymer that is insoluble in water (Zeng 
et al., 2007). This resinate was encompassed in ethylcellulose particles and 
coated with PEG 4000 dispersed in an aqueous suspending medium 
containing xanthan gum 0.5 % and HPMC 0.5 % w/w for sustained release. 
While resins have been seen to control release in a multiparticulate 
suspension containing different drugs, the resin can only be bound to specific 
drugs dependent upon the drug and resin functionality e.g. metformin with 
activated Indion 234 or etoricoxib  with Indion 234 resin and hence would not 
provide a uniform platform for a functionalized particle in suspension (Bhoyar 
and Amgaonkar, 2011, Singh et al., 2010, Roblegg et al., 2010). 
 
Multiparticulates in Suspension 
 
Relatively few suspensions of multiparticulates are available in the literature 
which may highlight the difficulties in formulation. A number of cellulose 
derivatives have been used as continuous phases for controlled-release 
microspheres/capsule suspensions. Both carboxymethylcellulose (CMC) and 
methylcellulose (MC) have successfully been used to form stable 
suspensions as have other suspending media like tragacanth and xanthan 
gum as seen in Table 1-8 and detailed below.  
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Table 1-8: Summary of Some Multiparticulate Suspensions in the Literature in terms 
of Polymers, Production Methods, Composition, Release and Stability (Kawashima 
et al., 1991, Dalal and Naruker, 1991, Morales et al., 2004, Morales et al., 2010, 
Emami et al., 2007) 
Drug Polymer Production 
Method 
Suspension 
Composition 
Release Stability 
Ibuprofen CAB and 
cellulose 
propionate 
Emulsification/ 
Solvent 
Evaporation 
Methylcellulose 
0.5 % 
Sustained 
blood 
levels in 
rats  
Redispersability 
and dose 
uniformity up to 
one month  
Ibuprofen Eudragit® 
RS-PM 
(Contains 
0.5 % talc) 
Emulsification/ 
Solvent 
Evaporation 
Acidic (< pH 2) 
solution of 
NaCMC 0.5% 
and D-sorbitol 
>28 %. 
100 % 
release at 
eight 
hours 
Resuspendable 
for six months 
and release 
profiles of 
microspheres 
identical 
Morphine EC Emulsification/ 
Solvent 
evaporation 
Not given 100 % 
release at 
25 hours 
No data 
Tramadol EC Emulsification/ 
Solvent 
evaporation 
Xanthan gum, 
carbopol or 
NaCMC 1% 
46-55 % 
release at 
8 hours 
No data 
Theophylline EC and 
HPMCP 
Organic Spray 
Drying 
Simple Syrup, 
Sorbitol, 
Distilled water, 
Tragacanth, 
Tween 80, 
Methyl-/ 
Propylparaben 
61-65 % 
dissolution 
after eight 
hours 
Release similar 
after one day 
and one week 
of storage 
 
The addition of D-sorbitol which acts by its dehydrating effect and pH below 3 
increased the absorption of NaCMC to ibuprofen/Eudragit® RS-PM solvent 
evaporation prepared microspheres (Kawashima et al., 1991). Hydrogen 
bonds form amongst CMC molecules so the microspheres were embedded in 
a CMC network to aid physical stability. Microspheres of 105 µm average 
diameter remained suspended for more than six months. As ibuprofen has a 
low solubility (pka 5.2) in the acidic medium, it was unable to diffuse out.  
Following storage for two years, the sedimentation value was 0.7 and this 
suspension was easily redispersed on shaking. The suspension had highly 
desirable rheological properties, showing shear thinning. In addition the zeta 
potential impacted on the stability since as the ibuprofen-Eudragit®  
microspheres had a low zeta potential at high pH due to the slight ionisation 
of its quaternary ammonium groups which became more ionised as the pH 
decreases and hence become positively charged below 3.2.  
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Similarly, at pH 3.5 a suspension of cellulose acetate butyrate (CAB) or 
cellulose propionate (CP) ibuprofen microspheres with a drug: polymer ratio 
of 1:2 and 1:3 was prepared although the mouth feel of this acidic 
suspension is not known (Dalal and Naruker, 1991). The CAB microsphere 
suspension had pH independent release less than 5% after thirty days, 
whereas the CP microsphere suspension showed pH dependent release of 
8% which may be due to the higher permeability of CPL. Both microsphere 
suspensions were easy to redisperse and showed uniformity of dose, even 
after storage for six months. The CAB microsphere suspension maintained 
blood levels for longer than the CP microspheres and produced the minimum 
gastric mucosal damage whereas the CPL suspension produced slightly 
more mucosal damage on increasing dose (thought to be due to dose 
dumping of ibuprofen crystals on the surface initially). 
 
Two different ethylcellulose suspensions of morphine were produced: one 
where the morphine was incorporated into the microspheres during synthesis 
and the other where the drug was absorbing to the surface of the 
microparticle (Morales et al., 2004). As may be expected the suspension 
produced by the former was able to hold more morphine, 92 % was 
entrapped compared to 15 % absorbed to the surface in the later case. A 
pseudolatex was formed from ethylcellulose 30 % (a pseudolatex is similar to 
a latex but is formed from an already existing polymer as compared to a latex 
which is made by polymerisation of monomers). In a diffusion model, the 
suspension with entrapped drug transferred the drug over 24 hours whilst the 
adsorbed drug suspension released over 5 hours.  A disadvantage of these 
suspensions was that they were produced using a solvent containing 85% 
benzene (a class 1 solvent meaning that there is evidence of this solvent 
being a carcinogen)! A suspension of tramadol was produced by a similar 
method by the same research group (Morales et al., 2010) 
 
A theophylline microcapsule suspension was prepared by spray drying from 
ethyl cellulose and hydroxy propyl methyl cellulose phthalate (HPMCP) either 
as a solution or dispersion feed.  The effect of different solvents 
(ethanol/water, acetone, ammonium hydroxide and methylene chloride), 
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polymer to drug ratios (1:1, 2:1 and 3:1) and two different continuous phase 
compositions on stability and drug release were investigated.   Only HPMCP 
in acetone (a solution feed) and ethylcellulose in methylene chloride (a 
suspension feed) in all polymer-to-drug ratios produced spherical 
microcapsules capable of sustained drug release (Emami et al., 2007).  
 
Administration technologies for multiparticulates are available such as straws 
(like the Clarosip® Straw containing clarithromycin [not longer marketed] 
which had multiparticulates encompassed within the straw) and, Parvulet® 
and Vismon® Technologies, both of which consist of commercial dry 
multiparticulates which become soft and semi-solid following the addition of 
water of unknown composition (Breitkreutz and Boos, 2007a, Egalet). There 
are however proprietary technologies with cost implications which may not 
offer significant advantages over other administration methods. 
 
In summary, multiparticulates can be formulated which are stable in a 
suspension and which  can provide taste masked or modified release in a 
liquid dosage form by either ion exchange resins or microencapsulation. By 
using a suspension form, we allow for swallowability and reduce the 
challenges of other multiparticulate administration methods such as food 
compatibility, choking or the use of expensive proprietary technologies. A 
suspension dosage form also offers the possibility of dosing by volume hence 
permitting the dosing flexibility that is often required by the diverse paediatric 
population.  By using a microencapsulation approach, a uniform 
multiparticulate for suspension should be able to be achieved compared to 
drug specific ion exchange resins. 
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1.6. Multiparticulates and Gastro-Intestinal Transit 
 
Functionalised multiparticulates are used in adults as they are thought to 
produce less drug variability due to delays in gastric emptying and intestinal 
transit and less local irritation/dose dumping, when compared to monolithic 
dosage forms. The knowledge of transit of multiparticulates in children is 
explored below. The general age differences in overall gastrointestinal 
factors relative to adult values (Bowles et al., 2010) are briefly summarised in 
Table 1-9. 
 
Table 1-9: Age differences in gastrointestinal factors relative to adult values (Bowles 
et al., 2010, de Zwart et al., 2004, Alcorn and McNamara, 2003) 
Physiological factors New born 
(Full term) 
Neonate (0-
1month) 
Infant (1month 
-2yo) 
Volume stomach 
(fasted) 
 
Acid /pepsin output 
 
Gastric pH 
 
 
Gastric emptying 
time 
 
Gastric Motility 
 
 
Intestinal surface 
area 
 
Intestinal transit time 
 
Pancreatic/biliary 
function 
 
Bacterial flora 
 
Enzymes/transporter 
activities 
- 
 
 
- 
 
Neutral at birth 
then 1-3 
 
Reduced 
(variable) 
 
Low in first days 
of life 
 
Reduced 
 
 
Reduced 
 
Very immature 
 
 
Very immature 
 
Very immature 
2.5ml 
 
 
Relatively low 
 
>5 
 
 
Reduced 
(variable) 
 
Reduced 
 
 
Reduced 
 
 
Immature 
 
Immature 
 
 
Immature 
 
Very immature 
 
2.5ml 
 
 
~ Adult (/BW) 
 
~ Adult 
 
 
Increased 
 
 
~Adult (6-8 
Months) 
 
~ Adult 
 
 
Increased 
 
~ Adult 
 
 
Immature 
 
Approaching 
adult 
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The main areas of gastro-intestinal transit which are specifically important 
with regard to the gastro-intestinal transit of multiparticulate dosage forms 
are: gastric emptying, fluid volumes, intestinal transit times and pH values 
which are examined further. 
 
1.6.1. Limitations of Available Data 
 
Little is known about how any non-disintegrating formulation, let alone multi-
particulates, would transit through the paediatric gastric-intestinal tract. There 
are a number of reasons for this gap in knowledge. Due to the radiation 
burden or invasive nature of diagnostic methods involved, the few available 
studies were generally carried out on paediatric patients already suffering 
from gastro-intestinal symptoms: hence most of the gastric emptying data 
available was from infants suffering from Gastro-Oesophageal Reflux 
Disease (GORD) and much of the intestinal transit information is from 
paediatric patients under investigation for constipation. Very little data is 
available from healthy or control patients as noted below. 
 
Often trials have a large age range classification in order to recruit enough 
patients and many reported the results only as a mean and standard 
deviation without age stratification. The significance of these averaged values 
seems debatable especially when details on how physiological parameters 
change from year to year or even week to week in pre-term infants are not 
known but are likely to be significant (see Table 1-9). The conditions of 
testing also affect the results achieved. Much of the data for gastric emptying 
was in pre-term and term infants using liquids (milk), due to the obvious 
restrictions in administering solids in this age group. In older children, food 
was used for transit studies but different types of meals were used which 
gave different results making trial comparison difficult. 
 
This is further complicated by the different methods used for assessing 
gastro-intestinal transit (commonly ultrasound measurements, scintigraphy, 
coloured/radiopaque makers and breath tests) and the variety of 
experimental protocols used covering parameters such as the patient’s 
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posture on measurement, the time period of pre-fasting and the method of 
reporting results (Hiorns, 2011). However it is important to explore published 
data in order to see how dosage forms are likely to be handled compared to 
the adults and what, if any, impact that may have on dosage form 
development and clinical outcomes. 
 
1.6.2. Gastric Emptying 
Gastric emptying time depends on the dosage form and the fed or fasted state 
of the stomach. In the fasted state the migrating myoelectric complex governs 
the activity of the stomach and hence the passage of intact dosage forms. It 
comprises of four steps ranging from inactivity through increasing contractions 
to very powerful contractions known as a housekeeper wave at stage three 
before returning to its inactive state at phase 4 as seen in Figure 1-10. This 
process may take a couple of hours and is repeated until food is eaten. During 
the fed state, the stomach relaxes ready to receive food and peristalsis occurs. 
During this fed period liquids and small particles such as multiparticulates can 
pass though the pyloric sphincter and onto the small intestine whereas larger 
dosage forms may need to wait for the next peristaltic wave, which may take a 
while (Kendall, 2007).  
 
Figure 1-10: Representation of the Different Phases of the Migrating Myoelectric 
Complex (Kudoh et al., 2009) 
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Thus multiparticulates spread out more uniformly in the GIT, reducing irritation 
compared to monolithic dosage forms, leading to more uniform drug 
distribution and absorption. This emptying also depends upon the size, shape 
and density of dosage form and presence and type of food (Davis et al., 1986). 
Multiparticulates are less affected by the different states of the GIT, thus 
causing less intra- and inter-subject pharmacokinetic variability. 
 
The structure of the stomach is largely developed by fourteen weeks of 
gestation and motility and secretion by around twenty weeks (Lu and 
Lebenthal, 1994).  Gastric motility and emptying develop further when the 
infant swallows amniotic fluid from around 28 weeks of gestation (Carlos et 
al., 1997). The proximal stomach or fundus is responsible for the regulation 
of fluid emptying through a pressure gradient between the fundus and the 
duodenum. In contrast, the distal stomach is responsible for the grinding and 
propulsive motion required to empty solids (Grill et al., 1985). There are no 
contractions of the stomach to propel solids during the first few days of life 
(Heyman, 1998) and hence gastric emptying can be delayed immediately 
after birth in both term and preterm infants (McLeod et al., 1992). In adults, 
one of reasons for the use of multiparticulates is to circumvent the need for 
the MMC stage III (housekeeping wave) as shown in Figure 1-10 for 
emptying into the intestine. Information related to the limiting size of particles 
for pyloric passage in various ages of children would be of great interest to 
see if which sizes empty more like liquids in different aged children. 
 
Scintigraphy showed that gastric emptying of milk was slower in premature 
infants born at a gestational age of less than thirty two weeks but in older 
preterm and term infants, the emptying time was the same.  A similar pattern 
of reduced gastric emptying time was also seen using ultrasound in patients 
born at 26 weeks gestational age and followed through until 32 weeks. 
Gastric emptying time of milk further decreases until it reached adult values 
by around six to eight months of age as commonly reported in textbooks 
since the 1960s (Heimann, 1980). 
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1.6.3. Gastric pH 
 
The pH in the gastro-intestinal tract varies from around 1 in the stomach to 7 
or 8 in the large intestine. Environmental pH can influence the ionisation hence 
absorption of drugs and is also important for the passage of enteric coated 
dosage forms as the enteric-coating polymer (cellulose acid phthalate, 
ethylcellulose and some methacrylic acid co-polymers) must not be soluble in 
the acidic environment of the stomach, usually to protect either the stomach 
from the drug or vice versa, but must be soluble in the higher pH of the 
intestine to allow drug absorption. 
 
A summary of the changes in gastric pH is shown in Figure 1-11. Generally, 
the gastric pH is rather neutral in neonates and then drops to acidic values 
over the first two years of life as acid secretion and feeding develop. For 
example gastric pH measured three to four minutes post birth ranged from 
1.4 to 7.8 (with a pH above seven being observed in all patients born before 
34 weeks) (Miclat et al., 1978). This alkaline pH is due to the presence of 
amniotic fluid (pH 6.9 – 7.9). It became acidic after removal of the gastric 
contents and drops to 2.2 (on average) 5 to 6 hours later (Ebers et al., 1956). 
There was a general trend of increasing pH from 1 to 3 hours, followed by an 
increase at 4 hours which is no longer seen by 24 hours of age (Avery et al., 
1966). Even preterm infants from 24 weeks of gestation were able to 
maintain pH below 4 when measured during their first 6 to 12 hours of life 
although the proportion of time the gastric pH is below 4, 3 or 2 were all less 
than in adults and correlate with the post delivery age (Sandheimer et al., 
1985) Lower gestational age premature infants were seen to have higher 
gastric acid values (especially within the first 3 days of life) (Kelly et al., 
1993). These pH values were seen to slightly rise but then have decreased 
again by day 17, with all infants having a median pH between 1.3 and 2.3 by 
their third week of life. 
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Figure 1-11: Fasted gastric pH changes with age and its effect on drug absorption 
(provided by S.D. Krämer, ETH Zurich, CH, adapted from Bartelink et al., 2006, 
Fackler et al., 2001) This graph shows the high pH at birth resulting from the alkaline 
amniotic fluid present in the neonates stomach at birth so the pH drops as this is 
removed – as milk feeding is established the Ph again increases due to the buffering 
effect of milk and by two years of age, acidic secretion is becoming more developed 
so is able to keep the gastric pH lower like in adults 
 
In adults, average values are available for many  gastro-intestinal variables 
including  fasted free stomach volume (45±18 ml), acid output (6-40 
mEq/hour), gastric pH (1.0-2.5) and small intestinal transit time (3-4 h) as 
discussed elsewhere (McConnell et al., 2008). The maximal acid output is 
similar to that of adults at 0.2 mEq/h/kg of body weight by 6 months of age 
hence is always quoted as the time at which gastric acid secretion reaches 
adult values (Boyle, 2003). This does not however mean that gastric pH 
profiles are the same. On continuous pH monitoring, adults maintain their 
gastric pH below two for around 65 % of time whereas for a group of children, 
a similar percentage of time below pH 2 was not achieved until around 14 
years (Nagita et al., 1996). The gastric acidity profile hence changes rapidly 
through infancy to 3 years old and then more slowly until it reaches adult 
values around 13 to 14 years old. Variations in pH amongst children under 2 
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or 3 are especially relevant when developing pH-sensitive multi-particulate 
formulations. The effects of gastric pH are further pronounced when gastric 
residence time is prolonged and depending upon the characteristics of the 
drug e.g. the pKa, solubility profile etc. 
 
1.6.4. Gastric Volume 
 
Fasted gastric volume increases with age and is frequently reported in the 
units of ml/kg (Cook-Sather et al., 2003). Difficulties in determining the age at 
which it meets adult values stem from the different fasting and sampling 
conditions. From one of the trials, an interesting effect was seen with 
temazepam elixir as a premedication (Meakin et al., 1987) The elixir was 
seen to significantly increase both gastric volume and pH which was not seen 
with temazepam capsules although the age of the capsule group was higher 
with a mean age of 9.1 years versus 6.6 years in the elixir group due to 
swallowing issues in younger children. This increase in gastric volume and 
pH are thought to be due to the composition of the elixir vehicle (Ethanol 9 %, 
Sorbitol 45 % and Glycerol 50 %). Glycerol is an irritant which stimulates 
mucus secretion and both glycerol and sorbitol have osmotic properties 
which can cause the influx of water into the stomach. Both mechanisms 
dilute and increase the volume of the stomach contents. Due to the 
mechanism of action, these effects will also occur in adults or older children 
and it is simply the ratio of dose volume to stomach content volume that 
renders them more significant in young children.  Hence it is not the 
excipients per se that are the issue, just their use level.  The elixir is an adult 
formulation containing ethanol and this example serves as a reminder of the 
problems of using adult formulations in paediatrics without due thought.  
 
1.6.5. Small Intestinal pH 
 
A radio-transmitting pH capsule (24 mm by 7 mm) was used to determine the 
time taken to pass through the gut and pH at various points in fasting patients 
(Fallingborg et al., 1990). This technique gave useful information about the 
conditions throughout the gastrointestinal tract but due to the large size of 
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capsule could only be used in older children. Twelve healthy 8 – 14 year olds 
(median age 12 years) were found to have a mean gastric pH of 1.5. The pH 
became more alkaline (6.4) in the duodenum up to 7.4 in the distal region of 
the small intestine before reaching 5.9 in the caecum. These pH values were 
similar to those found in adults. Similar values of small intestinal pH 
determined by aspiration have also been seen in children ranging from 
neonates to adolescents (Mean pH 6-7.8) (Ellett, 2004).  
 
1.6.6. Intestinal Transit 
 
There is lack of information on the developmental aspects of intestinal transit 
which ideally would be needed in the development of age appropriate 
formulations to determine fully how the intestinal transit of dosage forms may 
differ at different ages. The rhythmic activity of the intestine increased with 
gestational age with disorganised activity from 25 to 33 weeks giving way to 
a propagating MMC and eventually mature interdigestive motility at full-term 
(Commare and Tappenden, 2007). The choice of test to determine intestinal 
transit can be dependent upon age: there is a risk of harm by younger infants 
or neonates attempting to swallow pellets and lactose 13C Ureide test is 
unsuitable in infants less than 8 months as they lack the enzyme required to 
metabolise it (Van Den Driessche et al., 2000).  Hence most of the time 
carmine dye is used as it is easy to administer and appears to be well 
tolerated in all age groups but it only gives the time taken for the dye to 
transit from the mouth to excretion in the faeces.  
 
Lactulose-Hydrogen breath tests which measure oral-to-caecal transit time 
and hence remove the long colonic transit phase were found to have a transit 
time of 80 to 90 minutes on average in patients aged from 1 to 5 years old 
(Myo-Khin et al., 1999). However, lactulose increased the intestinal motility 
through its osmotic effects as was seen by the greater time of 255 minutes 
using the lactose 13C Ureide test in children aged from 3 to 17 years (Van 
Den Driessche et al., 2000). 
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Pre-term infants generally have longer intestinal transit times than infants 
born at term. The intestinal transit time of a pre-term infant decreases with 
enteral feeding (milk) and on increasing gestational age (Berseth, 1990). 
Despite the fact the intestine grows, the issue of when intestinal transit time 
reaches adult values is less clear. No difference in intestinal transit time were 
found in children aged from 2 months to 3 years versus 3 to 12 years (with 
large pellets of 5 mm which were swallowed with milk having an average 
whole gut transit time of 23.7±3.08 hours and 25.4±3.7 hours respectively) 
nor when children grouped by year from age 1 to 5 years were investigated 
using a breath test.(Myo-Khin et al., 1999, Corazziari et al., 1985). A 
standard time of normal transit is often used in constipation studies. It is 
defined as when a radioactive tracer reaches the caecum within 6 hours and 
is largely excreted within 24 hours (Clarke et al., 2009). Other data seemed 
to also support a whole-gut-transit-time of carmine somewhere between 12 
and 48 hours as normal in children aged 3 to 13 years (Dimson, 1970). 
 
Pellets have the advantage that they can be detected throughout the child’s 
stool so that they can be reported as a range unlike carmine which can only be 
reported as the first appearance of red stool. When children less than 3 years 
old were tested with cuboids pellets (2.7-3 mm) and carmine dye, the time to 
first red stool and first appearance of pellets were similar (17.5 hours versus 
19.7 hours respectively) and in the majority of children occurred in the same 
stool. However this was not the case for patients suffering from diarrhoea 
where there appeared to be sequestering of pellets in the bowel and the 
carmine streaming into the liquid phase (Higgs et al., 1975). Similar mean 
transit times of pellets (diameter 5 mm) were seen in older children (up to 12 
years old) (Corazziari et al., 1985). Transit of non disintegrating solids seems 
to be affected by size and smaller particles (3- 5 mm) seemed to behave more 
like liquids and semisolids than larger objects (20 mm). This pattern is similar 
in adults. The gastro-intestinal influences on multiparticulates is summarised in 
Figure 1-12. It can be summarised that there is still a lot that we don’t know 
about the transit of multiparticulate dosage forms: this lack of knowledge would 
have become more important had the work progressed on from taste masking 
to modified release multiparticulates. 
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Figure 1-12: Summary of Gastrointestinal Influences on Multiparticulates 
 
To summarise, multiparticulates offer a range of advantages for a dosage form 
for children including ease of swallowing, dose flexibility, chemical stability and 
increased excipient tolerability and the potential for functionalised delivery 
such as taste masking or controlled release in a uniform platform formulation. 
Multiparticulates can be administered by compaction into tablets which 
removes their swallowability, as a sprinkle with food or in a suspension which 
was the chosen form. Spray drying without organic solvents is a production 
method that produces multiparticulates that have a small size to be able to 
suspend and is industrially scaleupable.  
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1.7. AIMS AND OBJECTIVES 
1.7.1. Aims 
This project aims to prepare a universal platform formulation which contains 
functionalized microparticles in suspension, through aqueous spray-drying. 
Functionalised may be any functionality so includes taste masking as well as 
modified release. Table 1-10 proposes the product specification for the 
formulation from both the children and young people perspective and industry 
needs perspectives. It is proposed to develop this platform by aqueous spray 
drying of Eudragit® E PO with quinine and salt as model drugs. 
 
Table 1-10: Product Specification 
Consideration Specifications Minimum Advantage Disadvantage 
Patient 
Needs 
Stability Stable in liquid 
for 7 days 
Stable in 
Liquid for 
one month 
Stable in liquid for 
30 minutes 
(presented as a 
powder for  
dispersion) 
 Particle Size 
 
Acceptable 
grittiness  
- Slightly gritty if 
other specification 
met (washed down 
with  water) 
 Shape Spherical - Spherical but big 
 Drug Loading Polymer: Drug 
5:1 
More drug 
than 
polymer 
Polymer: Drug 
10:1 
 Density Self-suspending 
and not floating 
on the surface 
Disperses 
in any 
media  
Sediments but 
redisperses easily  
 Release 
Profile 
Taste Masking Controlled 
release for 
anything  
- 
Industry 
Needs 
Yield 50% 100% 30% but all other 
specifications met 
 Cost Considered in 
all ingredients 
and techniques 
- - 
 Solvents Minimal Organic 
Solvents (Class 
I)  
No 
organic 
solvents  
Organic solvents 
of a high ICH value 
used 
 Reproducibility Results 
reproducible 
(n=3) 
- - 
 Scale Up Large Scale - - 
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1.7.2. Objectives 
 
1. To investigate the influence of particle size and concentration 
characteristics in relation with  suspending media viscosity on the 
suspendability of  particles and grittiness/ acceptability of the resulting 
suspension 
 
2. To produce functionalized multiparticulates and suspensions 
 
3. To optimise the method of production by investigating the effect of  
different operating parameters/excipient levels on the multiparticulates 
characteristics and their behavior in suspension 
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2. SUSPENSION CHARACTERISATION 
 
2.1. Background 
 
2.1.1. Suspension Overview 
 
Multiparticulate dosage forms can be administered in capsules, sprinkled 
onto food or in the form of a suspension as discussed in Section 1.5. As 
examined in Chapter 1, liquids remain one of the most popular dosage forms 
for younger children because they can cater for a large variability of doses 
required in a growing child without any problems in swallowing and require 
less manipulation which has been associated with medication  errors and 
adverse events. As this research is attempting to make functionalised 
multiparticulates in a suspension platform, this section is about 
considerations in vehicle development, through examining some of those 
suspending vehicles commonly used in children at present, for the particles 
produced in Chapter 4. 
 
A suspension is defined as a dispersion of finely divided, insoluble solid 
particles (the disperse phase) in a fluid (the dispersion media or continuous 
phase) (Billany, 2007). Suspensions are commonly used due to their ease of 
swallowing, for hydrophobic drugs and to attempt to reduce the bad taste of 
medicines by reducing contact with the taste buds as described in Chapter 1. 
Despite these benefits of suspensions, they are not without their technical 
challenges of chemical, physical and microbiological stability of the dosage 
form with the impact on the physical properties of the suspending vehicle the 
main focus of this section. 
 
Suspension formulations often contain many different classes of excipients 
as summarised in Table 2-1 to try to overcome these various instabilities. As 
discussed in Chapter 1, liquid dosage forms require many different excipients 
and in higher levels compared to solid dosage forms: one of the reasons to 
use multiparticulate dosage forms to try to reduce this.  
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Table 2-1: Summary of Common Excipients Found in Suspensions and their 
Functions (Moreton, 2010, Billany, 2007) 
Excipient Function 
Thickening/Suspending 
agent 
Increases viscosity to increase physical stability 
e.g. tragacanth, alginates, xanthan gum, HPMC, 
MC, CMC, colloidal silica 
Density Modifier 
Reduces the difference in density between the 
particles and suspending media e.g. glycerol, 
sucrose, sorbitol 
Flocculating agent 
Causes flocculation of particles to increase 
physical stability e.g. surfactants, alginates, 
cellulosics, tragacanth, carbomers 
Wetting agent 
Helps disperse particles in the suspending media 
e.g. tweens, spans, cellulosics, xanthan, solvents 
Buffer 
Keeps the suspension at the desired pH range 
e.g. carbonates, citrates and phosphates 
Osmotic agent 
Keeps the suspension at the desired osmotic 
pressure  (often maintain similar to biological 
fluid) e.g. dextrose, sodium chloride 
Preservative 
Prevents microbial instability e.g. benzoic/sorbic 
acids and their salts, hydroxybenzoates and 
derivatives 
Antioxidant 
Prevents oxidation and hence instability e.g. 
ascorbic acid, sodium metabisulphate 
Flavour 
Improves the taste of the suspension e.g.  natural 
such as orange water or synthetic esters (cherry 
= ethyl aceto acetate) 
Sweetener 
Improves the taste of the suspension e.g.  
sucrose, sorbitol, syrup, aspartame 
Colourant 
Makes the suspension look elegant/aids in 
identification and can complement the flavour 
e.g. caramel, carmine, carrots (yellow) 
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The physical properties of a well-formulated suspension have been defined 
previously as (Marriott, 2007): 
- The suspension must remain sufficiently homogenous for a suitable 
period of time (at least for the period between shaking the suspension 
and removing the required dose) 
- Any sedimentation that occurs on storage must be easily 
resuspendable following moderate shaking of the container (the 
suspension may require controlled flocculation to achieve this) 
- If the settling rate of the disperse phase needs to be reduced, the 
continuous phase can be thickened but must not become so viscous 
that removal from the container is difficult.  
 
The determination of the flow or rheological characteristics of the suspending 
vehicle are hence very important to these physical properties of keeping the 
drug uniform in suspension and hence physical stability. Flow measurements 
are based on the principle that increasing the stress (σ) applied to a liquid 
will increase the flow of the liquid (γ) and that the proportionality between the 
two is the viscosity (ŋ) as shown in Equation 2-1. 
 
Equation 2-1: Viscosity 
 
Ŋ = σ/γ 
 
ŋ = Viscosity (Pa.s) 
   σ =  Shear Stress (Pa) 
   γ =  Shear Rate (s-1) 
  
Where the viscosity is constant over different shear rates, the liquid is said to 
be Newtonian. From the above desired suspension physical characteristics, 
it can be seen that it may be beneficial for the continuous phase to show 
thixotropic pseudoplastic (shear-thinning) behaviour as illustrated in Figure 
2-1. Pseudoplastic liquids show their apparent viscosity decrease on 
application of increasing shear rate until the minimum apparent viscosity has 
been reached, where the viscosity does not decrease any further despite 
increasing the shear rate. A similar phenomenon happens in thixotropic 
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liquids but when the shear rate is no longer applied, there is a lag period 
before the viscosity increases again. In terms of suspensions this is desirable 
as the suspension will be thick whilst sitting, become thinner on shaking so 
that during the lag time this thinner suspension can be poured but then re-
thicken again for physical stability during storage until the next time a dose is 
required. 
 
This shear-thinning behaviour is a phenomenon of long, high molecular 
weight molecules such as polymers in solution (Florence and Attwood, 
2006). At low shear stress, these molecules are entangled and contain 
entrapped solvent. As the shear rate increases these molecules become 
untangled and aligned in the direction of shear stress, releasing the 
entrapped solvent. This makes it easier for the molecules to move and hence 
reduce the apparent viscosity. The chains become entangled again following 
a reduction in shear rate. Materials which exhibit this type of flow include 
gums such as guar and xanthan, clays, tragacanth, methylcellulose, 
carmellose, PVP and polyacrylic acid (Marriott, 2007) 
 
 
Figure 2-1: Examples of how Viscosity Differs with Shear Rate in Newtonian, 
Thixotropic and Pseudoplastic Flow 
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2.1.2. Suspension Stability 
 
By virtue of existing of two phases (solid particles and liquid), suspensions 
can be inherently unstable with some of the types summarised in Table 2-2 
and illustrated in Figure 2-2 If any of these types of instability occur, the child 
we are trying to formulate for will not get the uniform dose that they require 
which may lead to either under dosing or overdosing so it is important that 
these are minimized. 
 
Table 2-2: Summary of Physical Instability  
Types of Physical Instability Description 
Flocculation/Aggregation Loose association of particles 
Sedimentation Particles settling to the bottom 
Caking Sedimentation where the particles 
cannot be redispersed easily 
Particle Growth Caused by dissolution and 
recrystallisation 
Creaming Floating of poorly wetted material 
on the surface of the suspension 
 
 
Figure 2-2: Diagram Illustrating (from left to right) a stable suspension, one which 
has sedimented and one where the particles have creamed 
 
It can be seen that while the suspending media is important for stability the 
interplay with the particles in terms of their properties e.g. for sedimentation 
and wetting is equally important. Sedimentation of particles in a suspension 
is often described by Stokes Law in Equation 2-2.  
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Equation 2-2: Stokes Law 
 
V = gr2( 1 – 2 ) 
                                                              9η 
 
V = Rate of sedimentation (m/s) 
g = Gravitational Acceleration (m/s2) 
r = Sphere radius (m) 
1 = Density of continuous phase (kg/m
3) 
2 = Density of disperse phase (kg/m
3) 
η = Viscosity of continuous phase (Pa) 
 
Stokes Law provides a simplistic assessment of sedimentation based on 
ideal, spherical, non interacting particles moving only in a laminar flow 
pattern which may not always be applicable to the real life situation of a 
pharmaceutical suspension. In spite of this it shows the importance of 
particle size and particle/suspending media density and viscosity on 
sedimentation with smaller, less dense disperse phase particles sedimenting 
more slowly especially in higher viscosities. However simplistic, the theory of 
Stokes Law may be important in that more viscous suspending agents or a 
denser suspending vehicle/ less dense particles may enable the suspension 
of larger multiparticulates.  
 
The surface properties of the disperse phase should also be considered 
since good wettability, appropriate charge and a narrow particle size 
distribution are helpful for physical stability.  Ostwald ripening is a potential 
cause of suspension instability where smaller particles dissolve and deposit 
on larger particles in suspension where there is a non uniform particle size 
leading to particle size growth and hence faster sedimentation. Ostwald 
ripening is less likely to be of concern where there is a narrow size range and 
slow dissolution rate, as is likely to be the case for the functionalized 
microparticles we aim to produce (Yao et al., 1993).  
 
Formulating functionalized multi-particulates into a suspension may be 
challenging for a number of reasons. Diffusion/release of the drug into the 
suspending media and interactions between the continuous phase and 
microparticles must be avoided in order to maintain reproducible drug 
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release. Water-soluble polymers swell and gel in contact with water leading 
to the diffusion of drug through the gel whilst hydrophobic water insoluble 
polymers may allow drug release either through pores or by diffusion through 
the polymer. In addition to the issue of avoiding premature drug release, 
functionalised multiparticulates will be larger than non coated drug particles 
so may be difficult to disperse or suspend as shown in Figure 2-3 especially 
as there may be problems with wetting of the polymers or agglomeration due 
to ‘sticky” polymers in contact with water. 
 
 
Figure 2-3: A diagram illustrating (from left to right) a stable suspension of drug 
particles, one with drug containing multiparticulates and the sedimentation likely to 
occur with multiparticulates which are larger than drug particles 
 
Chemical stability problems in suspensions are often overcome by 
minimising the contact between the disperse and continuous phase by 
formulating a dry formulation for reconstitution which can be made up 
immediately prior to patient issue which has a shelf life of up to around seven 
to fourteen days in commercial products. Difficulties may arise in applying 
this approach to suspensions containing functionalised microparticles due to 
the necessity for the microparticles to remain completely unchanged on 
drying/further formulation and subsequent reconstitution. It is important in a 
suspension containing microparticles that the microparticles themselves 
remain unchanged otherwise this would remove the functionality (e.g. taste 
masking or modified release) intended to be achieved in an end product for 
administration. The functionalised multiparticulates by virtue of being 
hydrophobic are likely to be difficult to wet in aqueous formulation so 
wettability may be a problem. 
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The assessment of the stability of suspensions is complex. In a brief 
overview common methods are presented below (Kulshreshtha et al., 2010, 
Nielloud and Marti-Mestres, 2000, Streng, 1985) 
1. Sedimentation volume is defined as the ratio of the equilibrium settled 
height to the original height  
2. Redispersability measured as the number of rotations required to 
restore the suspension to homogeneity 
3. Content uniformity of the drug/excipients 
4. Viscosity/Flow Curves (Rheology)  
5. Zeta Potential Determination 
6. pH Testing 
7. Microscopic Evaluation of Appearance 
8. Degree of Flocculation 
The degree of flocculation is estimated by comparing the 
sedimentation volume of the flocculated suspension to that of the 
suspension when deflocculated 
9. Stability Testing 
a. Freeze/Thaw Cycles  
Freeze/thaw cycles are where the physical and microscopic 
changes of suspensions which undergo a sudden temperature 
change are investigated. This can be achieved by keeping 
suspensions in a 40 °C oven for twenty four hours and then 
transferring them to a freezer at 0 °C for twenty four hours. 
b. Normal Temperature Fluctuation 
Normal Temperature Fluctuation is where the physical and 
microscopic changes of suspensions which undergo a gradual 
temperature change are investigated. Gradually decreasing the 
temperature from 40 to –5 °C and keeping the suspensions at 
each temperature for twenty-four hours can achieve this which 
could aid assessment for Ostwald ripening or polymer 
instability. 
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10. Microbial Stability 
Preservatives may be required in multidose preparations where the drug 
itself does not have anti-microbial activity especially in those suspensions 
that contain aqueous phases although in terms of minimizing excipients in 
paediatrics, single unpreserved dose formulations may be preferable 
(Breitkreutz and Boos, 2007a). The efficacy of an antimicrobial 
preservative may be enhanced or diminished by chemical interaction with 
the drug, excipients or container. Test for efficacy of anti-microbial 
preservation is by challenging the formulation with a variety of test 
organisms, namely Pseudomonas aeruginosa, Staphlyococcus aureus, 
Candida albicans and aspergillus niger) (British Pharmacopeia, 2012). 
The inoculated suspension is then stored at 20 to 25 oC. For the 
preservation to be effective, there should be a log reduction of three for 
the number of viable bacteria and one for the number of viable fungi 
found in the oral preparation at day fourteen compared with a control.  
There should be no-increase at day twenty eight for either type of 
microorganism. Preparations for oral administration should not contain 
more than 103 bacteria or 102 fungi per gram or millilitre and should be 
absent of Escherichia coli. 
 
In terms of experiments carried out in this chapter, macroscopic appearance 
as a measure of the content of larger particles, rheology, pH and density 
were characterised. Chemical and microbiological testing was not 
undertaken as no suitable formulation was achieved that would have 
required this. 
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2.1.3. Commonly Used Suspending Media 
 
In order to administer a suspension/dispersion to a child, there can be largely 
thought of as three different types of suspending vehicles (Electronic 
Medicines Compendium, n.d.): 
 
1. A prepared suspension or powders/granules for reconstitution 
produced and sold by pharmaceutical companies such as 
amoxicillin liquid for reconstitution or paracetamol suspension 
2. An extemporaneous preparation at the pharmacy of a 
drug/crushed dosage form in a commercial vehicle or prepared 
media  
3. Soft food recommended for dosage forms to be sprinkled on such 
as yoghurt or apple sauce such as pancreatin formulations or 
Epilim Chronospheres® (sodium valproate/valproic acid) 
 
Relatively few oral ready to use suspensions and powder/granules for 
reconstitution exist – possibly due to the difficulties in formulating a stable 
suspension which is essentially for a reproducible dose. Those which do 
exist commonly use xanthan or guar gum, cellulosic derivatives, sugar/sugar 
substitute syrups, glycerol and colloidal silica (Electronic Medicines 
Compendium, n.d.). 
 
Due to the historical lack of research into formulations for children as 
discussed in Chapter 1, extemporaneous dispensing still occurs despite the 
unlicensed status of the dosage form. While the onus is on the dispensing 
pharmacist to ensure that the dosage form is stable and fit for purpose, 
reports as to the quality and stability are variable ranging from no reported 
stability data through to validated formulations that are supported by industry 
such as the administration of Tamiflu® in Cherry Syrup, OraSweet® SF or 
Simple Syrup in an emergency (Genentech, n.d., Giam and McLachlan, 
2008, Kairuz et al., 2007, Nahata and Allen, 2008).  
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An overview of suspending vehicles used in extemporaneous dispensing or 
compounding is provided in Table 2-3. As highlighted in bold in Table 2-3, 
many of the suspending vehicles are based on syrup just with different 
flavours.  While having a sugary, flavoured vehicle may improve compliance 
through its pleasant and culturally acceptable taste, a vehicle containing 
predominantly sucrose is not without its issues including the potential for 
dental caries, calorific concerns, the requirement for a preservative and a 
high osmolality. Although syrup is used as a suspending vehicle, alone it 
may lack some of the properties of an ideal suspension as detailed above in 
that although it is a viscous vehicle of higher density, it has little/no shear 
thinning potential and thixotropic nature. 
 
Table 2-3: Summary of the Suspending Vehicles used in Compounding/ 
Extemporaneous Dispensing with bold highlighting a syrup and red highlighting 
commercial suspending vehicles (Compounding Today, n.d.) 
Suspending Vehicles Used in Compounding 
Acacia Syrup 
Cherry Syrup 
Cocoa Syrup 
Glycyrrhiza Syrup 
Isoalcoholic Elixir, Low 
Ora-Plus® Oral 
Suspending Vehicle 
Orange Flower Water 
Raspberry Syrup 
Sugar-free Suspension 
Structured Vehicle  
SyrSpend SF 
Vehicle for Oral Solution  
Wild Cherry Syrup 
Aromatic Elixir USP 
Citric Acid Syrup 
Compound Benzaldehyde 
Elixir NF 
Hydriodic Acid Syrup 
Ora Blend® Flavored 
Suspending Vehicle 
Ora-Sweet Sugar-Free 
(SF) Syrup Vehicle® 
Orange Syrup NF 
Sarsaparilla Compound 
Syrup 
Suspension Structured 
Vehicle USP 
Syrup NF 
Vehicle for Oral Solution, 
Sugar Free NF 
Xanthan Gum Solution NF 
 Aromatic Eriodictyon 
Syrup 
Coca-Cola Syrup 
Glycyrrhiza Elixir 
Isoalcoholic Elixir, High 
Ora-Blend Sugar-free 
(SF) Flavored 
Suspending Vehicle 
Ora-Sweet Syrup 
Vehicle® 
Peppermint Water NF 
Sorbitol Solution USP 
Syrpalta 
Tolu Balsam Syrup NF 
Vehicle for Oral 
Suspension NF 
 
From Table 2-3, it can be seen that there are relatively few commercial 
vehicles but they are extensively used in the extemporaneous dispensing of 
medicines. Commercial vehicles are used due to their ready to use nature 
providing ease of use without individual decisions having to be made about 
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such criteria as microbial stability and combinations of sweeteners/flavours to 
use. In commercially used suspending vehicles, stability data may be 
available from the company about various drugs. Some of their drawbacks 
include availability outside the United States and cost. Some of the most 
commonly used commercially available suspension vehicles are described in 
Table 2-4. e.g. 
 
 OraBlend® is a 50:50 mixture of the suspending agent (containing 
suspending polymers), OraPlus®, and the syrup vehicle, OraSweet®. 
Orablend® is marketed as the all in one flavouring and suspending 
agent (Paddock Laboratories Inc, n.d.) 
 SyrSpend® SF is marketed as being free from the laxative effects 
associated with sorbitol and has a low osmolality (< 50 mOsmol) 
which may mean less gastro-intestinal upset (Fagron, n.d,) 
 Versa Free® and Versa Plus® systems are marketed as unique in 
that they contain no parabens, dyes or sweeteners (Compounding 
Today, n.d.) 
 
It can be seen from Table 2-4 that the suspending media all contain similar 
types of excipient such as a viscosity enhancer, sweeteners (with the 
exception of Versa plus), buffering agents and preservatives. This 
formulations are similar to commercially prepared suspensions in 
composition and largely marketed as shear thinning/thixotropic (no 
information found for Versa®) 
 
The choice of suspending vehicle is important not only for ensuring physical 
stability but also as the taste may improve compliance, especially in bitter 
tasting medicines, and the texture should also feel pleasant, which may allow 
a larger volume of large particles in the disperse phase to be taken.  
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Table 2-4: Composition of Commercial Suspension Vehicles where red represents 
viscosity enhancers, blue sweeteners and flavouring agents, green buffers and 
purple preservatives. The concentration of each component is not publically 
available as these are commercial media 
 Ora-
Plus® 
Ora-
Sweet® 
Ora-
Sweet 
SF® 
Ora-
Blend® 
Ora-
Blend 
SF® 
SyrSpend 
SF® 
Versa 
Plus® 
Versa 
Free® 
Microcrystalline 
cellulose 
+ - - + + - + - 
Sodium CMC + - - + + - + - 
Xanthan gum + - + + + - + + 
Carrageenan + - - + + - + - 
Modified Food 
Starch 
- - - - - + - - 
Sucrose - + - + - - - - 
Glycerol - + + + + - - + 
Sorbitol - + + + + - - + 
Sodium 
saccharin 
- - + - + - - - 
Neotame - - - - - - - + 
Sodium 
Benzoate 
- - - - - + + + 
Sucralose - - - - - + - - 
Malic acid - - - - - + - - 
Flavouring agent - + + + + +/- - - 
Citric acid + + + + + + + + 
Sodium 
phosphate 
+ + - + + - + - 
Sodium citrate - - + - + + - + 
Methylparaben + + + + + - - - 
Propylparaben - - + - + - - - 
Potassium 
sorbate 
+ + + + + - + + 
Simethicone + - - + + + - - 
Purified water + + + + + + + + 
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Commonly used suspending media that were obtainable were assessed for 
their suitability as a vehicle for the taste masked particles discussed in 
Chapter 4. These included commercial media and others commonly used: 
 
 the Ora- suspending vehicles are the most commonly used so 
OraPlus®, OraSweet®, OraSweet® SF,  OraSweet®:OraPlus® blend 
1:1 (similar to OraBlend® ) and OraSweet SF®:OraPlus® blend 1:1 
(similar to OraBlend® SF) 
 SyrSpend®.   
 Methylcellulose (MC) and hydroxypropyl methylcellulose (HPMC) 
obtained from a Paediatric Extemporaneous Formulary (Nahata and 
Hipple, 2003). 
 Other known combinations e.g. syrup/MC and glycerol/MC 
  
Sprinkling medicines onto food is a pragmatic approach to trying to 
administer larger than individual drug particles to children and is being more 
and more accepted even by regulatory authorities as was seen by the 
commercially available multiparticulates in Chapter 1. The most commonly 
recommended soft foods for administration of medicines are apple sauce 
and yoghurt therefore these foods were additionally included for 
characterisation (Electronic Medicines Compendium, n.d.). 
 
In the suspendability experiments, microcrystalline cellulose pellets 
(Cellets®) were used as they are spherical inert particles available in a 
variety of narrow size distributions and as they contain no drug/only 
microcrystalline cellulose and water so could be administered as part of the 
grittiness trial in Chapter 3 safely. Cellets are a model hydrophobic larger 
particle so in a sense were useful to look at the suspendability of larger 
particles of narrow distributions but are likely to differ in hardness, 
morphology and from those particles produced by spray drying in Chapter 4 
density (with the particles produced by spray drying being softer/more 
deformable, less dense and less spherical) - hence only general 
assumptions can be made in trying to make a uniform suspension of larger 
particles. 
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This chapter aimed to investigate commonly used suspending vehicles to 
find the most suitable vehicle for the suspendability and grittiness testing of 
particles. This investigation was largely in terms of rheology since the 
rheology of a vehicle will differ depending on the sample 
preparation/handling and parameters chosen for the test (e.g. type of 
rheology test, forces used, sample volume, geometry, type of 
rheometer/viscometer used) so assessing all the candidate suspending 
vehicles using the same methods a more robust comparison than trying to 
compare vehicles from the literature which have been assessed under 
different conditions. 
 
2.2. Materials and Methods 
 
2.2.1. Materials 
Ora-Plus, Ora-Sweet and Ora-Sweet SF vehicles were obtained from 
Paddock Laboratories Inc, Mineapolis, USA and Syrup BP from William 
Ranson and Son plc, Hertfordshire, UK. SyrSpend SF was obtained from 
Gallipot Inc, Mineapolis, USA. Methylcellulose (400cP at 2% solution and 
25C) with structure as shown in Figure 2-4  and Glycerol (99.5%) were 
obtained from Sigma Aldrich, Germany. Hydroxypropyl methylcellulose 
((HPMC) 4000cP, substitution type 2906, grade 65SH-400) was from 
Shinetsu Chemical Company Ltd, Japan and Cellets® (Microcrystalline 
Cellulose Pellets) from Pharmatrans Sanaq, Switzerland.  
 
Vanilla mullerlight yoghurt (Molkerei Alois Müller GmbH & Co. KG, Germany) 
and Apple sauce (Tesco Value, Tesco, Cheshunt) were used. These were 
included as they are the most commonly recommended soft foods for  the 
administration of medicines (Electronic Medicines Compendium, n.d.). The 
apple sauce contained water, apples, sugar, modified maize starch, citric 
acid, antioxidant (ascorbic acid), preservative (sodium sorbate) and 
sweeteners (acesulfame K and aspartame). The yoghurt used contained 
“yoghurt”, water, fructose, modified maize starch, gelatin, flavourings, 
stabiliser (pectins), colour (carotenes) and sweetener (aspartame) 
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Figure 2-4: Structure of Cellulosic Polymers Where R is H, CH3, or CH3CH(OH)CH2 
for HPMC, H or CH3 for Methylcellulose 
 
 
2.2.2. Methods 
 
2.2.2.1. Media Preparation 
 
The materials which were used for pH and rheology measurements without 
modification were Ora-Plus, Ora-Sweet, Ora-Sweet SF, Syrup BP, SyrSpend 
SF, glycerol and yoghurt. In addition, mixtures were prepared of Ora-Plus 
and Ora-Sweet or Ora-Sweet SF (1:1), Syrup BP: Methylcellulose 1 % (1:1) 
and Glycerol: Methylcellulose 1 % (2:5). All of these mixtures were made at 
least three times. 
 
Aqueous solutions of methylcellulose and HPMC (0.1 to 10 %) were 
prepared. Methylcellulose solutions were made by adding methylcellulose to 
boiling distilled water, standing them on heat for fifteen minutes then making 
up to volume with cold water whilst stirring. Hydroxypropyl methylcellulose 
solutions were prepared by adding HPMC to boiling water with vigorous 
mixing until homogenous when iced water was added before the HPMC 
solutions were autoclaved at 121 °C for 20 minutes. The HPMC solutions 
were autoclaved as aqueous solutions of HPMC can be prone to microbial 
spoilage. A preservative could be added to the media if this was required. 
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2.2.2.2. pH 
The pH of all suspending media was measured three times using a pH meter 
(Hanna Instruments pH 211 microprocessor) after calibration with buffers at 
pH 4 and pH 7. 
 
2.2.2.3. Osmolality  
Osmolality refers to the solute concentration and is measured in osmoles per 
litre. There are a number of techniques which can be used to assess 
osmolality: the technique used was measurement of freezing point 
depression as shown in Figure 2-5. Osmotically active compounds depress 
the freezing point of a solution so the aqueous solution is cooled below the 
freezing point of pure water and cooling needle applied in the supercooled 
state which causes ice to form and fuse. The temperature of the aqueous 
solution increases until a constant temperature and the difference between 
this temperature and the freezing point of water is the freezing point 
depression which is a measure of the osmotic concentration. Distilled water 
is used in calibration since it freezes at 0°C with an osmolality of 0 Osmol/L 
as is sodium chloride 0.9% w/v with an osmolality of 300mOsmol/L. The 
osmolality of the samples was measured three times using a standard Micro 
Osmometer (Type 5R, Roebling, Camlab). 
 
Figure 2-5: Representation of Freezing Point Depression Method of Assessing 
Osmolality 
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2.2.2.4. Density 
The initial bulk and tapped density of microcrystalline cellulose pellets 
(Cellets®) were measured three times using a Copley Tap Density 
Volumeter as described in the Pharmacopeia. Briefly, around 100 g of the 
different sizes of Cellets® were poured into a 100 ml measuring cylinder at 
an angle of 45 ° with the initial volume and mass used noted. The cylinder 
was then tapped at intervals as defined below in Table 2-5 with the volume 
measured after each set of taps. If difference between the volume measured 
at 750 and 1250 taps was less than 2 %, the volume at 1250 taps was taken 
to be the tapped volume. If the difference was greater than 2 %, further 
intervals of 1250 taps were continued until a final, stable volume within 2 % 
difference of the last volume was achieved and noted as the tapped volume. 
This was repeated in triplicate and the results expressed as the mean and 
standard deviation of the initial and bulk density as defined by Equations 2-3 
and 2-4 in g/ml. 
 
Table 2-5: Tapping Intervals for Determining Tapped Density 
Interval Number of Taps Total Number of Taps 
Performed Overall 
10 10 
40 50 
50 100 
100 200 
300 500 
250 750 
500 1250 
 
Equation 2-3: Initial Bulk Density  
 
Initial Bulk Density = M/V0 
 
Equation 2-4: Tapped Bulk Density  
 
Tapped Bulk Density  = M/Vt 
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Equation 2-5: Carrs Index    
 
Carrs Index = (V0/Vt)/V0 x 100 
 
Equation 2-6: Hausner Ratio   
  
Hausner Ratio  = V0/Vt 
 
Where  M   =  Mass of sample (g) 
  V0  =  Poured volume (ml) 
Vt = Tapped volume (ml) 
 
The Carrs index as given by Equation 2-5 is a way of evaluating and 
reporting the compressibility of a powder while the Hausner ratio shown in 
Equation 2-6 gives an indication of the flowability as shown in Table 2-6 were 
also calculated. 
 
Table 2-6: Flow Character Nature as defined by Carrs Index and Hausner Ratio 
(Hausner, 1967, Carr, 1965) 
Carrs Index (%) Powder Character Hausner Ratio 
Up to 15 Good < 1.25 
16 – 20 Fair 
21 - 25  Passable 1.25 – 1.5 
26 – 31 Poor > 1.5 
> 32 Very Poor 
 
The density of suspending media was assessed by weighing 20 ml of each 
media measured accurately in a measuring cylinder in triplicate. 
 
2.2.2.5. Rheology 
 
All rheology measurements repeated in at least triplicate on a Bohlin Gemini 
HR Nano Rheometer at 25 °C for all measurements. All samples were 
inverted thirty times prior to each measurement to ensure homogeneity in 
either the manufacturer’s bottle or a 100 ml amber bottle. 
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2.2.2.5.1. Initial Measurements 
A 2 °/55 mm cone and plate with a gap of 70 µm was used with around 2 ml 
of sample added before the excess was trimmed. 
 
The tests performed were: 
 Viscosity flow curve (with shear rates ranging from 0.9 to 200 s-1) 
 Time to reformation/thixotropic step test (with a shear rate of 1 s-1 for 
60 s followed by 1000 s-1 for 60 s then twenty minutes recovery time)  
 Yield stress analysis (with a shear ramp from 0.33 to 38 Pa). 
 
2.2.2.5.2. Effect of Shaking 
20 ml HPMC solutions of differing concentrations (ranging from 0.1 to 2 %) 
were poured into sterile containers, one day prior to testing. After 24 hours, 
the viscosity of the undisturbed/sheared HPMC media was measured at a 
shear rate of 0.1 s-1. The solutions were then inverted 2, 4, 8, 16 and 32 
times and the viscosity again recorded at a shear rate of 0.1 s-1. 
 
 
2.2.2.5.3. Effect of Stirring 
The viscosity of the HPMC solutions (0.1, 0.5, 1, and 2 %) were measured at 
a shear rate of 0.1 s-1 before being stirred on the magnetic stirrer (t = 0 min). 
The HPMC was stirred at a speed of 60 % on the magnetic stirring plate for 
one minute (mimicking the conditions during the suspendability experiment) 
before the viscosity was immediately measured (t = 1 min). The viscosity was 
measured in triplicate after 5, 10, 15, 20 and 180 minutes for all 
concentrations. 
 
2.2.2.5.4. Oscillation 
Flow curves tell us about a materials viscous properties i.e. how it resists 
flow. Therefore in order to characterise the viscous and elastic properties of 
a material, oscillation is used. A stress/strain is applied which is constantly 
changing and the delay of the resulting response is measured. An amplitude 
sweep is applied to determine the linear viscoelastic region then a frequency 
sweep to determine the material’s response to different time scales by 
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examining response curves as shown in Figure 2-6. From the material’s 
response, the complex modulus and the phase angle can be determined.  
 
The complex modulus (G*, measured in Pa) is a measure of the stiffness of a 
material so the higher the G*, the tougher the material (e.g. the less it moves 
so the more stiff the material). It is described as a modulus as the shear 
stress/shear strain is constant in the Linear Viscoelastic Region (LVR) 
(above this, the structure breaks). This is a complex modulus as it is 
comprised of G’ and G’’ where G’ is the Storage (elastic) modulus and G’’ is 
the Loss (viscous) modulus: if G’ > G’’ then the material is solid-like and the 
reverse shows that a material is more liquid-like. 
 
The phase angle occurs when there is a lag phase between the stress 
applied to the material and the resulting strain: For purely elastic materials, 
stress and strain are in phase (so phase angle is zero) and for purely viscous 
materials, stress and strain are ¼ cycle out of phase (angle 90 o); where the 
phase angle is 45o the material is as much as solid as liquid so is a gel. It 
therefore follows the lower the angle, the more elastic or solid like material 
and vice versa. 
 
 
 
 
 
 
 
Figure 2-6: Figure Showing Amplitude and Frequency of a Wave as used in 
Oscillation Experiments 
 
By looking at the G’ or elastic/solid components over a range of different 
frequencies, this may help us find out which is the most stable suspending 
media e.g. if one is more solid at a low frequency indicating a long period of 
time required for sedimentation. This may be especially important in keeping 
our larger multiparticulates suspended and hence in providing a uniform 
suspension for patients. 
 
Amplitude 
Frequency 
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An amplitude sweep was performed on all samples to determine the linear 
viscoelastic region (LVR) using a 40 mm parallel plate with a 500 µm gap 
and around 2 ml of sample with the excess trimmed. An auto stress of 1 Hz, 
strain units from 0.005-0.5 and an initial stress of 0.5 Pa were used. The 
stress and strain values 2/3 of the way along the LVR (which differed 
between samples) were used as the initial values in a frequency sweep run 
from 0.01 to 10 Hz to assess the storage and loss moduli over the different 
frequencies and timescales associated with them. 
 
 
2.2.2.6. Suspendability 
 
Cellets® (ranging from 100-1000 µm) at a concentration of 500 mg/5 ml were 
added to MC and HPMC (0.1, 1 or 3 %) solutions and stirred for one minute 
on a RCT Basic magnetic stirrer (Ika Labortechnik, Germany) on setting of 
60 % after which the time taken for the pellets to completely settle was 
visually determined. 
 
 
2.3. Results and Discussion 
 
2.3.1. pH 
 
All media should be compatible with the roughly physiologically neutral pH of 
the mouth which is to be expected. The pH is of critical importance in 
administering multiparticulates, as the drug release from multiparticulates 
may be pH dependent e.g. in the case of taste masking or for enteric coating.  
An incompatible suspending media or food pH for a sprinkle will lead to 
failure of the dosage form functionality hence may affect medication 
compliance. For example, a bitter tasting drug could be released into food if 
taste masked particles designed to release at acidic pH release in the 
administration media. The pH values for different media are shown in Table 
2-7: those pH values which are acceptable are for administration of 
Eudragit® E which is soluble below pH 5.5 are highlighted in bold.  
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Table 2-7: pH Values (Mean ± SD) for Suspension Vehicles those pH values which 
are acceptable are for administration of Eudragit® E which is soluble below pH 5.5 
are highlighted in bold 
Vehicle pH Value Mean ± SD 
OraSweet® 3.79±0.01 
OraPlus®: OraSweet® (1:1) 3.97±0.02 
OraPlus® 4.19±0.01 
OraPlus®: OraSweet SF® (1:1) 4.2±0.01 
OraSweet SF® 4.28±0 
Yoghurt 4.28±0.01 
SyrSpend SF® 4.31±0.01 
HPMC (Range) 4.31 – 6.46 
Glycerol 4.79±0.14 
Glycerol: Methylcellulose 1% (20:50) 5.84±0.10 
Syrup BP: Methylcellulose 1% (1:1) A 6.31±0.05 
Methylcellulose (Range) 6.13 - 7.25 
Syrup BP 6.61±0.01 
 
 
It can be seen that the commercial suspending agents have an a slightly 
acidic pH thought to be largely due to being buffered to an acidic pH for the 
stability of the parabens preservative (with composition shown in Table 2-4) 
and flavouring/sweetening agents with all media within range of that 
expected by the manufacturers/Excipients Handbook. Given the criticality of 
pH in dosage form performance in this instance, it is likely that the 
suspending vehicle would need to be buffered to a neutral/alkali pH. 
 
2.3.2. Osmolality 
The osmolality of the gastro-intestinal secretions ranges from 127-357 
mOsm/L from saliva to faeces (adult data, paediatric unknown). A high 
osmolality in a suspension may be associated with gastro-intestinal side 
effects yet when oral solutions and suspensions were assessed 54 of 58 had 
an osmolality ranging between 1050-10,950 mOsm/L which is largely in 
keeping with the experimentally observed values in Table 2-8 (Dickerson and 
Melnik, 1988)  
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Table 2-8: Osmolality Mean Values of Various Suspending Media 
Media Mean Osmolality ±SD (mOsm/L) 
HPMC 0. 5% 0 
HPMC 1 % 0 
HPMC 2 % 17.3±0.6 
HPMC 1 % (Flavoured & Sweetened) 28.0+3,5 
MC 0.5 % 5.5+0.6 
MC1 % 9.3+3.1 
MC 3 % 12.5+0.6 
OraPlus® 244.0+13.0 
Yoghurt 481.7+105.1 
OraSweet® SF:OraPlus® (1:1) 1308.0+21.7 
Syrup BP Higher than 1999 mOsm/L 
Glycerol BP Higher than 1999 mOsm/L 
Methylcellulose: Syrup BP (1:1) Higher than 1999 mOsm/L 
Methylcellulose: Glycerol BP (5:2) Higher than 1999 mOsm/L 
OraSweet® Higher than 1999 mOsm/L 
OraSweet® SF Higher than 1999 mOsm/L 
OraSweet®:OraPlus® (1:1) Higher than 1999 mOsm/L 
Apple Sauce Higher than 1999 mOsm/L 
 
Many of the media, by virtue of containing glycerol and syrup, are over the 
maximum limit of the osmometer (1999 mOsm/L). Commercial vehicles 
osmolalities were in keeping with published values with the exception of 
OraBlend® SF (OraPlus: OraSweet SF 1:1 which is published at 1073 
mOsm/L and measured as 1308 mOsm/L (Paddock Laboratories Inc, n.d.). 
This media made in and mixed in the lab by manual shaking, may not be as 
accurately made and as well mixed as that made commercially. It can be 
seen that HPMC and MC have desired osmolalities but also highlights that 
this will be changed by every addition e.g. in that the flavoured and 
sweetened HPMC with Orange PermaSeal Flavour and Sucralose has an 
increased value. 
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2.3.3. Density 
 
The density of the Cellets® can be seen in Figure 2-7. It can be seen that the 
density of Cellets® increases slightly as the particle size range increases (as 
summarised in Table 2-9) which would be expected given that larger 
particles are less able to pack as closely and hence would have a higher 
volume and density. The density was found to be within range of that 
reported by the manufacturer. 
 
Figure 2-7: Mean Initial Bulk and Tapped Densities for Different Sizes of Cellets® 
Particles 
 
Table 2-9: Particle Size and Bulk Density Ranges of Cellets®  (PharmaTrans Sanaq 
AG Pharmaceuticals, n.d.) 
Type Particle Size range (µm) Bulk Density (g/ml) 
Cellets® 90 63-125 0.8±0.5 % 
Cellets® 100 100-200 0.8±0.5 % 
Cellets® 127 100-160 0.8±0.5 % 
Cellets® 200 200-355 0.8±0.5 % 
Cellets® 263 212-300 0.8±0.5 % 
Cellets® 500 500-710 0.8±0.5 % 
Cellets® 700 700-1000 0.8±0.5 % 
 
The Carrs Index and Hausner Ratio for the Cellets were seen to decrease as 
the particle size increased. The Carrs Index was seen to range from a mean 
of 10.18 to 7.47 which, as <15, is seen to indicate excellent compressibility 
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which is not unexpected for a starter core particle which is usually coated 
and often compressed into tablets with a Hausner Ratio mean ranging from 
1.11 to 1.08 which, as <1.25, can be seen to indicate good flow properties 
which are beneficial in terms of pharmaceutical processing  
 
It could be seen that as all of the particle sizes had a bulk density of around 
0.8 g/ml that they were all less dense than water which may be seen to 
suggest that suspending the particles uniformly would be difficult as they 
may float. The densities of some commonly used suspending vehicles are 
shown in Table 2-10, it can be seen that methylcellulose, HPMC and 
OraPlus were more similar to water and others were more dense. Again this 
compares with their sugar and glycerol content and may be useful in 
reducing the sedimentation of larger particles as per Stokes Law by reducing 
the difference in density between the particle and the media and hence 
forming a more stable suspension. 
 
Table 2-10: Densities of Commonly Used Suspending Vehicles 
Same Density as 
Water 
Higher Density than Water  
(Results given as Mean±SD in g/ml) 
Methylcellulose 1 % OraSweet® SF 1.04±0.01 
HPMC 1 % OraSweet® SF:OraPlus® (1:1) 1.05±0.00 
OraPlus® Yoghurt 1.10±0.00 
 Apple Sauce 1.13±0.02 
 OraSweet®:OraPlus® (1:1) 1.15±0.01 
 Methylcellulose: Glycerol BP (5:2) 1.15±0.04 
 Methylcellulose: Syrup BP (1:1) 1.22±0.00 
 Glycerol BP 1.26±0.00 
 OraSweet® 1.33±0.05 
 Syrup BP 1.34±0.02 
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2.3.4. Rheology 
2.3.4.1. Viscosity  
It can be difficult to compare rheology between different literature since 
everything a sample experiences  prior to measurement (the so called 
sample history) can change the rheology as can factors of the measurement 
itself including shear conditions, temperature and type of 
rheometer/viscometer/geometries. It can be seen from Figure 2-8 that the 
reproducibility of HPMC was better than that of MC at 1 %, this may be due 
to the difficulties in wetting MC and the effect that it foams more making 
accurate measurement less straight forward. 
 
Figure 2-8: Shear Rate vs. Viscosity for Different Batches of HPMC and MC 1% 
 
From Figure 2-9 it can be seen that as the concentration of MC or HPMC is 
increased, viscosity also increases as expected since the increased amount 
of polymer has more chains to intermingle and trap water. It can seen that 
MC has a higher viscosity than HPMC (despite both reported as 4000 cps) 
which may be due to its formation as a structured gel or may be that it is 
slightly more concentrated due to difficulties with it foaming in making to 
volume accurately. 
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Figure 2-9: Mean Viscosities of Suspending Media against Ascending Shear Rate 
(a, b and c covering different viscosities of suspending media) 
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It can be seen that OraPlus® had a similar viscosity to the MC and HPMC 1 
% solutions whereas the SyrSpend SF® is more viscous, but not as viscous 
as the MC or HPMC 3 % solutions which Is likely to be due to the 
compositions of their viscosity modifiers.  The “Ora®” Suspending vehicles 
(composition given in Table 2-4) shown in Figure 2-9 have a viscosity in a 
similar range to MC and HPMC 0.1 % solutions with OraSweet® having a 
more Newtonian nature than the other media. Figure 2-9 shows  that the 
viscosity of glycerol and syrup decreased through combination with MC 1 % 
aqueous solutions. Syrup was discovered to be very slightly shear thinning 
which is not expected but this may be an experimental artifact based on the 
stickiness causing some resistant to flow on initiation. 
 
The viscosities of commonly used vehicles which are not pharmaceutical 
suspending agents can be seen to range from the less viscous water through 
to yoghurt (which can suspend fruit or flavours). The viscosity of water was 
seen to be similar to MC and HPMC 0.1 % solutions whereas yoghurt was 
seen to be similar to MC and HPMC 3 % solutions in Figure 2.9. In summary: 
water, commercial suspending vehicles and yoghurt where seen to have 
viscosities in a similar range of MC and HPMC 0.1, 1 and 3 % solutions 
respectively and to all be shear thinning. These suspending media provided 
a model suspending media to be taken forward in suspendability studies. 
 
It can be seen from Figure 2-10 that autoclaving did not have an effect on the 
viscosity of HPMC as long as it was shaken after to ensuring mixing – this 
lack of effect of autoclaving has been reported by others. 
 
 
Figure 2-10: Effect of Autoclaving on the Viscosity of HPMC 0.5, 1 and 2% Solutions 
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2.3.4.2. Time to reformation 
The time a media takes to reform its internal structure after being sheared 
can be assessed by  exposing a sample to a low, high and then low again 
shear rates as shown in Figure 2-11  by the pink line to see how long the 
suspending vehicle takes to return to the same viscosity again as shown by 
the blue line. In the case of this illustrated MC: glycerol 1:1 mixture, it can be 
seen that it rebuilt very quickly. 
 
Figure 2-11: Step Test for Glycerol: Methylcellulose showing how Viscosity and 
Shear Rate changed with Time 
 
The time taken to reform may be important as if the product reforms too 
quickly after shaking, the patient or carer may not be able to withdraw and 
administer the dose before the vehicle becomes more viscous again but if it 
takes too long to reform, drug or microparticles which are suspended in the 
media may sediment and cause problems with dose reproducibiltiy if they are 
not able to be easily resuspended. 
 
From Figure 2-12, it can be see that media such as water and yoghurt 
reformed instantly whereas others took longer: those that were not shown 
had not reformed after twenty minutes. Although 100 % reformation has 
been looked at, assessing the time taken for the media to reform to certain 
percentages may give a more overall view and is a potential area for future 
work. It is possible that the structure of the media didn’t reform after twenty 
minutes, that the high shear rate chosen damaged the structure (it was 
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deliberately chosen to be a high shear rate in excess of normal shaking to 
assess for how long reformation would take) so it was unable to reform or 
that  the vehicle may have been shear thinning under the initial rate and 
hence carried on shear thinning. This could be better assessed in the future 
through shearing the sample without an initial stress and watching time to 
percentage reformation at different shear rates so as to ensure the structure 
is not broken or performing a thixotropic loop sweep. 
 
 
Figure 2-12: Mean Time Taken for 100% Reformation of Various Suspending Media 
 
It can be seen from the data that was obtained we either have a time less 
than 100 sec or >20 minutes.  Ideally a midpoint time would be acceptable 
for a multiparticulate suspension vehicle to allow pouring but also ensure 
reformation so future work would benefit from the improvements above. 
 
 
2.3.4.3. Yield Stress  
 
The yield stress is the maximum stress below which no flow will occur. Not 
all materials have one as can be seen from Figure 2-13: 
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Figure 2-13: Mean Instantaneous Viscosity of Yoghurt and Glycerol against Shear 
Stress 
 
In trying to keep microparticles suspended, a suspending vehicle with a 
higher yield stress may keep them suspended better since it would have a 
value of stress that must be overcome for the vehicle to start to flow: If this is 
the case it can be seen from Figure 2-14 that vehicles like the higher 
concentrations of MC and HPMC may be prefered although the shear rate of 
sedimentation is likely to be below the lowest stress used and shaking has 
not been well quantified.This experiment would benefit with being run at 
lower stresses to differentiate more between vehicles at the lower end which 
may still be able to provide protection against sedimentation and to directly 
quantify which lower materials have a yield stress. 
 
No Yield Stress/Less than 0.3 Pa 
OraSweet, Syrup, Glycerol SyrSpend OraSweet: Plus, 
MC 0.1 to 1%  and HPMC 0.1 to1 %  
 
Yield Stress less than 1 Pa 
OraSweet SF, OraPlus and OraSweet: OraPlus SF 
 
Yield Stress less than 5 Pa 
MC:Glycerol, MC:Syrup, MC 3 %, Yoghurt 
 
Yield Stress less than 20 Pa 
HPMC 3 and 5 %, Apple sauce 
 
Yield Stress more than 38 Pa 
MC 5 and 10 % 
 
Figure 2-14: Yield Stresses of the Suspending Vehicles Tested 
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2.3.4.4. Effect of Shaking and Stirring 
According to the British Pharmacopoeia, 30 inversions are recommended for 
the particles to disperse well in a suspension for homogeneity whereas a 
patient is unlikely to invert the bottle 30 times – hence the change in viscosity 
of different concentrations of HPMC (0.1-2%) was studied over a range of 
manual inversions ranging from 2 to 32. It can be seen from Figure 2-15 that 
there is no effect on number of inversions on the viscosity of the media which 
is highly variable as shown by the large standard deviations. This may 
however be useful to perform in more people in the future to see whether 
there is an effect of shaking on viscosity than in just one person and to try to 
define the shear rate of normal shaking which is not well defined. 
 
Figure 2-15: The Effect of Different Numbers of Inversions on the Viscosity of 
Different Concentrations of HPMC Solutions (0.1, 0.5, 1 and 2%) 
 
 
Figure 2-16: The Effect of Different Times of Stirring on the Viscosity of Different 
Concentrations of HPMC Solutions (0.1, 0.5, 1 and 2%) 
0
4
8
12
16
0 2 4 8 16 32
V
is
c
o
s
it
y
(P
a
s
)
Number of inversions
0.10%
0.50%
1%
2%
0
4
8
12
0 1 5 10 15 20 180
V
Is
c
o
s
it
y
 (
P
a
s
)
Time (Mins)
0.10%
0.50%
1%
2%
CHAPTER 2: SUSPENSION CHARACTERISATION 
110 
 
It can be seen from Figure 2-16 that there is little clear effect on time after 
stirring on the viscosities of HPMC but that there seems to be a trend 
towards thickening after standing for 10-15 minutes in the most concentrated 
media which may be due to sedimentation of undispersed particles. This was 
undertaken to see the effect of stirring initially since it is recognized that 
many pharmacies in reconstituting/making a suspension will only be able to 
shake manually or have a stirrer for dispersion. 
 
 
2.3.4.5. Oscillation 
In order to assess the Linear Viscoelastic Region (LVR) for frequency 
assessments, an amplitude sweep was performed. It can be seen from the 
example in Figure 2-17 that OraPlus that as G’ (the storage modulus shown 
by the blue line) is higher than G’’ (the loss modulus shown by the red line) 
and the phase angel <45º (as seen by the orange line) that the OraPlus® 
can be seen to be solid-like under these conditions.  The LVR (region where 
G’ and G’’ are parallel) is shown by the box and marked as two thirds of way 
along the LVR with an initial stress of 0.0073 Pa and Strain of 0.0051)  
 
 
Figure 2-17: Amplitude Sweep on OraPlus ®  (pp40, 1Hz auto stress, 0.005-0.5 
strain units, 0.5Pa initial stress) with strain on the X axis against shear stress 
(green) G’ or storage modulus (blue), G’’ or loss modulus (red) and phase angle 
(orange) on the Y axis. The box illustrates the Linear Viscoelastic Region (e.g. the 
strain values over which the G’ and G’’ are parallel) within which region the 
Frequency Sweep should be undertaken. As the G’ is higher than the G’’, OraPlus® 
can be thought of as solid like 
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The raw data from a frequency sweep can be seen in Figure 2-18 from the 
example of Oral Sweet SF®: OraPlus® (1:1) where because at lower 
frequencies G’ shown by the red line is lower than G’’ shown by the blue line, 
the vehicle will be is liquid like at lower frequencies whereas as the G’ and 
G’’ lines cross it will be solid like at higher frequencies (shorter timescales). It 
may be desirable for stability to have a solid like structure over higher 
frequencies to prevent settling and liquid at lower to aid pouring. 
  
 
Figure 2-18: Frequency Sweep of Oral Sweet SF®: OraPlus® (1:1) (0.01-10 Hz, 31 
samples, initial stress 0.0364 Pa/Strain 0.0314) with frequency on the X axis against 
instantaneous viscosity (green) G’ or storage modulus (red), G’’ or loss modulus 
(blue) and phase angle (orange) on the y axis. As the G’’ is higher than the G’ over 
low frequencies corresponding to longer timescales OraSweet SF®:OraPlus® can 
be thought of as liquid like whereas it changes to being more solid like at higher 
frequencies as shown by G’ and G’’ crossing over 
 
From Table 2-11 , all of these all initially had their G’ or G’’ higher in the initial 
frequency (10 Hz) of the frequency sweep with the exception of OraPlus and 
OraSweet: OraPlus which initially had a higher G’ – the cause for this is likely 
to be the very close magnitude between the viscous and elastic modulus (1.4 
vs. 1.3) of OraPlus meaning that both components had virtually equal effect.  
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Table 2-11: Higher G' or G'' in the Frequency Sweep 
G’ Higher G’’ Higher 
OraSweet SF 
OraSweet SF: OraPlus  
MC 
MC:Syrup 
MC:Glycerol 
OraPlus 
OraSweet 
OraSweet: OraPlus  
Glycerol 
Syrup 
HPMC 
 
From Table 2-12, glycerol and syrup were the only two media that showed 
little frequency dependent change in viscosity – this shows as the frequency 
sweep confirms by the constantly higher viscous modulus that these media 
are viscous liquids. Good storage stability e.g.  in preventing sedimentation 
may be shown by being elastically dominated at lower frequencies 
corresponding to longer time scales so those with G’ higher or transition to G’ 
over lower frequencies would be preferred which corresponds to yield stress 
measurements. Hence in future, assessment of desired viscoelastic 
properties could be performed more quickly and easily by assessing the yield 
stress e.g. force required for the media to flow. 
 
Table 2-12: Changes in G' and G'' over Frequency 
G’ Higher at All Frequencies G’’ Higher at All Frequencies 
MC 
MC: Syrup 
MC:Glycerol 
Apple Sauce 
Yoghurt 
Glycerol 
Syrup 
Initially G’ Higher but Crossover at: Initially G’’ Higher but Crossover at: 
OraPlus – 1Hz and again at 0.0126 
Hz 
OraSweet: OraPlus: 3.981 Hz and 
0.03981 Hz 
OraSweet SF – 0.1995 Hz 
OraSweet SF:OraPlus – 0.631 Hz 
HPMC  - ~1 Hz 
OraSweet – 0.0126 Hz 
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2.3.5. Suspendability 
 
There is no official method for the assessment of suspendability. Initially the 
suspendability experiment was attempted in measuring cylinders to allow for 
the measuring of sedimentation volume. However, it was found that even 
with vigorous shaking it was not possible to disperse the Cellets® in the MC 
or HPMC solutions (the Cellets® aggregated either on top if they were added 
to the suspending media or at the bottom if the suspending media was added 
to the Cellets® probably due to their hydrophobicity) as shown in Figure 2-19 
 
 
Figure 2-19: Poor Dispersion of Cellets in a Measuring Cylinder with Suspending 
Media added first (left) and second (right) after shaking 
 
The experiment was then transferred to small beakers where the height of 
sediment was to be measured using a ruler and stirring with a magnetic 
stirrer on setting six for one minute to disperse the Cellets®.   A similar 
aggregation of Cellets® occurred again with the thicker suspending media 
which was partially overcome by having the magnetic stirrer mixed the dry 
particles so that they were moving while the suspending media was poured 
on so hence less able to aggregate.  
 
Some Cellets® did become suspended by this method as shown in Figure 2-
20; however they were not uniformly suspended. The Cellets® closer to the 
magnetic stirrer were more likely to be suspended and at a higher height 
than those further away, hence it was not felt appropriate to assess by 
sedimentation height. Consequently, the time taken for all the suspended 
particles to sediment was visually measured but unfortunately this is a fairly 
subjective assessment with poor inter-observer reproducibility. 
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Figure 2-20: Dispersion of Cellets® (200 µm) after stirring in a Beaker in MC 1 % 
(left) and 3 % (right) 
 
As shown in Figure 2-21 and expected from Stoke’s Law, smaller particles 
took longer to sediment than larger particles and thicker suspending agents 
slowed sedimentation the most. MC 3 % solution was the best suspending 
agent at slowing sedimentation with results in excess of seven hours and 
water the worst lasting only seconds for the smallest Cellets®. However the 
dispersibility was worse in the thicker suspending agents. MC was found to 
be more difficult to disperse the particles in than HPMC due to the higher 
viscosity and so HPMC was chosen as the suspending media with which to 
perform the grittiness assessment in as shown in Figure 2-22.  
 
 
 
Figure 2-21: Particle Size versus Sedimentation Rate in Different Media as 
assessed by watching how long all the particles took to sediment (n=3) 
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Figure 2-22: Time taken for Particles of Different Sizes of Cellets to Settle in 
Different Concentrations of HPMC as assessed by watching how long the particles 
took to sediment (n=3) 
 
Once dispersed by mixture of stirring/shaking/mixing in plastic containers as 
seen on the top of Figure 2-23 which was not standardized and assessed by 
visual distribution of particles, a mechanical wheel as seen in Figure 2-23 
was used to keep the suspensions for the grittiness tests on so as to keep 
the samples moving and to try to prevent sedimentation whilst the testing 
occurred and was removed just prior to administration to the volunteer for 
grittiness testing as described in Chapter 3. 
 
 
Figure 2-23: Mechanical Wheel used to try to Keep Particles Suspended in Samples 
for Grittiness Trials (after the particles had been dispersed by stirring/mixing/shaking 
until just prior to administration) 
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As the problem with the Cellets® was more trying to suspend them rather 
than the sedimentation, further work would need to look at how to get the 
Cellets® to disperse better. This may include finding a better method of 
dispersion or adding a surfactant (but would have to be balanced with the 
desire to minimise excipients in paediatric formulations) which may also 
allow such good dispersibility/suspendability that longer term stability or 
resuspendability may be able to be assessed.  
 
In the future, a better method of assessing dispersibility and sedimentation 
may be to look at percentages of particles dispersed/suspended (if particles 
are) such as by light scattering or image analysis and the time taken for 
certain numbers/percentages of particles to sediment in order to make a 
more objective measurement or using a sedimentation balance approach.  
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2.4. Conclusions 
 
The choice of a suspending vehicle is always going to be a decision 
weighing up a variety of factors including stability and acceptability along with 
minimising numbers and levels of excipients, especially in children. Some 
suspending vehicles commonly used in children were characterised to 
determine a suitable vehicle for the administration of functionalised 
multiparticulates (which ideally could be the same vehicle for all particles 
made from the same polymer if the particles produced were robust enough).  
 
As the pH of suspending media is of critical importance in the development 
of a functionalised suspension since if the pH is incompatible with the 
multiparticulates, the functionality is lost and hence we are left with a bitter 
tasting medicine with the potential that the child will not take it and so not be 
able to take advantage of the therapeutic benefit of the medicine. In this case 
only higher concentrations of HPMC and all methylcellulose concentrations 
including those in combination with glycerol and syrup along with syrup on its 
own are the preferred media of those tested although are likely to need to be 
buffered. Other suspending media not tested of desired pHs include NaCMC 
and xanthan/guar gums which should be assessed in any future work 
especially as they are easier to wet than HPMC and MC and can be used in 
a powder for reconstitution which in terms of particle stability, may be what is 
needed. 
 
It was thought that rheological measurements would be the key to finding a 
vehicle that was able to produce a stable suspension of multiparticulates 
which would be larger than individual drug particles in most suspensions and 
hence more difficult to keep in a uniform suspension. There are a range of 
tests which can be used to investigate the rheology of suspensions and in 
this case a flow curve was used, the yield stress (that is stress that requires 
to be overcome before the vehicle can flow) determined and a thixotropic 
step test applied to see how quickly the suspending vehicle reforms after 
shearing.  
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No clear effect on viscosity on number of inversions to a mix a suspension or 
on the viscosity reformation post stirring was observed which would have 
been interesting in assessing the in use performance of suspensions (since 
in a pharmacy, a stirrer or shaking are likely to be the only two methods 
available to make suspensions where needed). Future work on the stresses 
exhibited on a formulation in terms of shaking would be interesting as this 
has not been well studied – it may be that by assessing the viscosity after 
shaking that population effects will be found if it is performed in more people. 
 
It was found that all the suspending vehicles were shear thinning with the 
exception of OraSweet® and glycerol with apple sauce, yoghurt and higher 
concentrations of HPMC and MC (3 %+) having the highest viscosities under 
the conditions used. As HPMC and MC from 0.1 to 3 % were seen to cover 
the range of viscosities of suspending media from water to soft foods, these 
media were used in suspendability studies. The yield stress assessment did 
not differentiate  well between those of lower, more in use yield stresses 
such as those associated with sedimentation and should ideally be rerun, 
similarly the thixotropic loop test shear rate may have been too high either in 
the initial or harsh shearing phase as many liquids did not completely reform 
within 20 minutes – this may be due to slow reformation, shear thinning 
during the initial period or structure breakdown by high shear rates .A better 
way to examine this in future would either be to have no initial shear rate 
phase and shear the sample under different shear rates and watch rebuilding 
time, to calculate percentages of reformation over time or to perform a 
thixotropic loop sweep. Oscillation experiments showed little structure not 
already determined by higher values of yield stress and hence in future, this 
would be a quicker way to assess for structural stability under sedimentation 
conditions. 
 
By using only HPMC and MC solutions in suspendability testing it is 
acknowledged that only the effect of similar viscosities is assessed – 
different properties of vehicles due to excipients, wetting etc are not 
examined so an area for future work may be to look at suspendability 
compared to commercial suspending agents and with more comparable 
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particles than Cellets.  In terms of suspendability, smaller particles and more 
viscous suspending media caused the particles to take longer to sediment as 
per stokes law however smaller particles however dispersibility (and hence 
potential dose uniformity) of the smaller pellets (still >100 µm) in the thickest 
solutions was difficult. Further work is needed to improve this dispersibility 
which is likely to be by the addition of “child-friendly” excipients (e.g. those 
with ideally a history of use in the food industry or long standing 
pharmaceutical use and tolerance) such as a surfactant or use of a 
commercial suspending media as the other main alternative of using a 
different mixer would be difficult for parents or pharmacies to implement as a 
way of producing suspensions. Methods of assessing dispersibility should 
also be improved by methods which are more reproducible and quantifiable 
such as the use of light scattering or image analysis or using a sedimentation 
balance 
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3. GRITTINESS OF SUSPENSIONS 
3.1. Introduction 
 
3.1.1. Acceptability 
 
Medicine compliance is a problem in paediatric therapy with compliance 
rates ranging anywhere from 11-93 % depending on many factors including 
factors such as the frequency of therapy and taste being critical to 
compliance (Matsui, 2007). These reasons for the lack of compliance are 
important since they may be overcome through the use of age appropriate 
taste-masked or modified release formulations such as functionalised 
multiparticulates. By virtue of their larger size when compared with individual 
drug particle size, the suspendability as examined in Chapter 2 and grittiness 
of suspensions were thought to be key in the use of functionalised particles 
in medicines. 
 
Acceptability has been defined by the European Medicines Agency as the 
“overall ability of the patient and caregiver (defined as ‘user’) to use a 
medicinal product as intended” (European Medicines Agency, 2011). It can 
be seen from this definition whether a medicine is accepted will depend on 
both the user and the medicine.  
 
One aspect of acceptability is palatability which has been defined as “the 
overall appreciation of an (often oral) medicine by organoleptic properties 
such as smell, taste, aftertaste and texture (i.e. mouth feeling), and possibly 
also vision and sound” (European Medicines Agency, 2011). Palatability will 
depend upon the nature of the active ingredient, the excipients and how it 
has been formulated. As can be seen from palatability above, other sensory 
components rather than just taste, such as texture or mouth feel, are 
important.  Mouthfeel and texture are often studied in the food industry where 
grittiness is undesirable. It is often assessed in the comparator testing of 
products such as chocolate and dairy products where the opposite property 
of creaminess is pleasurable for consumers or in consumer healthcare for 
products such as toothpaste where a gritty texture may adversely affect 
performance although these are at smaller sizes (<30 µm) compared to the 
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>100 µm multiparticulates that may be required to control release in the 
sense of taste masking or modified release. 
 
If the suspended particles feel gritty in suspension (where grittiness can be 
thought of as the sensation of sand in the mouth), the paediatric patient may 
refuse to take their medicine with the potential for clinical deterioration. This 
may be of particular significance if the particles had been dispersed or 
suspended in a food or drink for administration leading the already ill child to 
refuse these. Grittiness is therefore of great importance in paediatric 
formulations. Yet  there are no definitive answers of what particle size 
produces a gritty sensation with figures ranging from anywhere up to 1mm 
often quoted with no reference (Billany, 2007). This acceptable particle size 
is known to be dependent on the shape/hardness of the particle and viscosity 
of the suspending media it is given in. There are a limited number of 
formulations that contain large particles in suspension such as activated 
charcoal, though this is often used in emergency situations and little is 
reported about its acceptability (Cheng and Ratnapalan, 2007, Engelen et 
al., 2005b, Tyle, 1993, Imai et al., 1995, Engelen et al., 2005a, Tyle et al., 
1990). 
 
The majority of pharmaceutical sensory analysis in children involves 
assessing liquid medicines (drug solutions/suspensions) for taste, aftertaste 
and Mouthfeel (Cohen et al., 2009, Hames et al., 2008, Baguley et al., 2012). 
Very few have examined multiparticulates or the larger sizes of 
multiparticulates in suspension although a bead size of less than 1.5 mm-
2mm has been recommended for a sprinkle (Nagavelli et al., 2010, FDA, 
2011, Van de Vijver et al., 2011).  Given that weaning is generally advised 
from four to six months of age it is expected from then that children are able 
to cope with semisolid foods, although it is unlikely that they have a texture 
like pharmaceutical particles in a suspension. Few studies have been 
undertaken on the acceptability and preference of different dosage forms in 
children and those which have employed various methodologies including 
different scales and caregiver assessments (Davies and Tuleu, 2008, Cram 
et al., 2009, Bays et al., 2010). Hence it may be interesting to assess the 
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grittiness and acceptability of larger particles in suspension in young adults 
to screen grittiness samples and then hopefully one day, to apply this to 
children to assess their views on acceptability. Adults have a number of 
benefits including ease of access and the ability to undertake a larger 
number of samples without getting bored but obviously are not children (Liem 
et al., 2004)! 
 
 
3.1.2. Sensory methods 
 
Ways of assessing for taste can include chemical analysis which often works 
by generating a fingerprint assessment (often potentiometrically by electronic 
tongue) of the dissolved organic and inorganic components in a sample and 
relating these chemometrically with the taste of a product (Alpha MOS, 
Anand et al., 2007b).  As such it needs to be trained using data from human 
subjects. Time was not available for such a training exercise during the 
period of this project and hence this technique was not used. Measurements 
of texture or mouthfeel can be assessed in vitro through the use of a texture 
analyser instrument. Again these need to be correlated with human hedonic 
responses to provide fully reliable data. 
 
As well as these instrumental measurements it is possible to standardize the 
assessment of formulations for organoleptic characteristics using the 
methodologies of sensory analysis and thus obtain reliable and objective 
data from otherwise subjective assessments (Meilgaard et al., 2007).  The 
area of mouthfeel assessment is particularly difficult to assess by any other 
method and so sensory analysis was employed in this research. Details of 
the methodology employed are given later. 
 
There are a number of different categories of sensory methods depending 
upon what the study aim is. For each category there are different types of 
tests which can be employed as summarised in Table 3-1 with scaling tests 
and affective tests chosen in this research to get an overview into how gritty 
suspensions are found to be and what level of grittiness is acceptable since 
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this has not been extensively covered in the literature for larger particles 
(<100µm). A visual analogue scale (shown later) was used to record this 
range of grittiness with controls given to be the most and least gritty (Lim, 
2011). 
 
Table 3-1: Different Types of Sensory Methods (Meilgaard et al., 2007) 
Category Description Tests 
Descriptive Testing 
 
Differentiating between 
samples 
Difference tests 
Ranking 
Scaling Tests Scoring a sample on an 
attribute 
Scoring 
Affective Tests Measuring how much a 
product is liked or 
disliked 
Preference 
Acceptability 
Descriptive Methods Objective Description Flavour Profiling 
 
Sensory testing often involves assessing a product in terms of its profile (e.g. 
assigning different intensities to qualities such as appearance, taste, aroma, 
flavour, texture, mouthfeel and aftertaste). Grittiness is classed as the 
amount of particulates perceived by the mouth which is sometimes included 
into the more generic criteria of texture or mouthfeel. Mouthfeel can also 
cover where the sample feels chalky, oily or astringent. The suspending 
media itself can also affect grittiness, texture (viscosity) or mouthfeel. 
 
As grittiness is often dependent upon viscosity, the rheology of a range of 
commonly used suspending vehicles (Nahata and Hipple, 2003) were 
measured and compared in Chapter 2. The results of these experiments 
allowed a logical determination of the viscosities of suspending media to be 
used in an investigation of the influence of viscosity of suspending media, 
particle size and particle concentration on the sensation of grittiness here. 
HPMC was chosen from rheology experiments in Chapter 2 and its 
use/tolerability as a food additive. Microcrystalline cellulose pellets (Cellets®) 
were chosen as the placebo particles due to their non swelling, non-
disintegrating form, range of sizes, narrow stated size distribution, 
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reproducibility, generally regarded as safe acceptability, acceptable hardness  
and the fact that they have been used as starter seeds for coating for 
formulations and therefore have a history of pharmaceutical use. 
 
In this chapter, the aim was to use a human panel to assess various 
formulations for grittiness and to test the influence of particle sizes along with 
concentration of particles and viscosity of suspending media together on the 
sensation of grittiness.  The data will then be used to inform the target size of 
spray dried particles in Section 4 that would be acceptable for the platform  
 
 
3.2. Materials and Methods 
 
3.2.1. Materials 
 
Hydroxypropyl methylcellulose (4000 cP, substitution type 2906, grade 
65SH-400) was obtained from Shinetsu Chemical Company Ltd, Japan and 
Sucralose Granular NF (Emprove, NF) from Merck KGaA, Germany.  
Cellets® (97 µm-1000 µm) (Microcrystalline Cellulose Pellets) were kindly 
received from Pharmatrans Sanaq and Orange Flavour Givarome 
Permaseal/Orange Flavour Permaseal both received from Givaudan, United 
Kingdom. 
 
 
3.2.2. Methods 
 
3.2.2.1. Initial Grittiness Trial 
 
Ethical Approval for the use of human volunteers in these grittiness trials 
were given by the University Of London School Of Pharmacy Research 
Ethics Committee (REC/A/09/01) with recruitment Information and consent 
forms in the Appendix. The sensory set up is shown in Figure 3-1. This set 
up was chosen as it was clean with no distracting noises or smells to intrude 
on the sensory test and not a chemical laboratory where placing food in the 
mouth would have been prohibited. The spoon shown in Figure 3-1 was 
chosen as it can hold the full 10ml of sample required for the test whereas 
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other spoons tried could only hold around 7 ml (the sample was removed 
from the sample tube and placed on the spoon immediately before giving to 
the volunteer). It was felt that trying to use two standard 5 ml medicine 
spoonfuls may cause variability in two spoonfuls had to be sampled for each 
formulation or may allow the volunteer an addition chance to see the 
particles which may modify their assessment of grittiness (e.g. if they saw 
more, larger particles – they may score the sample even higher than if they 
had not seen these particles). 
 
 
 t  
 
 
 
 
 
 
Figure 3-1: Sample preparation area in dispensary and sensory station (top left and 
right) with spoon used (bottom) 
 
Twenty subjects (aged between 18-24 years of age including an equal 
number of males: females) were recruited as these were the youngest age 
group that could easily be assessed for research. Each subject tested 27 
samples overall and two controls in each session due to the grittiness trial 
taking place over two sessions to allow for subject comfort. Each sample had 
one of three levels of HPMC concentration (to give different viscosities), 
microcrystalline pellets (Cellets®) concentration and Cellets® particle size 
with all combinations of each sampled (as seen in Table 3-2) with sample 
order in Table 3-3 
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Table 3-2: Composition of Grittiness Samples and Controls 
 HPMC 
Concentration 
(%) 
Particle Size 
(µm) 
Particle 
Concentration 
(mg/ 5ml) 
0.1 100 5 
1 200 100 
3 500 500 
Negative Control 0.1 No Particles Added 
Positive Control 0.1 1000 500 
 
All participants were given the samples in the same randomised order. 
Subjects rinsed 10ml of sample around their mouths for 15 s to cover all oral 
surfaces. The negative and positive controls were tested first and the 
participant told that these samples will be the smoothest/most gritty samples 
respectively that they will receive in order to rate the texture in relation to 
these benchmarks. Immediately upon spitting out the sample, participants 
rated the intensity of grittiness on a bipolar 100 mm Visual Analogue Scale 
(VAS) as shown in Figure 3-2.  
 
 
 
 
 
 
 
 
Figure 3-2: Example of the Visual Analogue Scale used to Assess Grittiness 
(100mm – not to scale) where the volunteer makes a mark on the scale to represent 
how smooth/gritty they feel the sample is which ranges from 0 for very smooth to 
100 for very gritty when measured with a ruler from start of the very smooth line 
 
Participants waited for a minute between experiments and rinsed their 
mouths with water before and after each sample. The subjects were also 
asked to record the two samples that they felt were the most pleasant to test 
in each session (from here on, known as the “most acceptable samples”).  
 
 
VERY 
SMOOTH 
 
 
VERY 
GRITTY 
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Table 3-3: Randomisation Order: Initial Trial showing the control samples 
composition and those samples assessed during each session 
When 
Sample 
was 
Assessed 
Sample 
HPMC 
Concentration 
(%) 
Particle 
Size (µm) 
Particle 
Concentration 
(mg/5 ml) 
Both 
sittings 
Positive Control 0.1 1000 500 
Negative Control 0.1 - - 
A
s
s
e
s
s
e
d
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n
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s
t 
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ti
n
g
 
1 1 500 5 
2 0.1 200 5 
3 1 500 100 
4 3 200 500 
5 0.1 500 5 
6 3 500 100 
7 0.1 100 100 
8 3 100 100 
9 3 200 5 
10 3 200 100 
11 1 200 5 
12 1 200 100 
13 0.1 500 100 
14 0.1 200 100 
A
s
s
e
s
s
e
d
 O
n
 s
e
c
o
n
d
 s
it
ti
n
g
 
15 0.1 100 5 
16 1 200 500 
17 3 100 5 
18 0.1 200 500 
19 0.1 500 500 
20 1 100 100 
21 1 500 500 
22 0.1 100 500 
23 3 500 500 
24 1 100 5 
25 3 100 500 
26 3 500 5 
27 1 100 500 
 
Basic descriptive statistics were calculated using Excel 2007 and repeated 
measures ANOVA (Within subjects factors) run using SPSS 17 (SPSS, 
Illinois). The “most acceptable” samples were determined from assessing 
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which five samples were chosen as most acceptable most often (e.g. as a 
frequency of the number of times chosen).  
3.2.2.2. Refined Grittiness Trial 
 
Based on results achieved from the initial trial, a number of modifications 
were made as shown in Table 3-4. Orange was chosen as a flavor as it is 
one of the most common flavours in the United Kingdom and sucralose due 
to its sweetening and excipient safety/tolerability profile. 
 
Table 3-4: Modifications with Rationale to the Refined Grittiness Trial 
Modification Rationale 
Sample Size increased to 30 (16 
females: 14 males) 
To try to reduce high standard 
deviation 
Particle size range narrowed to: 90, 
127  263 µm  
To focus more on a more narrower 
size range 
Particle concentration range 
narrowed to 125, 250 & 500 mg/5ml  
To focus on a narrower particle 
concentration 
HPMC concentration range 
narrowed to 0.5, 1, & 2 %.  
To focus on  easier to handle & 
better accepted concentrations 
sweetener and flavouring agent  
included * 
To reduce the mouth coating effect of 
HPMC alone 
Individual randomisation  & blinded 
controls added  
To allow for order effects to be 
investigated with individual orders 
shown in the Appendix 
 
 
Due to supply issues, the composition of flavouring agent used differed 
between the 2 batches used during the trial as shown in Table 3-5. The 
relative compositions used differed between the flavours but the composition’s 
were chosen as they had a comparable flavour intensity according to the 
manufacturer and had a similar orange flavour as assessed by the 
researchers (n=2).  
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Table 3-5: Flavouring Composition of HPMC Batches used in the Refined Trial  
Batch 1 (Given to volunteers 01-12) Batch 2 (Given to volunteers 13-30) 
Orange Flavour Permaseal®  
0.5 % w/v 
(Contains:  Volatile oils 9-11 %, 
                   Water content 6 % 
                   Maltodextrin 87.5 % 
                   Modified Starch 3.5 % 
                   Ascorbic acid 0.6 % ) 
 
 
 
 
 
 
 
Sucralose                          0.1% w/v 
Orange Flavour Permaseal®  
0.37 %  w/v 
(Contains:    Volatile oils 9-11 %, 
                     Water content 6 % 
                     Maltodextrin 87.5 % 
                     Modified Starch 3.5 % 
                     Ascorbic acid 0.6 % ) 
 
Orange Flavour Givarome 
Permaseal®  0.044 %w/v  
(Contains:     Volatile oils 16-20 %, 
                     Maltodextrin 77.5 % 
                     Modified Starch 3.5 %) 
 
Sucralose                           0.1% w/v 
 
The rheology of HPMC 0.5, 1 and 2 %, unflavoured was slightly lower than 
that of the flavoured and sweetened as expected by the increased solids 
concentration. Each of the two orange flavouring agents with sucralose 
(composition as detailed in Table 3-5) was investigated as detailed in Section 
2.2.2.5.1. and the similarities between the two batches are illustrated in 
Table 3-6 
 
Table 3-6: Comparison between the Viscosities of Different Batches of Flavoured 
and Sweetened HPMC 
 HPMC 
Concentration 
(%) 
Mean±SD of Viscosity at 50 s-1 
(mPas) 
Mean±SD Yield Stress 
(Pa) 
Batch 1 Batch 2 Batch 1 Batch 2 
0.5 19.5 ± 0.4 24.7 ± 1.3 <0.3 
1 161.9 ± 0.5 169.3 ± 1.48 1.8 ± 0.4 2.2 ± 0.5 
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2 1632.5 ± 13.4 1625.5 ± 21.9 3.5 ± 1.1 4.0 ± 0.98 
3.3. Results and Discussion 
 
3.3.1. Initial Grittiness Trial 
 
The sample with the highest grittiness score contained HPMC 0.1 % with 
particles of 500 µm at 500 mg/5 ml (which scored an average of 84 ± 16 mm) 
with all 500 mg/ 5ml samples scoring high as seen in Figure 3-3. The sample 
with the overall lowest grittiness score as well as the sample which was most 
commonly ranked the lowest grittiness sample by individuals contained 
HPMC 0.1 % and particles of 100 µm at 5 mg/ 5 ml (which scored 11 ± 11 
mm), with all 5 mg/ 5ml samples scoring low.  
 
 
  
Figure 3-3: Mean Grittiness Scores (±SD) for all Samples containing HPMC 0.1 %, 
1 % and 3 % solutions 
 
Using a repeated measures ANOVA to assess the grittiness scores, particle 
size and particle concentration were found to have a significant effect on 
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grittiness (p < 0.005) whilst the effect of viscosity was not significant with the 
raw SPSS output shown in the Appendix (Field, 2009).   
The reason for this lack of significance for viscosity may be due to the poorer 
suspending ability of the less viscous HPMC 0.1 % solutions and difficulty in 
dispersing the particles in the more viscous HPMC 3 % as seen in the 
suspendability assessment which may mean that the Cellets® separated out 
from the suspending media and hence felt gritty. The reason for this lack of 
significance may also be due to the unpleasant, mouth coating feel and taste 
of HPMC as reported orally by participants and shown through the lack of 
HPMC 3 % samples being rated as “most acceptable” in Table 3-7. It can be 
seen that the least gritty sample was not the most accepted and that the 
most important influence on acceptability was the particle concentration then 
viscosity as long as it didn’t contain HPMC 3 %. Large ranges in grittiness 
scores were observed which are common in sensory research.  
 
Table 3-7: Top Five “Most Acceptable” Samples for the Initial Trial showing the 
samples that were ranked as “most acceptable” with the highest frequency (out of 
the twenty volunteers along with the composition of the samples and the range of 
grittiness scores for each of the five most acceptable samples 
Rank Frequency 
(/20 
volunteers) 
HPMC 
Concentration 
(%)  
Size 
(µm)  
Particle 
Concentration 
(mg/5 ml)  
Grittiness 
Score 
(mm) (Min 
- Max)  
1 14  1  500  5  2 – 88 
2 13  1  100  5  1 – 43 
3 11  0.1  100  5  1 – 43 
4 6  1  200  5  3 – 74 
5 5  0.1  500  5  3 – 50 
 
For females in the initial trial, concentration, size and viscosity were all 
significant effects as was [concentration* viscosity] and [concentration*size] 
whereas for the males there was a significant effect of concentration, size 
and [concentration*viscosity] only (overall: concentration, size, 
[concentration*viscosity], [concentration*size] and [viscosity*size] were seen 
to have a significant effect).  The mean grittiness scores were similar 
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between males and females overall at 50 ± 33 mm and 46 ± 34 mm 
respectively. The Independent-Samples T Test procedure was used to test 
the significance of the difference between two sample means for the two 
sexes and as Levene statistic is greater than 0.1, the variances were not 
statistically significantly different. 
 
 
3.3.2. Refined Grittiness Trial 
 
The results of the refined grittiness trial can be seen in Figure 3-3. It can be 
seen that the grittiness scores appear to be similar for those 90 µm particles 
at 125 and 250 mg/ 5ml in all viscosities and that those suspensions 
containing 500 mg/5 ml at 263 µm have higher grittiness scores. 
 
  
  
 
Figure 3-4: Mean Grittiness Scores (±SD) for all Samples Containing Hydroxypropyl 
methylcellulose 0.5 %, 1 % and 2 % Sweetened and Flavoured Solutions 
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From the ANOVA, it was be seen from the highlighted significance values 
that particle size, viscosity and size*viscosity have a significant effect on 
grittiness (p<0.005 with the raw SPSS output available in the Appendix) 
which suggests the acceptability of the HPMC was improved and narrowing 
the variables reduced grittiness.  
 
In terms of acceptability in the refined trial, the most frequently rated as the 
most acceptable “sample” was the blinded negative control (containing 
HPMC 0.5 % with no particles) as expected. This sample was, 
unsurprisingly, the least gritty and only not reported as the least gritty on six 
occasions: when it was given.  The most acceptable of the samples (not the 
controls) is shown in Table 3-8 where it can be seen that there seems to be 
little difference between particle sizes of around 100 µm and particle 
concentration of 125-250 mg/5 ml on acceptability scores. Again it is seen 
that the most acceptable score is not necessarily the least gritty and that 
there is a large spread as shown by the large range. 
 
Table 3-8: Top Five “Most Acceptable” Samples for the Refined Trial showing the 
samples that were ranked as “most acceptable” with the highest frequency (out of 
the twenty volunteers along with the composition of the samples and the grittiness 
score for each of the five most acceptable samples to show that the most 
acceptable samples are not necessarily the least gritty 
 
Rank Frequency 
(/20 
volunteers) 
HPMC 
Concentration 
(%) 
Size 
(µm)  
Particle 
Concentratio
n  
(mg/ 5ml)  
Grittiness  
Score (mm)  
(Min – 
Max) 
1 10 0.5 127 125 0 – 60 
2 9 1 90 125 0 – 65 
3 8 0.5 90 125 1 – 60 
4 6 0.5 90 250 0 – 66 
5 5 2 127 125 0 -86 
 
Reproducibility of the grittiness scores was assessed by comparing the 
scores of the announced controls with the blinded controls. It was found that 
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the majority of times, the controls were within 5 mm of the announced 
negative controls and 10 mm of the announced positive controls, the slightly 
higher range of the positive control may be due to more varied 
suspendability/dispersibility of larger particles as seen in Chapter 2. Although 
the means were not always the same, the negative control was only not 
voted the least gritty 6 times (very low score so within 5 mm of the sample 
the participant scored the least gritty) showing good reproducibility. No 
effects on the order of sample presentation on grittiness scores were 
identified as samples of similar composition scored similarly irrespective of 
sample timing (e.g. those containing low concentrations of particles scored 
low grittiness scores wherever they came in the order of sampling). This 
study did not use trained volunteers so a degree of variability can be 
expected between results. The participants had not been pre-screened or 
trained as the aim of the study was not to be able to put samples into order 
of grittiness due to concentration etc, more to see what the average 
consumer found gritty.  
 
 
3.3.3. Comparison between the Two Trials 
 
In the initial trial, all individuals were aged between 18-24 years but individual 
data is not available whereas in the refined trial, the average age was 
22.4±1.03 years (range: 20.6 – 25.3) 
 
 Male and female groups average was similar but the standard 
deviation and range being higher in the male group due to the oldest 
male being 25.3 years compared with 23.9 years for females  
 Grittiness scores had similar means, standard deviations and ranges 
for those aged 21, 22 and 23 years 
 There were few 20 year olds, no 24 year olds and one 25 year old so 
the impact of age not be assessed  
 
It is unsurprising given the narrow age range of healthy adults that no age 
related effects on grittiness were seen. 
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In summary, from comparing the two trials it can be seen, by narrowing the 
particle concentration, size and viscosity with improved mouthfeel, particle 
size and viscosity become significant impacts in grittiness unlike with  the 
unacceptable HPMC of the first trial where particle concentration and size 
effect grittiness. Acceptability in the first trial largely depended upon particle 
concentration and rejected all more viscous HPMC concentrations whereas 
that of the refined trial found both lower particle concentrations and sizes to 
be acceptable along with all viscosities. 
 
Particle concentration and size have both previously been seen to have a 
significant effect on grittiness whereas the effect of viscosity is less clear 
(Engelen et al., 2005b, Imai et al., 1995, Tyle, 1993). One study which 
looked at the significance of viscosity reported a difference and the other not: 
this may be due to the two viscosities of the group that did not find a 
difference being too close together for it to be noticeable but the lack of clear 
rheological testing complicates the issue (Engelen et al. 2005, Imai et al. 
1995). 
 
Although not strictly valid for assessing significance due to the difference in 
variables between the two trials, a t-test was used as a method of comparing 
the two trials. The most similar samples were compared:  
 
 The HPMC 1 % solution with 100 µm Cellets® at 500 mg/ 5ml of the 
initial trial compared with the 127µm Cellets® at 500 mg/ 5ml in the 
refined trial  
 The HPMC 1 % solution with the 200 µm Cellets® at 500 mg/5 ml of 
the initial trial compared with the 263 µm Cellets® at 500 mg/5 ml.  
 
The newer samples scored lower (p values of 0.000922 for the 100 µm 
Cellets® and 0.000831 for the 200 µm), so it was concluded that narrowing 
the particle concentration, size range and viscosity along with flavouring and 
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sweetening the media reduced grittiness scores as a trend, as can be 
observed through looking at the raw data. 
  
In both grittiness trials, participants were given announced positive and 
negative standards against which to base their scores which was given at the 
start only which may be a potential source of variation as individuals may be 
unable to remember accurately the grittiness of the controls but not having a 
freely available negative and positive control reduced the number of samples 
in a session which was already high. In this trial, a constant blinded control 
would be difficult to have freely available due to suspension stability as 
examined in Chapter 2 and the requirement for the samples to be kept 
rotating whilst waiting to be given to keep the particles suspended in the 
media which would not be achievable in real life but allowed for grittiness 
assessment. Despite the lack of constant controls, blinded controls were 
given in the refined trial which showed good reproducibility with the 
announced controls especially in the case of the negative control. 
 
Magnitude estimation is a technique used in sensory analysis to attempt to 
account for the variety in a response between individuals. Through the use of 
this technique, responses received from participants can be normalised 
through comparison to the mean grittiness score of all samples for each 
participant to remove the effect of participants who rank all samples low or 
high to show a similar difference in score between samples hence the 
magnitude or gradient of the response is often similar.  The samples are 
placed in an order since the technique of magnitude estimation depends on 
the gradient of the response e.g. the gradient of grittiness scores and hence 
cannot be calculated if the results are not in an increasing or decreasing 
order of magnitude. While it was found more people were able to score size 
and concentration into the expected corresponding order of grittiness than 
viscosity, less than half of the people could put the samples in the correct 
order. This may be due to the number of samples and their variables being 
tested being confusing or tiring for the volunteer (despite being within limits 
of other studies) or it could be that people perceive no real difference 
between these samples. It was seen that by increasing the number of 
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volunteers and narrowing the ranges, the number of people who could put 
the samples into the correct order increased but was still low meaning that 
magnitude estimation could not successfully be used due to the small 
numbers of volunteers’ responses that could be used in determining similar 
gradients or magnitude of response for particle size, particle concentration or 
viscosity.  
 
A Principal Component Analysis would be another way to analyse the data 
but again the variability and number of results for each sample which has 
three variables would make it unlikely a meaningful analysis and loadings 
plot could be obtained. 
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3.4. Conclusions 
 
The importance of a child not rejecting a medicine is critical to therapeutic 
outcomes so the impact of different sizes and concentrations of pellets in a 
commonly used suspending media (HPMC) at different concentrations 
(viscosities) was on grittiness and acceptability of the resulting suspensions 
in young adults aged 18-24 years of age as this was the lowest age group 
that the researchers had easy access to. 
 
An initial trial found that grittiness of larger particles (>100 µm) depended 
upon particle concentration and size whereas viscosity showed no 
correlation. This trial highlighted the importance of acceptability of medicines 
in all ages given that the young adult participants did not find the thicker (3 
%) HPMC to be acceptable due to its unpleasant mouth coating effect. 
Acceptability was seen to depend largely on particle concentration and any 
viscosity apart from the HPMC 3 % although large deviations of grittiness 
scores were seen for these samples. 
 
The refined trial aimed to remove the lack of acceptability of HPMC by 
adding a popular flavour of orange and a sweetener, sucralose, and reducing 
the highest concentration which reduced the mouth coating effect. This trial 
made improvements on the methodological design by increasing participant 
numbers, randomising orders and checking reproducibility of results with 
“blinded” controls along with narrowing the range of particle sizes and 
concentrations since these were seen to have a significant effect in the initial 
trial so it was interesting to look at a narrower region to see if this 
significance would still hold. 
 
The refined trial showed a significant impact of particle size and viscosity on 
grittiness, whereas particle concentration did not. From observation of the 
data, this appears to be due to similar grittiness scores of the 125 and 250 
mg/ 5ml particle concentrations. In terms of acceptability, all HPMC 
concentrations were in the top five most acceptable rated formulations, with 
both of the lower particle sizes and particle concentrations. This suggests 
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that an acceptable formulation can be made with a particle size of around 
100 µm (since 90 and 127 µm are similar) with a particle concentration of 
250 mg/ 5ml (with up to 500 mg/ 5ml possibly not have unacceptable 
grittiness but not being rated as acceptable) and any viscosity from HPMC 
0.5 - 2 % showing acceptability so more viscous media may be preferred in 
keeping a multiparticulate suspension stable and uniform over time/masking 
grittiness. It is however acknowledged that Cellets may have different 
densities, morphologies and particle sizes to those produced by spray drying 
so different results may occur and would be worthy of future study. 
 
Future work to develop on this topic would be to try a smaller particle size to 
see if a region where particle size does not have a significant effect on 
grittiness could be assessed.  It would be interesting to try a smaller range of 
grittiness samples in children to assess whether they find the same things 
gritty and acceptable as young adults. While it is believed that children will 
have similar orders to adults in sensory tests, the magnitudes of their 
responses may vary. The visual analogue scale scoring system used has 
been used in children before so a similar trial may be achievable in older 
children. Alternatively hedonic “smiley face” scales or care giver observations 
may be used, dependent upon the age of the child. 
 
Taken together the work reported above on particle suspendability (Chapter 
2) and grittiness/mouthfeel (Chapter 3) provides targets for the particles that 
need to be produced in Chapter 4 and the suspending vehicle that any 
successful particles could be suspended in for paediatric dosing.  The major 
factor that can be controlled by varying the spray drying parameters is the 
particle size hence a particle size of ca 100µm or less was targeted in the 
work described below. 
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4. PRODUCTION OF MULTIPARTICULATES 
 
4.1. Background 
 
Multiparticulates offer one attractive route to generating a platform (e.g. non 
drug containing base) formulation approach addressing the issues 
associated with dosing of API’s to paediatric patients of a wide range of ages 
as discussed in Chapter 1.  The overall aim of this project was to produce 
coated particles that could be suspended in a suitable vehicle as discussed 
in Sections 2 and 3 to produce a stable, liquid dosage form that would allow 
range of doses to be administered with acceptable grittiness. Hence this 
section discusses the production of taste masked multiparticulate 
formulations of insoluble and soluble model drugs (Quinine base and Quinine 
hydrochloride respectively) as an example of functionalised multiparticulates.  
It can be envisaged that other modified release profiles could be generated 
in a similar manner using alternative polymers as the coating agents 
although time constraints mean that this has not been demonstrated yet. 
 
4.1.1. Bitter Tasting Drugs 
 
As mentioned in Chapter 1, many drugs suffer from a bitter taste which can 
adversely affect compliance. Drug families which suffer from a bitter taste 
include a wide range of drugs required commonly in paediatrics including: 
 
 Anti-Malarials (Shah and Mashru, 2009, Shah et al., 2008, Shah and 
Mashru, 2008b, Shah and Mashru, 2008a) 
 Antibiotics  (Sollohub et al., 2011, Hu et al., 2009, Ishizaka et al., 
2007) 
 Anti-HIV medicines (Chiappetta et al., 2009) 
 Corticosteriods (Orlu-Gul et al., 2012, Hames et al., 2008) 
 Gastro-intestinal medicines (Bora et al., 2008, Xu et al., 2008b, Khan 
et al., 2007) 
 Analgesics (Guhmann et al., 2012, Hejaz et al., 2012) 
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Quinine was chosen as a model drug due to its extreme bitterness as it is 
used in the gustatory response scale where bitterness is equated to different 
molarities of quinine solution (British Pharmacopeia Online, 2012). Quinine is 
an anti-malarial currently only available in the United Kingdom as tablets due 
to its bitter taste or an injection for those children who cannot swallow (British 
Medical Association and the Royal Pharmaceutical Society, 2012). A variety 
of approaches have been tried to mask the taste of the medicine (Kayumba 
et al., 2007, Kayitare et al., 2010, Woertz et al., 2010). Quinine exists both in 
a water insoluble basic form and a variety of very soluble salt forms including 
the hydrochloride salt as illustrated in Figure 4-1 which enabled the effect of 
different solubilities to be examined. Quinine possesses a chromophore so is 
easy to detect and quantify by ultraviolet spectrophotometry.  
 
 
Form Base Salt 
Aqueous 
Solubility 
1 g in 1900 ml 1 g in 16 ml 
 
Figure 4-1: Structure and Properties of Quinine and Quinine Hydrochloride 
dihydrate (Merck Index, 2006) 
 
 
4.1.2. Taste Masking by Spray Drying 
 
As discussed previously in Section 1 there are two general methods of 
overcoming the problem of objectionable taste: either to mask it by the 
addition of excipients such as flavours, sweeteners or taste blockers or to 
prevent the drug coming into contact with the taste buds e.g. by coating or 
microencapsulation.  This work examines an example of this latter approach 
utilizing a pH sensitive polymer to form microparticles that are resistant to 
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releasing drug in the conditions found in the mouth but which would be 
expected to rapidly dissolve in gastric acid to allow the compound to be 
released for absorption with minimum adverse effect on the pharmacokinetic 
profile compared with uncoated drug particles. 
  
There are relatively few reports of microspheres production for taste masking 
by spray drying with most preparing orally disintegrating tablets (ODTs) as a 
way of administering the prepared particles with individual microsphere 
release not always characterized (Xu et al., 2008b). Most reports of spray 
drying for taste masking use drugs which are less soluble than the quinine 
hydrochloride salt used for much of this research and have a higher 
bitterness threshold than quinine (Bora et al., 2008, Xu et al., 2008b, Yan et 
al., 2010). The Eudragit® Polymers (especially L30D55 and E PO) along with 
cellulosics such as HPMC are the most commonly used polymers for 
preparation (Xu et al., 2008b, Janczyk et al., 2010). In terms of using 
hydrophobic polymers such as the Eudragits®, organic solvents have 
generally been used to solubilise the polymer which allows a reduction in 
spray drying temperatures compared to those of aqueous processes as 
discussed later (Bora et al., 2008, Shishu et al., 2010). An interesting 
approach using food industry components of sodium caseinate and lecithin 
exhibited some degree of release retardation of paracetamol (Hoang Thi et 
al., 2012). 
 
Eudragit® E is the one of the most commonly spray dried polymers for taste 
masking. Eudragit® E PO is a cationic copolymer of dimethylaminoethyl 
methacrylate and neutral methacrylic esters as shown in Figure 4-2. This co-
polymer dissolves below pH 5 so is soluble in the stomach so that the 
bioavailability of this medicine is not affected, but it remains intact in the adult 
buccal cavity (pH 5.8-7.4).  
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Figure 4-2: Structure of Eudragit® E PO 
 
Eudragit® E has been used for film coating for protecting medicines from the 
moisture in the atmosphere in addition to taste masking due to its properties 
such as low vapour transmission as detailed in Table 4-1 
 
Table 4-1: Properties of Eudragit® E (Evonik Industries, n.d.) 
Eudragit® E 
Molecular Weight (g/mol) 47 000 
Glass Transition Temperature (°C) ~ 48 
Water Vapour Transmission Rate with stearic acid (g/m2.d) ~ 100 
Elongation at Break with 10%SDS+15% stearic acid (%) ~ 60 
Thermal Stability Maximum Temperature for 1% damage (°C) ~ 210 
 
While Eudragit® E has not had extensive use within paediatrics, it was 
chosen due to its pH profile (Evonik Industries, n.d.). Eudragit® E is 
biocompatible meaning that the body should tolerate the polymer and that it 
should not cause any adverse events, but it is not biodegradable so is not 
broken down by the body. Company data suggests a maximum of 20 
mg/kg/day based on rat and dog toxicity studies with the highest amount in a 
dosage form of 566 mg) (Evonik Industries, n.d.). It can be seen from Table 
4-2 that Eudragit E has precedence of use in the United Kingdom including in 
older children although the levels used are unknown (Electronic Medicines 
Compendium, n.d.). 
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Table 4-2: Oral Formulations Available containing Eudragit® E (basic butylated 
methacrylate copolymer) (Electronic Medicines Compendium, n.d.) 
Formulation  Age Licenced From Form Used 
Amisulpride tablets 400 mg Sandoz 
Limited 
<15 years E100 
Calpol 6+  Fastmelt Orodispersible 
Tablets 250 mg  (Paracetamol) McNeill 
Products Ltd 
< 6 years E100 
Liskonum Tablets 450 mg (Lithium 
Carbonate) GlaxoSmithKline UK 
< 12 years E12.5 
Salofalk  Gastro-resistant Tablets 500 mg 
(Mesalazine) Dr Falk Pharma UK Ltd 
< 6 years - 
Risperidone Orodispersible Tablets 0.5, 1 
and 2 mg Sandoz Limited 
< 5 years - 
Paroxetine Film Coated Tablet 10 mg 
Actavis UK Ltd 
< 18 years - 
Siklos  Film Coated Tablets 100 mg 
(Hydroxycarbamide) Nordic Pharma 
Limited 
< 2 years - 
Venaxx XL Tablets 75 and 150 mg 
(Venlafaxine hydrochloride) Mercury 
Pharma Group 
< 18 years E12.5 
Zispin SolTab Orodispersible Tablets 15, 
30 and 45 mg (Mirtazepine) Merck Sharp 
and Dohme Limited 
< 18 years - 
 
Despite Eudragit® E PO having been sprayed from organic solvents and 
exhibiting retarded release as microparticles no reports were found of 
aqueous spray drying with release controlled by microparticles (only one 
which tabletted the microspheres without assessing release) (Xu et al., 
2008b).  
 
Two other reverse enteric polymers were found in the literature. Methyl 
methacrylate – diethylaminoethyl methacrylate copolymer (6:4) 
(commercially known as Kollicoat Smartseal® 30D) only become available 
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after much of this research had been undertaken but looks to be an 
interesting prospect due to its low water vapour transmission (BASF, Chivate 
et al., 2012) Another polymer polyvinylacetal diethylaminoacetate appeared 
interesting but no source could be obtained (Hashimoto et al., 2002). Hence 
Eudragit® E was used to try to taste mask. 
 
4.1.3. Spray Drying 
 
4.1.3.1. Overview 
An introduction to spray drying was given in Chapter 1. Briefly it involves the 
atomisation and drying of a feed to form a dry product. Spray drying was 
chosen as the technique to attempt to develop taste masked 
multiparticulates due to its scaleupability and desired product characteristics. 
The spray dried formulation will depend on a variety of variables including 
those of the drug, excipients and processing parameters. 
 
Different types of spray drier, although largely working on the same 
principles, can have different atomisers (such as two fluid, pressure and 
ultrasonic nozzles or a rotating disk) and different patterns of drying media 
flow (e.g. co-current where the feed is sprayed in the same direction as the 
hot air flow, counter current where product and drying air flow in opposite 
directions or in a disk atomiser in the same direction as drying air). Both 
machines used in this research have a two fluid where the spray is due to the 
air and feed combining and co-current flow. 
 
In terms of producing product by spray drying, the evaporation of the solvent 
from the droplet involves coupled heat and mass transport. The spray-drying 
process is driven by the vapour pressure of the solvents and their partial 
pressure in the gas phase (Vehring, 2008). The rate of evaporation depends 
on the vaporisation energy of the solvent and the energy that is available at 
the surface of the droplet (Handscomb et al., 2009). This process is shown in 
Figure 4-3 
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Figure 4-3: Schematic showing Different Particle Morphologies that can occur on 
Spray Drying along with a Temperature Profile for a Particle (where AB is where the 
particle is rapidly heated to the wet bulb temperature, followed by constant drying as 
the surface is still saturated with water shown by BC then CD when the moisture on 
the surface can no-longer be retained and a small rise shown by DE when the 
moisture boils off before all free moisture has been removed and EF is the 
temperature of the air) (Handscomb et al., 2009) 
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Microparticles produced by spray-drying possess a large surface area and 
hence can be thermodynamically unstable. These microparticles may have 
not reached equilibrium due to the short drying times employed and so may 
crystallise, coalesce or undergo polymorphic transformation – all of which 
could lead to the failure of the microparticles desired drug release profile. 
 
The glass transition temperature of a material is important in spray drying. 
This is where the material goes from a brittle to a rubbery state as the 
molecules become more mobile and occurs with change in heat capacity. 
Below the glass transition temperature (Tg), the polymer will be more hard 
and rigid whereas above the Tg, the polymer is more soft and sticky as 
shown in Figure 4-4. Plasticisers, solvents and residual solvents can act as 
plasticisers and hence reduce the glass transition temperature and increase 
the elasticity and permeability, hence it is has been recommended to keep  
Eudragit E at 40 °C for at least 2 hours after coating to prevent this (Evonik 
Industries, n.d.). 
 
 
Figure 4-4: A Representation of Glass Transition Temperature and Physical State 
(University of Bolton, n.d.) 
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4.1.3.2. Excipients 
 
Different excipients are required in a spray drying feed in order to produce a 
product with acceptable properties. The most obvious excipient as covered in 
the previous section is the polymer which will be responsible for the 
functionalised release and the solvent as discussed in the next section. 
Other excipients are largely required to ensure optimum conditions for this 
polymer. Exact composition depends on the polymer and drug whether the 
feed is a suspension, solution or emulsion feed. 
 
Components can be added to solubilise the other constituents such as pH 
modifiers e.g. stearic acid is used as a salt former with the Eudragit® E 
polymer. Stearic acid also reduces the water transmission rate of Eudragit E 
when compared with that of the organic formulation (~350 g/m2.d) 
 
Anti-tacking or anti-adherent agents (also known as glidants) are used to 
reduce the tendency of the product to stick to the spray drier and hence can 
increase yield. Common examples include talc, glyceryl monostearate and 
colloidal silica. The use of anti-adherents can increase permeability by 
decreasing effective concentration of polymer for film formation and hence 
solubility retardation or by providing a ‘wick’ to draw solvent inside the coated 
particle. Magnesium stearate is less commonly used and additionally lowers 
permeability possibly via generating small discontinuities, or holes in the 
coat. 
 
Components such as Polyethylene glycol can act as permeability enhancers 
where required as well as a plasticiser and stabiliser. Plasticisers may be 
used to reduce the temperature needed to form the film especially where 
organic solvents are used. Other components used to stabilise the 
formulation include low viscosity NaCMC or SDS to 
solubilise/suspend/disperse polymers and antifoaming agents may be 
required. 
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4.1.3.3. Solvents 
 
The desirable attributes of a solvent for microencapsulation have been 
defined as (Li et al., 2008): 
 
1. Be able to solubilise the required polymer to ensure encapsulation 
2. Have a high volatility and low boiling point to ensure the solvent 
evaporates 
3. Have a low toxicity 
 
Unfortunately no individual solvent seems to achieve all of these criteria and 
hence decisions have to be made into which solvent to use.  
 
The use of organic solvents can be problematic, especially in the scale-up of 
pharmaceutical production due to the potentially toxic hazards of both the 
fumes and residual solvents and flammability risks. It is for these reasons 
that no organic solvents will be used in the production of the microparticles – 
only aqueous methods. 
 
The international conference on harmonisation of technical requirements for 
registration of pharmaceutical use (ICH) has a guideline which sets limits for 
the residual solvent that may remain in products after processing (European 
Pharmacopeia, 2008).  The ICH guidelines categorise solvents into one of 
three classes depending upon their toxicity: Class 1 are solvents to be 
avoided such as known or suspected carcinogens or environmental hazards, 
Class 2 are solvents to be limited as they may be animal carcinogens or 
cause other irreversible toxicity and Class 3 are solvents with low toxic 
potential so have no health-based safety limit and a permitted daily exposure 
of 50mg/day or more. Ethanol is increasingly being used as a class 3 solvent 
or non-organic solvent containing methods are being developed 
 
The ICH expects that testing for solvents should be carried out when 
production or purification processes result in the presence of solvents: only 
those solvents known to have been used or made have to be tested for. 
CHAPTER 4: PRODUCTION OF MULTIPARTICULATES 
150 
 
Individual components can be tested or the complete medicinal product can 
be tested for impurities.  The limits can be given as a concentration limit 
(ppm) or permitted daily exposure (mg/day). Residual solvents are usually 
determined by chromatography, for example by static headspace capillary 
gas chromatography. Obviously when we are trying to minimize chemicals in 
children’s formulations as discussed in Chapter 1, having no residual 
solvents of toxicological concern would be an advantage. 
 
It is reported that storing Eudragit® RS/RL microspheres of ketoprofen in 
sealed containers after storing in a dessicator caused them to lose their 
spherical shape and form clusters. This is thought to due to residual solvent 
acting as a plasticiser since those microparticles stored in open containers 
did not exhibit this behaviour so this is may be an additional reason that 
organic solvents should be minimised. 
 
Aqueous spray-drying is desirable but due to the higher temperatures 
required to remove the water and lack of solubilising ability for hydrophobic 
polymers, it has still not been completely conquered with microparticles 
formed often being less spherical and more aggregated than those formed 
during organic solvent spray drying (Kendall, 2007). Drug loading may also 
be reduced as more excipients need to be added to solubilise/suspend the 
polymer and drug which is important as the lower the drug loading, the 
higher the mass of multiparticulates we would have to give to the child which 
may impact compliance. 
 
The rate at which the solvent is removed is dependent on temperature, 
pressure and amount of water in the process. High temperatures can harden 
the microsphere whereas very high temperatures may damage them due to 
the very sudden evaporation of solvent. The thermal stability of the 
encompassed drug must also be taken into account. 
 
In order to optimise both the efficiency of the spray drier and product 
production, the feed properties must be looked at. When organic solvents are 
used to solubilise the polymer and drug a solution feed is formed versus a 
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suspension feed when the drug is not solubilised (Emami et al., 2007). The 
different types of feeds can form different particles: from a solution feed the 
products formed may be polymer or drug spray-dried individually without any 
coating, the spray dried drug within a polymeric film or on the surface of it, 
whereas a suspension feed mainly produces microencapsulated drug with 
smoother surfaces than those formed from a solution feed (Rattes and 
Oliveira, 2007). Increasing the polymer to drug ratio further decreases 
dissolution rate compared to lower ratios, probably due to increased polymer 
coating thickness (Emami et al., 2007). 
 
It is known to be difficult to produce smooth, spherical particles by aqueous 
spray drying due to insufficient forces being present to prevent the formation 
of fibres. A number of the papers on spray-drying report that their spray-
drying apparatus is not equipped with a trap and hence smaller and lighter 
particles are lost in the exhaust gas. Adhesion of the powder to be spray 
dried to the walls of the drying chamber and cyclone collector are also 
another common limitation which can be reduced by the addition of an anti-
sticking agent such as colloidal silica or talc to the spray drying feed which is 
of relevance as it reduces drug loading. 
 
Aqueous dispersions contain polymer latex particles rather than the 
dissolved individual polymer molecules which require the evaporation of 
water to move closer and form a film dependent upon the particles elasticity 
and surface tension are a potential alternative approach (McGinty and 
Felton, 2008).  
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Aqueous dispersions of water-insoluble polymers have traditionally been 
used for the coating of tablets and pellets due to their lack of organic 
solvents: some examples are: 
 
 Eudragit® RS 30D contains 30 % w/w co-polymer of ethyl-acrylate, 
methyl-methacrylate and trimethyl-ammonioethyl-methacrylate 
chloride in the ratio of 1:2:0.1 and 0.25 % sorbic acid (Rassu et al., 
2008) 
 Kollicoat® SR 30D contains polyvinyl acetate 27 %, 
polyvinylpyrrolidone 2.7 % and sodium lauryl sulphate 0. 3% (Al-Zoubi 
et al., 2008a) 
 Surelease® is an aqueous dispersion of ethylcellulose, dibutyl 
sebacate as a plasticizer and ammonium oleate as a stabilizer (Rattes 
and Oliveira, 2007) 
 
These dispersions are  beneficial for medicines that are highly water soluble but 
poorly soluble in organic solvents such as buspirone hydrochloride (Al-Zoubi et 
al., 2008a). Spray dried microspheres of buspirone with Eudragit® RS 30D or 
Kollicoat® SR 30D. Microspheres with high (1:1) drug: polymer ratios with large 
agglomerates are formed due to coalescence caused by the crystallisation of 
the buspirone with those formed Kollicoat® being more spherical than those 
formed by Eudragit®.  The yield was low (7.2 – 31 %) but this has been seen 
before during aqueous spray-drying as shown in Table 4-3: the yield was higher 
for Eudragit® which is thought to be due to the presence of PVP (a known 
binder) in Kollicoat® causing increased adherence of droplets to the internal 
surfaces of the spray dryer. The presence of PVP is also thought to be the 
reason for the slower drug release from tabletted microspheres made with 
Kollicoat® compared to that of microspheres made with Eudragit®. 
 
Surelease® and Eudragit® RS 30D were used to produce diclofenac 
particles by aqueous spray-drying with a drug-to-polymer ratio of 1:1. Both 
were able to sustain drug release for several hours at pH 6.8 and provide 
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less than 10% release at acidic pH time (Rattes and Oliveira, 2007). Similar 
results were provided by both polymeric dispersions (Zeng et al., 2007). 
 
The ethylcellulose aqueous dispersions, Surelease® and Aquacoat®, are 
stabilised by anionic surfactants and thus solutions/suspensions containing  
cationic drugs such as chlorpheniramine maleate, pseudoephedrine or 
propranolol hydrochloride may be unstable whereas Eudragit® RS and RL 30D 
are stabilised by quaternary ammonium groups and should be compatible with a 
wider range of drugs. (Zeng et al., 2007) 
 
To summarise, quinine hydrochloride and base were chosen as model drugs for 
taste masking and Eudragit® E PO for the encompassing polymer along with 
water as a solvent for spray drying. 
 
 
  
CHAPTER 4:PRODUCTION OF MULTIPARTICULATES 
Table 4-3: Summary of Some Aqueous Spray Drying Papers (key: -: designated information not given): 
Drug Polymer Drug: 
Polymer 
Ratio 
Additional 
Chemicals 
Operating Parameters Size/ 
Morphology 
Yield 
(%) 
Encapsulation 
Efficiency (%) 
Theophylline 
(Takeuchi et 
al.) 
Eudragit® 
L30D, 
L100-55 
and E30D 
8:3 -1:3 PEG 6000 and colloidal silica or 
ammonia water 
Inlet temp: 150-170 
o
C,  
Outlet temp: 105-110 
o
C,  
Solution flow rate: 1000 ml/h 
Rotation speed of atomiser 
16500 rev/min 
10-30 µm 
Agglomerated/ 
rough surface at 
high drug: 
polymer ratios 
- - 
Buspirone 
(Al-Zoubi et 
al., 2008b) 
Eudragit® 
RS 30D 
and 
Kollicoat® 
SR 30D 
1:1 -1:9 - Nozzle: 406 µm 
Inlet air temp: 133-136 
o
C, 
Outlet air temp: 70-80 
o
C, 
Spray air pressure: 1 kg/cm
3
,  
Feed rate: 6 ml/min 
- 
Agglomerated 
and not spherical 
7.2-31 98-104 
Paracetamol 
(Billon et al., 
1999) 
NaCMC, 
HPMC, 
HEC, HPC, 
MCC and 
EC 
1:1 – 
10:1 
PVP with MCC, DBS with EC and 
PEG 6000 and 
succinic/phthalic/oxalic/tartaric/citric 
acid with NaCMC 
Nozzle: 500 µm 
Inlet temp: 140 °C or 160 °C 
Spray flow: 700 NL/hr; 
Atomizing air pressure: 1 
kg/cm
2
 
Feed Flow: 4 ml/min.  
- 
Agglomerated, 
rough particles 
17-70 - 
Depending on polymer, 
plasticiser and inlet 
temperature 
Diclofenac 
(Rattes and 
Oliveira, 
2007) 
Suralease® 
and 
Eudragit® 
RS 30D 
1 :1 Propylene glycol, talc, colloidal 
silica and titanium dioxide 
Feed flow rate : 3-6 g/min 
Inlet temp : 100-150 
o
C 
Atomising gas pressure: 1 bar 
Air flow rate: 60 m
3
/h 
9.1+/-6.2 – 
24.5+/- 15.1 µm  
Agglomerated 
but smooth 
particles 
- 63.9 -97.9 
(Higher for 
Suralease®) 
Famotidine 
(Xu et al., 
2008b) 
Eudragit® 
E PO 
1:2 SLS, Stearic acid, PEG 400 and 
colloidal silica 
Nozzle Size: 700 µm 
Inlet Temp: 110 °C 
Air Flow Setting: 600 NL/h 
<10 um 
Rough particles 
33.25-
41.23 
37.59-61.56 
Theophylline 
(Wan et al., 
1992) 
HPMCAS, 
HPMC, 
MC, 
NaCMC 
1:5 - 
5.5:1  
Triethylcitrate and citric acid 
monohydrate 
Inlet temp: 140 
 o
C 
Feed rate: 9 ml/min 
Air Flow rate: 0.5 m
3
/min 
Atomising air pressure: 1 
kgf/cm
2
 
- 
Very aggregated, 
non-spherical 
particles 
- - 
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4.2. Materials and Methods 
 
4.2.1. Materials 
Eudragit® EPO and colloidal silica (Aerosil® 200) were obtained from Evonik 
Industries, Germany. Stearic acid and polyethylene glycol 400 were obtained 
from Fluka Analytical, Germany. Sodium dodecyl sulphate, sodium chloride 
and di-sodium hydrogen ortho phosphate were obtained from BDH 
Chemicals Ltd, Poole. Quinine (99 % anhydrous) and phosphoric acid from 
Acros Organics, Belgium. Quinine hydrochloride dihydrate and Acetonitrile 
Chromasolv® (Gradient Grade for HPLC) from Sigma Aldrich, Germany. 
Trifluoroacetic acid (HPLC grade), potassium dihydrogen phosphate, sodium 
hydroxide and hydrochloric acid (5 M volumetric solution) were obtained from 
Fisher Scientific UK Ltd, Loughborough. 
 
 
4.2.2. Methods 
 
4.2.2.1. Feed Preparation 
 
Initially a method was used as previously described (Xu et al., 2008b). An 
aqueous dispersion of Eudragit® E PO (15% w/v) was prepared by 
dispersing the Eudragit® in 100 ml of distilled water with Sodium dodecyl 
sulphate 1.5 g and stearic acid 2.25 g using a high shear rate homogenizer 
(Silverson 44RTs, USA) at 100 RPM for 30 minutes. Quinine or quinine 
hydrochloride dihydrate 7.5 g to assess for the impact of drug (or no drug) 
and colloidal silica 7.5 g were added to distilled water. The Eudragit® E PO 
dispersion was added to this drug solution/suspension along with 
Polyethylene glycol 400.  
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4.2.2.2. Experimental Parameters 
 
The formulation was spray dried using a Niro SD Micro® spray dryer (Niro, 
Denmark) as shown in Table 4-4. All experiments were repeated in triplicate. 
 
Table 4-4: Initial Spray Drying Parameters 
Initial Spray Drying Parameters Used 
Atomising gas flow 2.5 kg/h 
Chamber inlet flow 25 kg/h 
Inlet Temperature  110 ºC 
Feed concentration 13 mg/ml 
 
Following initial settings, future experiments were modified in light of results 
as discussed throughout 4.3.1. by: 
 
- Changing homogenization settings/conditions to 10 minutes each 
for the polymer and drug dispersions and then 10 minutes after 
both were mixed at 1000 RPM (after 5 sec at 3000 RPM for both of 
the dispersions) 
- Changing the atomizing gas flow, chamber inlet flow and inlet 
temperature to 3 kg/h, 30 kg/h and 140 ºC respectively. 
- Changing the spray drier to a Büchi Mini Spray B191 (Büchi, 
Switzerland) with inlet temperature 140 ºC, aspirator setting 90 % 
and pump setting 20-35 %. 
 
 
4.2.2.3. Design of Experiments 
 
A design of experiments approach was employed due to the fact that there 
are a large number of variables to be considered within the spray drying feed 
and particles so some method of handling this number of experiments was 
required. The advantages of an experimental design approach compared to 
a “one factor at a time” method of changing variables to assess for the effect 
of variables are shown in Table 4-5 
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Table 4-5: Comparison between One factor at a Time and Factorial Designs 
One Factor at a Time Factorial Design 
Vary one factor at a time Varies multiple factors 
Estimates effects at Set conditions Estimates effects at different conditions 
No interaction effects Able to estimate interactions 
Averages by replication Averages throughout 
Lots of runs Fewer runs 
Design space not covered well Design space well covered 
 
There are many different types of design of experiments, each with their 
pros/ cons. An example of a full fractional design is shown in Figure 4-5: in 
this type of design all three factors are investigated at 2 levels (as given by -
1, +1).  
 
Figure 4-5: Full Fractional Design with Three Factors, Two Levels and a Midpoint  
(Cecchi et al., n.d.) 
 
For a design with three factors, the number of experiment required for a full 
factorial design is 23 = 8. It can be seen from this that as the number of 
variables to be assessed increases; the number of experiments required will 
increase exponentially: in part due to this reason fractional factorial designs 
can be used to reduce the number of experiments whilst still assessing a 
design area. As the spray drying formulation chosen had 5 components, 25 
would make 32 experiments (without midpoints) to screen the effect of 
different levels of the five excipients. For this reason a fractional factorial 
design was run which took 16 runs (without midpoints), whilst this reduces 
CHAPTER 4: PRODUCTION OF MULTIPARTICULATES 
158 
 
time and money spent experimenting, a reduction in the level of interaction 
effects which can be assessed additionally occurs. 
 
A fractional factorial design with three midpoints was run as described in 
Table 4-6 (Design Expert 8) to screen for the effect of different excipient 
levels on the particles formed. The factors are the independent variables 
which in this case were the excipients with levels as shown and the 
response/dependent variables were: 
 Yield (%) 
 Encapsulation Efficiency (%) 
 Drug release at pH 6.8 in 1min (%) 
 Particle Size (% of fines) 
 Particle Density (g/ml) 
 
Table 4-6: Output showing Experimental Design Runs from Design Expert. (Red 
illustrates high levels of excipient, yellow middle levels and green low levels) 
Std Run Eudragit® ®  SDS SA SiO2 PEG400 
    (x Drug) (% Polymer) (% Polymer) (% Polymer) (% Polymer) 
18 1 3.75 30 32.5 75 30 
17 2 3.75 30 32.5 75 30 
14 3 5 10 50 100 10 
9 4 2 10 50 100 10 
15 5 2 50 50 100 10 
13 6 2 10 50 100 50 
11 7 2 50 15 100 50 
1 8 2 10 15 50 10 
8 9 5 50 50 50 50 
16 10 5 50 50 100 50 
3 11 2 50 15 50 50 
12 12 5 50 15 100 50 
5 13 2 10 50 50 10 
10 14 5 10 15 100 10 
6 15 5 10 50 50 10 
7 16 2 50 50 50 50 
4 17 5 50 15 50 50 
2 18 5 10 15 50 10 
19 19 3.75 30 32.5 75 30 
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Basic descriptive statistics were determined using Microsoft Excel 2007 and 
analysis with Design-Expert Version 8.0.7.1 (Stat-Ease Inc, Minneopolis). 
 
Levels chosen for SDS, Eudragit and colloidal silica were based on values 
found from the literature as to ratios/percentages of these excipients used in 
spray drying. For stearic acid and PEG 400, no relevant information was 
found so the arbitrary but realistic levels were chosen based on discussion 
with colleagues. 
 
All formulations were spray dried on Büchi Mini Spray B191 (Büchi, 
Switzerland) and the feeds prepared in a similar way to the initial feed. All 
formulations contained quinine hydrochloride dihydrate (since this is likely to 
be the more difficult one to taste mask due to its aqueous solubility) and all 
had a total solids content of 50 g sprayed.  Scoping work was initially 
undertaken to try to enhance the solids concentration of the feed and 
increase the spray rate by modifying homogenization and spray parameters 
as described in Section 4.3.3.  
 
 
4.2.2.4. Analytical Method Development for Testing Microparticles 
 
4.2.2.4.1. HPLC 
A HPLC method for the determination of quinine hydrochloride dihydrate was 
developed to enable the quantification of drug both encapsulated in the 
microspheres and released by them to be determined. All method 
development used an Agilent Technologies 1200 HPLC with UV detection 
and a Phenomenex Kinetex 2.6µ C18 100 x 30 mm column at 40 °C and 
solvent flow rate of 0.5 ml/min. The solvents used were Acetonitrile + 
Trifluroracetic acid (TFA) 0.05 % w/v and TFA 0.05% v/v (aq) in differing 
proportions and under different wavelengths of detection. Standards 
solutions were prepared from a stock of 100 µg/ml in a range of 5-50 µg/ml 
by dilution in both acetonitrile 40 % +TFA 0.04 % v/v (aq) and distilled water 
in order to meet ICH criteria as detailed below with results and final 
conditions found in the HPLC Development Results in Section 4.3.2.1. 
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Specificity:  is the ability to analyse the drug in the presence of other 
components. This was assessed by: 
 Running standard solutions to find relevant wavelengths 
to use for HPLC and absorbance peaks 
 Changing HPLC conditions to ensure peak resolution of 
multiple drug peaks 
 Running all excipients in the microparticles individually 
to check whether they interfered with drug retention time 
and absorbance 
 Deliberately subjecting standard solutions to extremes of 
temperature and light exposure to see whether 
degradation products interfere (stress test of the quinine 
salt  200 µg/ml solution diluted 1:1  in acidic (0.2 M HCl), 
basic (0.2 M NaOH) and neutral conditions (distilled 
water) at 75 °C at periods of 30, 60 and 180 minutes and 
overnight were undertaken as well as photo degradation 
using a Suntest CPS+  for periods of 30, 60 and 120 
minutes and overnight at a setting of 500 W/m2 
 
Linearity is the ability for the absorbance to be proportional to the 
concentration of drug. This was assessed by running standard 
solutions and plotting standard curves with a regression line 
with linearity found from the 5-100 µg/ml tested. 
   
Sensitivity   involves determining the detection and quantification limits of 
the drug which are given as three times and ten times baseline 
noise as seen in equations 4.1 and 4.2 respectively  
 
Equation 4-1: Limit of Detection 
 
 
Limit of Detection  =  3 Sy/x 
           b 
 
 
CHAPTER 4: PRODUCTION OF MULTIPARTICULATES 
161 
 
Equation 4-2: Limit of Quantification 
 
Limit of Quantification  =  10 Sy/x 
                      b 
 
 
Where  b    =   Slope of the linearity correlation line 
  Sy/x = (yi – y)
2/n -2    
  N =   number of data points 
 
Accuracy refers to the closeness of reported measurements to the actual 
content and was assessed by running standards of known 
concentration at least three times.  Accuracy of the method was 
demonstrated.  
 
Precision refers to the closeness between repeated measurements and 
was assessed by running multiple standards on different days 
over at least a week at least three times although no other 
analyst ran samples (all experiments using HPLC were 
undertaken by the same individual)  
 
 
4.2.2.4.2. Filter Compatibility and Filtration Optimisation 
 
Filter compatibility was assessed for by drawing two standards of known 
concentrations of quinine hydrochloride dihydrate through the syringe 
attached filters which were available in the lab (filter units as detailed in 
Table 4-7) and assessing the quantity which passes through the filter by 
HPLC as detailed in Section 4.3.2.1. Filtering was used to ensure that only 
dissolved drug was sampled compared to that contained within 
microparticles which may release after sampling but prior to analysis and 
provide a source of variation. This is important since only dissolved and not 
encapsulated drug is free to interact with the taste buds and taste bad. 
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Table 4-7: Details of Syringe filter units used (from http://www.millipore.com) 
Name Pore Size 
(µm) 
Diameter Size 
(mm) 
Membrane Material 
Millex® GP 0.22 25 Polyethersulfone 
Millex® MP 0.22 33 Hydrophilic 
Polyethersulfone 
Medical Millex® HA 0.45 33 Mixed Cellulose Esters 
 
The effect of filtering microsphere samples was assessed by weighing 
around 20 mg of particles containing formulation F1 which as the first 
midpoint, contained all excipients at the mid level, into a vial with 20ml of 
water which was shaken for 30 inversions before being filtered and analysed. 
 
As the particles would be expected to release their entire content in an acidic 
environment initially samples assessed for acid release had not been filtered 
due to operator error. To assess for the effect of filtering and location of 
sample removal on dissolution, three different conditions were investigated 
on dissolution testing in 900 ml 0.1 N HCl at 37 °C in a paddle apparatus 
over 45 minutes: 
 
1. Samples removed using a syringe from the same location using as a 
sampling location an indwelling tube before being filtered using a 0.22 
µm filter as chosen above  
2. Samples removed using a syringe from the same location using an 
indwelling tube but without being filtered 
3. Samples removed using a syringe randomly anywhere from the 
dissolution vessel with no regard for location without filtering 
 
The effect of these conditions was investigated by HPLC analysis using 
different sizes of particles. To represent the range of particle sizes seen 
throughout the spray drying runs F6 and F16 particles were assessed. F6 
has a particle size of largely less than 25 µm and F16 has a particle size of 
over 1 mm where filtration was seen to effect results. 
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4.2.2.4.3. Washing Microparticles 
 
In order to remove any drug attached to the surface of formed microparticles 
it is necessary to wash them. Different centrifuge speeds, times and 
centrifuges were tried in an attempt to optimise washing to remove 
unencapsulated drug from the surface of the formed microparticles since 
unencapsulated drug would be free to interact with the taste buds and 
produce a bitter taste. Initially around 200 mg of formulation F1 in 35 ml of 
deionised water was used in a centrifuge (Sigma 3k30) and around 200 mg 
in 1ml using a Heraeus Microcentrifuge from Thermoscientific. Visual 
observations were made and samples taken and filtered for HPLC analysis. 
 
 
4.2.2.4.4. Content 
 
Eudragit® E PO (1 g) is reported as soluble in 7 g of methanol, ethanol, 
isopropyl alcohol, acetone, ethyl acetate, methylene chloride and 
hydrochloric acid (1 N). As on method development of HPLC in section 
4.3.2.1, three peaks were seen using acetonitrile as a solvent compared to 
two with deionised water; 5 ml of ethanol, methanol, acetonitrile and 
hydrochloric acid 1 N were added to microparticles (100 mg) and inverted 30 
times before being left for 5 minutes. Particles were also dissolved in 
hydrochloric acid 0.1 M by diluting 5 ml of 1 N to 50 ml. These samples were 
then filtered and analysed for content by HPLC in triplicate which enables the 
drug loading and encapsulation efficiency to be determined as shown in 
Equations 4-3 and 4-4 respectively. A high encapsulation efficiency means 
that drug is not left unencapsulated and able to interact with the taste buds or 
that drug is not being lost and drug loading is important since the higher the 
drug loading, there will be a lower excipient to drug ratio which is beneficial in 
minimizing excipients in children, a higher drug loading will also mean a 
lower mass of particles which will have to be administered to provide any 
given dose and hence a lower concentration of particles in suspension which 
may affect grittiness as detailed in Chapter 3. 
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Equation 4-3: Drug Loading  
 
Drug Loading =  Total mass of drug – mass of drug unencapsulated x 100 
                    Mass of particles 
 
 
Equation 4-4: Encapsulation Efficiency 
 
Encapsulation Efficiency = Total mass of drug – mass of drug unencapsulated x 100 
                                                                 Mass of drug expected 
 
 
 
4.2.2.4.5. Drug Release 
 
It is important to quantify the release of drug from the formulation at pH 1.2 
so as to be a immediate release dosage form and without intentionally 
changing the drug release and hence potentially pharmacokinetics, 80 % 
must be released within 40 minutes, It is also important to quantify the 
release at pH 6.8 as this is around salivary pH. The higher the concentration 
of drug released from the microparticles, the worse the bitter taste of the 
dissolved drug interacting with taste receptors and hence low drug release at 
pH 6.8 is desired. Ideally the release would have been tested in food or a 
suspending media which the particles would be given as these could extract 
drugs or impede release rate however suitable foods and media were not 
found in Chapter 2 (the foods tried were acidic which would have caused 
dissolution of the Eudragit® E PO and hence drug release). 
 
For release at pH 1.2, washed formulations underwent testing in 900 ml 0.1 
N HCl at 37 °C in a Pharmatest dissolution bath with paddle apparatus with 
manual sampling of 1 ml every 5 minutes for 45 minutes, the volume was 
kept constant by replacing the sample volume with further 0.1 N HCl and all 
samples filtered and analysed by HPLC in triplicate. 
 
To evaluate release in water/buffers simulated saliva was employed, the 
composition of which is shown in Table 4-8.  The methods used to assess 
release were either manual inversions in a 50 ml standard flask or by using a 
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Ika Vibramax at 200 RPM to shake 20 ml vials of the media, with around 200 
mg of sample accurately weighed for up to 30 minutes in an attempt to 
provide a lower volume dissolution vessel where the flask could also 
represent a suspension bottle. In both cases, sampling was at 1 minute and 
then 5 minute intervals for 30 minutes with 1 ml of media being withdrawn 
and replaced with fresh media before samples were filtered through a 0.22 
µm filter and analysed by HPLC. After 30 minutes, 1 ml of 1 N HCl acid was 
added which reduced the pH to less than 2 before an additional sample was 
removed after 5 minutes. 
 
Table 4-8: Composition of Release Media Used to Assess for Taste Masking 
(Marques et al., 2011) 
Simulated Salivary Fluid Phosphate Buffer 
Disodium hydrogen phosphate 23.8 g 
 
Potassium dihydrogen phosphate . 
                                                      9 g 
 
Sodium Chloride                            8 g 
 
 (Phosphoric acid or Sodium 
hydroxide to pH 6.8) 
 
Deionised water                       to 10 L 
 
Disodium hydrogen phosphate 35.3 g 
 
Potassium dihydrogen phosphate                      
                                                    34 g 
 
- 
 
 (Phosphoric acid or Sodium 
hydroxide to pH 6.8) 
 
Deionised water                       to 10 L 
 
 
4.2.2.5. Product Characterisation 
 
4.2.2.5.1. Yield 
 
The yield is a measure of the mass of particles recovered compared to that 
sprayed – this is very important as product which is not recovered because it 
has been removed as fines or coated the spray dryer is unable to be used 
and hence a waste of product and money especially in terms of trying to 
make an industrially viable formulation. The yield was calculated after 
measuring the weight of particles recovered using Equation 4.5 
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Equation 4-5: Yield 
 
Yield = Weight of particles recovered x 100 
   Total Weight of Solids Sprayed 
 
 
4.2.2.5.2. Size and Morphology  
 
Particles produced from the initial spray drying were sized using a Sympatec 
Helos Particle Size Analyser with RODOS/M dry dispersing unit (Sympatec, 
Germany) and 0.5-350 µm lens using the Fraunhofer diffraction method. 
Each measurement was performed on around 100 mg (around ¾ of a 
dispersing bottle) in triplicate and the mean/standard deviation reported of 
the X10, X50 and X90 which are the sizes that 10, 50 and 90 % of particles are 
below respectively. The sizes reported by this laser diffraction method were 
confirmed by microscopy.  
 
Particles produced in the experimental design were produced in a different 
size and so underwent sieve stack analysis instead.  Around 10 g accurately 
weighed was used where possible and initially a set of sieves (125, 180, 250, 
355, 500, 710 and 1000 µm) were used in a Sonic Sifter (Endcotts, UK). 
Where greater than 50 % of the particles were found to be less than 125 µm 
on the initial sieve stack analysis, these particles were subjected to another 
analysis using a set of smaller set of sieves (25, 38, 53, 75, 106 and 150 µm) 
with results reported as size and/or percentage of fines less than 25 µm due 
to the limited range of sieve stacks available not allowing for full size 
determination. This test was only undertaken once due to the quantity of 
material required compared to that obtained since re-assessing the same 
sample would have given different results due to product breakdown or 
agglomeration. 
 
The morphology was assessed using a scanning electron microscope 
(Philips XL30 TMP). 
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4.2.2.5.3. Density 
 
Density of the particles was assessed since it will be important in suspending 
the particles to make a uniform suspension and it also allows assessment of 
how well the product which is important for processing powders on an 
industrial scale and compactability potential which may allow the 
microspheres to be administered as a orally disintegrating dosage form if 
required due to stability or requirements of other ages of patients. The initial 
bulk and tapped density of the particles were measured three times using a 
Copley Tap Density Volumeter as described in the Section 2.4. Briefly, 
around 10 g of the different particles were poured into a 100 ml measuring 
cylinder at an angle with the initial volume and mass used noted. The 
cylinder was then tapped at defined intervals with the volume measured after 
each set of taps until a final, stable volume within 2 % difference of the last 
volume was achieved and noted as the tapped volume. This was repeated in 
triplicate with the bulk and tapped density calculated and reported as 
mean/standard deviation and Carrs Index and Hausner Ratio calculated as 
previously reported. 
 
4.2.2.5.4. X-Ray Diffraction 
 
X ray powder diffraction can be used to assess the degree of crystallinity/ 
amorphism of powders. The diffractometer which is used to assess the 
powder works by applying an x-ray to the sample and has a detector which 
measures the intensity of the diffracted x-ray beam as shown in Figure 4-6 
as determined by Bragg’s Law as shown below in Equation 4-6 
 
 
Figure 4-6: Representation of Braggs Law (Bertranda et al., 2012) 
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Equation 4-6: Bragg’s Law 
 
nλ = 2d sin θ 
 
Where n  =  Order of diffraction 
  λ = Wavelength 
  d = Inter-planar spacing in the crystal  
θ = Angle between the incoming rays and powder  
plane 
 
A PW3710 Scanning X-Ray Diffractometer (Philips, Cambridge UK) was 
used to characterise the particles. Particles were compressed into a sample 
holder to provide a smooth surface and scanned at 0.02 °/sec from 6 ° to 35 
° with a voltage and current of 45 KV and 30 mA respectively with data 
shown using X’Pert High Score software (Version 2.0a). 
 
 
4.2.2.5.5. Differential Scanning Calorimetry 
 
A DSC 7 Differential Scanning Calorimeter (Perkin Elmer Instruments, UK) 
was calibrated with indium. Quinine hydrochloride dihydrate or microparticles 
(around 3 mg accurately weighed) were placed in an aluminium pan and 
sealed. The samples were heated from 10 to 300 °C at a rate of 10 °C/min 
with data recorded using Pyris Thermal Analysis software. 
 
 
4.2.2.5.6. Suspendability 
 
Suspendability of the Formulations was assessed similarly to that described 
in Chapter 3. Concentrations of particles tried ranged from 1 g/10 ml, 1 g/ 
20ml and 1 g/ 40 ml was tried in HPMC 1 % media with particles stirred for 1 
minute on a 60 % setting of a magnetic stirrer then 
dispersibility/suspendability assessed visually. 
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4.2.2.5.7. Feed Characterisation 
 
The formulation showing the greatest degree of release retardation at pH 
6.8, F16 containing high levels of SDS, stearic acid and PEG, underwent 
characterisation of its feed properties following initial (low) conditions of 
homogenisation and increased homogenisation conditions. The samples 
under increased homogenisation were assessed by removing 20 ml both 
initially and after standing on a magnetic stirrer whilst the feed is being spray 
dried for two hours. The properties of: pH, particle size, zeta potential, 
viscosity and homogeneity of content were attempted in triplicate. A placebo 
(blank) formulation of F16 which had underwent increased homogenisation 
was also assessed before and after standing. 
 
A Zetasizer ZS (Malvern) was used to determine the size and zeta potential 
of the spray drying feed at 25 °C with three repeats of 100 runs. The zeta 
potential was calculated automatically using Henry’s Equation. 
 
  
CHAPTER 4: PRODUCTION OF MULTIPARTICULATES 
170 
 
4.3. Results and Discussion 
 
4.3.1. Initial Spray Drying Experiments 
 
4.3.1.1. Initial Conditions 
 
Using the initial conditions, the spray dryer clogged many times. As every 
time the spray dryer clogs, it must be turned off so that the tubes and nozzle 
can be cleaned; and the spray dryer takes several hours to reach the desired 
inlet temperature when restarted; much time and product was lost. An 
example of the type of “particles” initially formed is shown in Figure 4-7: it 
could be seen that there are particles of different sizes which may be an 
indication of poor droplet size control or that each component has dried 
separately and clumped together. 
 
 
Figure 4-7: SEM Image of Spray Dried Eudragit® EPO: Quinine Base (2:1) at 
10000X Magnification (Initial Conditions) showing aggregated particles  
 
The extent of clumping can also be seen from looking at the size distribution 
as summarized in Figure 4-8 and Figure 4-9 . Some of the clumps were 
larger than 350 µm and the size profile saw multiple peaks showing different 
sizes of aggregates which is likely due to the stickiness of the polymer 
resulting from its low glass transition temperature (Tg). 
   
CHAPTER 4: PRODUCTION OF MULTIPARTICULATES 
171 
 
Figure 4-8: Laser Diffraction Particle Size Profile of Spray Dried Eudragit® 
EPO: Quinine hydrochloride dihydrate (2:1) under Initial Conditions showing 
aggregated particles of drug loading 20% 
 
 
Figure 4-9: Size Distribution of all Spray-Dried Particles using Initial Conditions 
showing aggregated particles of drug loading 20 % 
 
Several unsuccessful approaches were attempted to overcome the problem 
of the blockages which included decreasing the solids concentration of the 
feed (by increasing the volume of water) and increasing pumps rates. From 
sieving the feed, it became clear that there were lumps of solid in the feed 
which were blocking the tubes and nozzle so increased mixing was 
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attempted but still the lumps persisted. Blockages occurred even after 
sieving suggesting the blockages were due to particles aggregating or 
sedimenting whilst waiting prior to reaching the nozzle, despite the feed 
being stirred constantly.  As mixing did not remove the lumps which occurred 
not only in the drug containing dispersions but also in the drug free feed, it 
was concluded that the suspension preparation required optimisation and the 
homogenisation conditions were investigated. 
 
 
4.3.1.2. Increased Homogenisation Conditions 
 
Initially the polymer dispersion was homogenised for 30 minutes as per the 
reference method as described in Section 4.2.2.1. and as no rate was stated, 
100 RPM was used.  It became evident that the addition of the drug 
solution/suspension to the polymeric dispersion could also cause visible 
lumps so the drug dispersion also needed to be homogenised (the lumps 
were expectedly worse with the quinine base but also present on occasions 
with the quinine salt). The time and conditions used for homogenization of 
the dispersions needed to be a balance between minimizing the shear rates 
and homogenization time the formulation was exposed to due to the potential 
for damaging the polymer but also ensuring the feed did not have lumps. 
 
Higher shear rates (e.g. around 1000 RPM) removed most of the lumps. 
However any particles at the top of the beaker (such as quinine base, which 
is hydrophobic and hence difficult to wet) remained there with the potential to 
block the spray dryer. Higher shear rates (e.g. around 3000 RPM) were able 
to provide enough energy to move the top of the dispersion and hence bring 
the particles into the bulk where they could be incorporated into the 
suspension but also obviously placed more stress on the formulation as well 
as  seen by foaming. 
 
A compromise was made whereby the drug and polymer dispersions were 
each homogenised for ten minutes and then for a further ten minutes once 
they were mixed together so as to reduce the time of homogenisation and to 
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homogenise each for 5 seconds at 3000 RPM (to enable surface particles to 
be brought into the bulk) and the rest of the time at 1000 RPM. 
 
During the first drying run following this optimized preparation procedure, a 
whole batch of non-drug, quinine salt and base containing feeds were able to 
be successfully spray dried as seen by the particles in Figure 4-10. These 
particles are not perfectly spherical which is a common feature of spray 
drying without organic solvents and the morphology is generally poorer for 
the quinine containing feeds due to its hydrophobic nature so this was seen 
as something which needed to be developed by examining different 
processing conditions and excipient levels. 
 
   
Figure 4-10: SEM Images of Spray Dried Eudragit® ® EPO with (From left to Right) 
No Drug, quinine hydrochloride dihydrate and quinine all at 5000X Magnification 
made using increased homogenisation showing particles of drug loading 20 % 
 
 
The size distribution of the particles produced under the increased 
homogenisation is further proof of the reduction in clumping caused by the 
increase in homogenisation as can be highlighted by ninety percent of all 
particles being less than around 27 µm as seen in Figure 4-11 and Figure 
4-12 compared to the 200-300 µm values seen for particles produced under 
the initial conditions seen in Figure 4-9.  
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Figure 4-11: Laser Diffraction Particle Size Distribution of Spray Dried Eudragit® 
EPO: Quinine Hydrochloride (2:1) under Increased Homogenisation showing 
particles of drug loading 20 % 
 
Figure 4-12: Size Distribution of Spray-Dried Particles made with Increased 
Homogenisation showing particles of drug loading 20 % 
 
 
The higher purple line in Figure 4-12 is thought to be due to the soluble salt 
being encompassed into the particles more effectively than the base, which 
appears to have spray dried separately from the polymer as suggested by 
the morphology on SEM. This increased encompassment of the soluble salt 
compared to the base is further suggested by the smoother line of quinine 
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salt particles compared with that of the base shown in Figure 4-13 and 
Figure 4-14 showing less crystalline drug in the salt form. This shows that the 
drug is in the amorphous form which is common post spray drying but can be 
detrimental to dosage form development as this form is unstable and hence it 
would be difficult to control the stability and release rate of the formulation as 
these can change e.g. over time. 
 
Figure 4-13: X-ray Powder Diffraction of Spray Dried Eudragit® E PO: Quinine Base 
(2:1) under Increased Homogenisation for particles of drug loading 20 % 
 
 
Figure 4-14:X-ray Powder Diffraction of Spray Dried Eudragit® EPO: Quinine 
Hydrochloride dihydrate (2:1) under Increased Homogenisation for particles of drug 
loading 20 % 
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4.3.1.3. Increased Conditions of Temperature/Flow Rate 
 
In an attempt to improve the particles and yield; the inlet temperature was 
increased to 140 ºC, the atomizing gas flow set at 3 kg/h and chamber inlet 
flow set to 30 kg/h.  When the size distribution of the particles was compared 
with those made at lower temperatures and flows, it was seen that the 
quinine salt particles produced by the increased temperature/flow conditions 
were smaller than those produced by the initial conditions as shown in Figure 
4-15. This is thought to be due to the increased atomizing pressure 
generated by the higher atomizing gas flow reducing the size of the spray 
dried droplet and hence particle size produced. For the base at initial 
conditions, the particle sizes were smaller than the salt particles which may 
be due to increased encapsulation of the soluble salt whereas as the settings 
were increased, the particle sizes increased which could be due increased 
stickiness caused by the higher temperature or gas flow. 
  
 
 
Figure 4-15: Size Distribution of Spray-Dried Particles made with Different Settings 
at drug loading 20 % 
 
The morphology of the particles by SEM was similar to those seen in Figure 
4-10 and increase in yield was observed as shown in Figure 4-16. It can be 
seen that under the initial conditions the yield was the worst with that of 
quinine base being poorest, most likely due to having a less uniform feed 
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suspension compared to the blank and salt which seems to be supported by 
the way the yield increased under increased homogenisation conditions 
although the yield was still better for all conditions tested in the salt which 
would have been more in solution versus the suspension of the quinine. 
 
 
Figure 4-16: Yields of Spray-Dried Particles made under Different Conditions (All 
yields are n=3 except for initial conditions where the highest yield obtained was 
reported and drug loading 20 %) 
 
 
4.3.1.4. Büchi Compared with Niro Spray Dryer 
 
The effect of using a different spray drier (Büchi Mini Spray B191) on particle 
characteristics and blocking tendency was investigated Examples of the 
Büchi and Niro spray dryers are shown in Figure 4-17. Both machines exhibit 
co-current flow with two fluid nozzles but it can be seen by visual inspection 
that the sizes and set up differ. The Niro spray dryer allows organic solvents 
to be spray dried safely by virtue of a nitrogen atmosphere and is marketed 
as being the smallest spray drier with the same fluid dynamics as larger, 
industrial models for scale up (GEA Process Engineering). 
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Figure 4-17: Büchi Spray Dryer (Left) compared to the Niro Spray Dryer Used 
(Right) 
 
The spray drying conditions used were picked to be similar to the increased 
temperature/spray rate conditions used in the Niro but only using the quinine 
base as this had previously been the more difficult to spray dry. When these 
conditions were used on the Büchi, the nozzle and tubes clogged repeatedly 
(despite using the same homogenization conditions as used successfully 
with the Niro spray dryer) and what little particles were produced were 
destroyed by water managing to reach the collecting vessel. When the spray 
pump was reduced to 20 % (from 30 %), the spray dryer was still repeatedly 
clogged and very little product was produced with most of the product that 
did manage to be sprayed coating the spray dryer. Scanning electron 
microscopy images of the particles were of clumps and this is further 
suggested by the size distribution as shown by Figure 4-18.   
 
Figure 4-18: Size Distribution of Eudragit and Quinine Base (2:1) Spray-Dried 
Particles made with Different Spray Dryers 
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From observation, the nozzle of the Büchi spray dryer is different in design to 
that of the Niro spray dryer in that particles seem to be able to accumulate in 
the nozzle until they cause a blockage, unlike in the Niro where a lump 
causes an outright blockage which can be seen in Figure 4-19. This serves 
to highlight that although the Niro and Büchi are similar designs of spray 
dryer, formulations and parameters cannot be used interchangeably. 
Alternative atomization techniques such as a rotating disk may improve this. 
In order to try to improve particles, it was decided to look at the effect of 
excipients by experimental design by screening levels of excipients as 
reported in Table 4.6 above. 
 
                
 
Figure 4-19: Büchi Spray Dryer Nozzle compared to the Niro Spray Dryer Nozzle 
Used 
 
The data from this section demonstrates the importance of formulation and 
preparation of the spray drying dispersion. It may be that the current 
formulation is not optimal for spray drying hence the effect of different levels 
of excipients will be examined using an experimental design. 
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4.3.2. Analytical Method Development 
 
4.3.2.1. HPLC 
An HPLC method was developed to quantify drug release/content from the 
particles after excipient interference on UV spectrometry. Initial HPLC 
parameters used a UV detection wavelength of 250 nm with the mobile 
phase changing from 5 – 95 % v/v Acetonitrile/0.05 % v/v TFA over 10 
minutes for each sample with a washout period between samples of three 
minutes. A wavelength of 215 nm was tried for detection to see whether this 
gave an improved spectrum but the 215 nm spectra had a more uneven 
baseline. A triplet was observed as seen in Figure 4-20 which was attributed 
to the drug since the size of it increased as the drug concentration of the 
samples increased. The triplet was analysed as its three component peaks 
which gave a large relative standard deviation (throughout to be due to the 
autointegration setting the peak boundaries slightly differently with each 
sample). When the area under the whole triplet was manually calculated, the 
relative standard deviation was vastly decreased thus supporting this idea.  
 
 
Figure 4-20: An Example of Incompletely Resolved Peaks of Quinine Hydrochloride 
dihydrate standard in Acetonitrile (100 µg/ml) 
 
Further work was undertaken on trying to separate out the triplet so that the 
area of one peak could be analysed: 45 %:55 % of A: B as detailed in Table 
4-9 was tried as this corresponded to the parameters at the 4 minutes elution 
time of the triplet. As this did not allow complete separation of the peaks (e.g. 
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there was still a raised baseline) 35 %:65 % A: B was then tried which also 
did not allow separation of the peaks so a new, slower method was started 
with 10 % organic solvent increasing to 40 %. 
 
This new method was found to separate out the peaks and allow peaks to be 
analysed from baseline to baseline although– coming off at around 90 s with 
the solvent front at about 60 s. 93 % A vs. 7 % B was tried and was 
successful as shown by the final conditions in Table 4-9 . 
 
Table 4-9: Final HPLC Conditions Chosen for Analysis 
Final HPLC Conditions 
Column Phenomenex Kinetex 2.6µ C18 100 x 30 mm 
Mobile Phase A: TFA 0.05% v/v (aq) 
B: Acetonitrile + TFA 0.05%v/v 
Gradient 7 to 40 % B over 10 minutes (3 minutes recovery) 
Flow 0.5 ml/min 
Temperature 40 °C 
Detection UV at 250 nm 
 
No interference around the 6 minute mark where quinine elutes was 
observed from any of the additional excipients in the microspheres with the 
chromatogram for SDS (typical of all excipients under these conditions) 
shown below in Figure 4-21. 
 
Figure 4-21: Example of a HPLC Spectra using Final Conditions for SDS 0.5mg/ml 
(no drug) showing a lack of interference of this excipient in the region of 6 minutes 
where quinine elutes 
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In terms of stability, three peaks were found in the standard (20 µg/ml 
solution in 40 % MeCN/0.04 % TFA) and all the photo degradation samples 
whereas two peaks with some smaller peaks (noise) were found in all the pH 
conditions. All of the photo degradation samples had around 48 % of the 
peak areas in the first peak and the highest peak height was reduced which 
fits with the literature as quinine is photo unstable. It was not the purpose of 
this work to fully investigate the degradation profile of quinine so further 
analytical development was not undertaken. The analytical conditions used 
are adequate for the purposes of this work. 
 
When the DOE samples were analysed, it was found that the samples in 
water appeared to have a higher release than those in acetonitrile/TFA. 
Further analysis found that the acetonitrile TFA samples had an additional 
peak. In order to try to determine what this peak was, standards of quinine 
were made in acetonitrile, in TFA (aq) and in water. The acetonitrile samples 
both showed the additional peak hence water was used for standard 
preparation in all subsequent experiments.  
 
The linearity of the standard curve was around 100 % as shown by Figure 
4-22 and it was found that 100 µg/ml gave an absorbance of around 1000 
mAU as shown by Figure 4-23 so this concentration level could be increased 
if required. 
 
Figure 4-22: Quinine hydrochloride dihydrate HPLC Calibration Curve in Water 
(n=3) 
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Figure 4-23: Example of a HPLC Spectra using Final Conditions for a Standard 
Solution of Quinine hydrochloride dihydrate 100mcg/ml 
 
 
4.3.2.2. Filter Compatibility/Filtration 
 
Based on the results shown in Figure 4-24 , the Millex® MP filter unit was 
chosen. This was due to the low retention of both strengths of standard as 
well as a low standard deviation.  
Figure 4-24: Percentage of Quinine hydrochloride dihydrate in water recovered after 
filtration through various filters 
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It can be seen from Figure 4-25 that filtering resulted in a lower drug 
concentration by only considering unencapsulated drug which is important 
since in taste masking, it is important to know exactly how much drug has 
been released since this is the drug which is available to interact with the 
taste buds. 
 
Figure 4-25: Effect of Filtering on F1 
 
It can be seen that filtering has an effect especially on the initial time points 
up to 15 minutes when less of the drug might be released compared to that 
still contained within the particles due to the time taken for the polymer to 
dissolve. As a result of this, when the two formulations were filtered, more of 
a gradual increase in drug was seen compared to the other non filtered 
conditions. It is unsurprising that F16 which contained high levels of SDS, SA 
and PEG exhibited slower release of the drug as seen by comparison with 
F6 following filtered release due to the larger particle size of F16  possessing 
a smaller surface area and hence prolonged dissolution time.  This 
prolonged dissolution time may also be why the filtered F16 has a larger 
variability as seen by the standard deviation compared to that of F6. When 
the samples are not filtered but removed from the same location, it can be 
seen that flatter lines representing more constant “drug release” are obtained 
which may correspond to the similar range of particles being in the same 
location, this is also seen when F6 is not filtered or sampled from the same 
location due to the small particle size being easier to disperse and having the 
drug contained throughout more, smaller, particles which is the opposite of 
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that of F16 where the location and hence number of larger, drug containing 
particles can vary widely as shown by the pale green line in Figure 4-26. 
meaning that formulations must be filtered. 
 
Figure 4-26: Effect of Different Filtering Conditions on Drug Release from F6 & F16 
 
4.3.2.3. Washing Microparticles 
 
In order to try to remove any unencapsulated drug which would be free to 
interact with the taste buds and taste bitter, different centrifuge speeds, times 
and centrifuges were tried in an attempt to optimise washing. A Sigma 3k30 
centrifuge with 35ml tubes was used to assess how much drug was removed 
as shown in  
Figure 4-27.  
 
Figure 4-27: Effects of Different Centrifuging Conditions on F1 which was the 
first midpoint containing mid levels of all excipients 
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Similar results were obtained for lower times and centrifuge speeds (100 and 
150 RPM for 1 minute gave a drug release of 48.5±2.8 %  of the expected 
drug content and 49.8±0.8 % respectively) as well as for a longer time at a 
higher speed (at the centrifuge’s maximum of 21,000 RPM for 120 minutes, 
43.1±1.9 %). Similar release results also occurred from washing the particles 
using filter paper to trap the washed particles, but the filter paper method of 
washing was time consuming as it did not allow for washing multiple samples 
concurrently and it was difficult to remove particles from the paper.  When all 
different formulations were centrifuged, it became very difficult to rewash 
them to remove all remaining drug or to obtain the microparticles as a “pellet” 
which was not removed by removing the supernatant. A pellet only occurred 
with formulations F9, 10, 11 and 12 and even then this was partially 
dispersible on movement. A Heraeus Microcentrifuge from Thermoscientific 
which can only take eppendorf tubes of 1-1.5 ml appeared to perform better 
as the particles had the base of the eppendorf to settle into. Moreover it was 
easier to gently remove 1 ml than 35 ml of supernatant. This washing was 
then repeated 5 times using similar relative centrifugal forces and durations 
as with the 3K30 centrifuge before drying at 40 °C until constant weight 
(within 24 hours). 
 
 
4.3.2.4. Content and Release 
 
Methods of assessing encapsulation efficiency (defined as the percentage of 
expected drug encompassed in particles) were assessed as Eudragit® E is 
soluble in selected organic solvents or 1 N HCl. When organic solvents such 
as ethanol, methanol and acetonitrile were used to dissolve the 
microparticles, a triplet was seen on the HPLC spectra compared to the 
usual duplet. When 1 N HCl was used, less drug was measured on HPLC 
analysis. A compromise was reached by adding 5 ml of 1 N HCl to the 
particles which was then diluted in distilled water to 50 ml after shaking to 0.1 
N HCl. 
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As media and techniques for assessing taste masking in vitro are not rigidly 
set in stone, two different media were compared to that of deionised water 
for release and in two different methods. The release was not tested in food 
or a suspending media as suitable foods and media were not found in 
Chapter 2. 
 
From the results below in Figure 4-28, water appeared to show the lowest 
release but was close to the others. Increased release in buffer may be due 
to the higher pH of the unbuffered water when particles are present. 
 
Simulated salivary fluid was chosen for further release experiments due to 
the presence of chloride ions making the media more physiological relevant 
and because it is buffered. The vial method described was chosen as its 
lower volume is more physiologically similar to the low volumes of saliva in 
the mouth although still higher than the salivary volume. This volume (20ml) 
allowed for withdrawing and replacement of 1 ml of media from 1 minute then 
every 5 minutes for 30 minutes. This work also suggests even the buffered 
media doesn’t appear to ensure retardation of drug release for a prolonged 
so a sachet formulation may be needed to permit dosing. In this case the 
short residence time in the mouth may allow sufficient taste masking to be 
achieved. 
 
Figure 4-28: Drug Release from F1 under Different Conditions for Assessing Taste 
Masking 
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In summary, an HPLC method was developed and a compatible filter and the 
importance of filtering samples found. A method was optimized to wash the 
particles by centrifugation and a method of assessing release and content 
chosen for the experimental section below. 
 
4.3.3. Experimental Design 
4.3.3.1. Scoping Work 
 
It was attempted to increase the solids content from the 4 % w/v tried in the 
initial work to a more industrially viable 20-40 % w/v. However at 40 % w/v, it 
was not possible to make a suspension, merely a semisolid mass of lumps. 
At 20 % w/v, initially a stick style of homogenizer (Ultra Thurax®) was used 
to form a sort of visibly lumpy suspension which blocked the spray dryer so 
another homogeniser (Silverson® with an emulsifying head was used) The 
balance between the time of homogenising for a suspension with no visible 
lumps versus the suspension becoming too foamy was seen to be using the 
homogeniser at 3000 RPM for 30 minutes overall due to the higher solids 
content. However, the 20 % w/v suspension blocked the spray dryer 
constantly despite attempts to try to overcome this by changing spray dryer 
settings including increasing/decreasing temperature (in the range 110-160 
°C) and increasing/decreasing spray rate (from 5-20 %). The little amount of 
20 % w/v feed which was sprayed prior to blocking produced large 
aggregated particles of several mm as shown by Figure 4-29. 
 
 
Figure 4-29: The large size of F1 Particles Produced at Solids Concentration 20 % 
w/v when compared to a coin 
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When the solid content was decreased to 10 % w/v, the suspension 
intermittently blocked, hence the experimental design was restarted at 140 
°C/20 % pump setting and 5 % solids concentration. Although this is not very 
industrially viable, it was attempted to see whether satisfactory particles 
could be made to then try to improve solids concentration on that feed. 
 
A higher spray rate of 20 % of pump capacity was tried to attempt to make 
the process faster which would also minimize the time the product was 
exposed to the high temperatures required for particle drying. Using the 20 % 
pump setting, the initial midpoint scoping batch yield was less than 10 % so 
eventually a spray rate of 5 ml/min (corresponding to a pump setting of 7 %) 
was set with the best conditions able to be achieved summarized in Table 
4-10 
 
Table 4-10: Optimum Spray Drying Conditions Achieved 
Parameter Value 
Inlet Temperature 140 °C 
Air Flow Rate 600 L/hr 
Aspirator Setting 90 % 
Spray Rate 5 ml/min 
Solids Concentration 5 % w/v 
 
 
4.3.3.2. Yield 
 
No significant effect was found of any excipient on yield. The maximum yield 
achieved was 39.2% for Formulation 9 as shown in Figure 4-30 . This 
formulation, as a result of the higher levels of both polymer and plasticizer, 
may have been thought to be likely to stick to the chamber of the spray dryer 
and hence reduce the yield. However this highest yield might be due to its 
high stearic acid and SDS levels. However this means for all formulations, 
more “product” is being lost than is recovered which obviously has a financial 
impact on the process.  
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Figure 4-30: Yields for All Experimental Design Formulations 
 
4.3.3.3. Size, Morphology and Density 
 
Particle size for the majority of Formulations (F) were >500 µm or < 25µm 
and most particles showing some degree of aggregation on SEM as shown 
in Figure 4-31 and particle size analysis (given by percentage of fines less 
than 25 µm) in Figure 4-32. The percentage of fines is not a commonly used 
way to report size but was used due to the equipment limitation of only 
having to sieve stacks which did not adequately characterise the 
formulations in terms of size whereas the percentage of fines corresponded 
to the particle sizes seen visually and on SEM (e.g. formulations with a large 
particle size had low percentage of fine particles less than 25 µm). Complex 
effects on size were seen. Increased size can be seen to be due to 
increased aggregation on SEM and as expected this can be correlated with 
increasing polymer or plasticiser levels which would be expected to make the 
particles more “sticky” as shown by F9 on the right. 
 
 
Figure 4-31: Morphologies and Size Ranges of Particles (F6, 10 and 9 from left) 
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Figure 4-32: Percentage of Fine Particles (<25 µm) for Each Formulation 
 
The density of the particles ranged from 0.14-0.31 g/ml as seen in Figure 
4-33. This is fairly light compared to a drug and is likely to be due to the 
presence of colloidal silica: this low density would make the particles difficult 
to disperse and suspend, making them likely to float on top of the 
suspending media and the particles stick to the side of the container causing 
problems with dose uniformity as seen with Cellets in Chapter 2 and 
discussed later. 
 
 
Figure 4-33: Poured and Tapped Density Mean ± SD of All Formulations 
 
From Figure 4-34, it can be seen that colloidal silica and SDS have an effect 
on density. 
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Figure 4-34: Interaction of Colloidal Silica and Sodium dodecyl sulphate on 
Percentage of Fine Particles with other Excipients at Midpoint levels 
 
From Equations 2-5 and 2-6, the Compaction Compressability and Hausner 
Ratio were calculated and the results shown in Table 4-11. It can be seen 
that most particles had at least acceptable flow properties and compaction 
characteristics except F6 and F13. Both contained low polymer and SDS 
levels along with high stearic acid concentrations so may lack as uniform a 
coat/particle size as those formulations with less hydrophobic components. 
Table 4-11 hence shows that if desired e.g. for a tablet or orally 
disintegrating tablet formulation, the majority of formulations have acceptable 
compactability and all formulations have acceptable flow which can be an 
advantage for pharmaceutical processing. 
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Table 4-11: Compaction Index and Hausner Ratio for all Formulations (where for 
Carrs Index good < 15 %, fair 16-20 %, passable 21-25 % and poor >26 % while for 
Hausner Ratio good/fair < 1.25, passable 1.25-2.5 and poor >1.5) 
Formulation Compaction Index Hausner Ratio 
1 Good Good 
2 Good Good 
3 Fair Passable 
4 Passable Passable 
5 Good Good 
6 Poor Passable 
7 Fair Good 
8 Passable Passable 
9 Passable Passable 
10 Good Good 
11 Passable Passable 
12 Fair Good 
13 Poor Passable 
14 Passable Passable 
15 Fair Passable 
16 Passable Passable 
17 Fair Good 
18 Passable Passable 
19 Passable Passable 
 
 
4.3.3.4. Release 
 
It can be seen in Figure 4-35 that all of the samples meet the requirement for 
immediate release dosage forms to release at least 80 % of their content 
within 45 minutes in the hydrochloric acid 0.1 M with the majority 
formulations releasing greater than 80% within five minutes (with the rest, 
formulations 7-12, releasing by ten minutes). This is desired so that the 
pharmacokinetic profile of the medicine we are trying to taste mask is not 
altered. 
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Figure 4-35: Release in Acidic Media of all DOE Formulations (n=3) 
 
Taste masking was approximated by the mass of drug released in 1 minute 
in simulated salivary media compared to that of the quinine bitterness 
threshold of 0.000008M.  It can be seen be seen from Figure 4-36 that drug 
release was highly variable as shown by the large standard deviations of 
many of the samples. This suggests that a uniform product was not made 
which may be due to aggregation of particles or may be due to individual 
components of the formulation separating out. It can be seen that all 
formulations released the drug even at the short time point of one minute. F9 
and F16 both exhibited the most release retardation under the pH conditions 
designed to be similar to that of the mouth. However both formulations were 
over 1 mm in size and seen to be highly aggregated: even these formulations 
did not adequately retard release so as to have release below the bitterness 
threshold of quinine. A low colloidal silica concentration was seen to reduce 
drug release which may be due to less anti-adherent causing larger 
aggregates as suggested by the morphology as seen by SEM. The reduced 
drug release may also be due to an improved polymeric film retarding 
release or due to a reduction in the hydrophilic component retarding release 
possibly via reduction in their solvent wicking effect. 
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Figure 4-36: Encapsulated Drug Released at 1 minute at pH 6.8 for All DOE 
Formulations (n=3) 
 
 
4.3.3.5. Content 
 
Many particles exhibited low encapsulation efficiencies and drug loadings as 
shown by most particles in Figure 4-37. Increasing the encapsulation 
efficiency is desirable as it can prevent the loss of medicine and extend the 
duration of action and dose of the medication. No excipient was found to 
have an effect on drug loading and encapsulation efficiency of the 
formulations (which were calculated as described by Equations 4-3 and 4-4 
respectively) when assessed using Design Expert®. The large standard 
deviations of the individual formulations show that the particles produced by 
spray drying were not uniform and hence some have more drug than 
others/are more aggregated than others as shown by the varied size 
distribution. The large variability between formulations in terms of drug 
loading and encapsulation efficiency is the result of the drug composition of 
the spray drying feed. The low drug loading is due to the high proportion of 
excipients required to retard drug release in the simulated salivary fluid. The 
drug composition varied as shown in Table 4-6 where the proportion of drug 
is set as 1, the proportion of polymer related to that of drug and the other 
components present as a function of the percentage of polymer present. 
Therefore the drug loading can be seen to be dependent on the proportions 
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of other components as to what proportion of drug was present in the feed 
and hence there is a variability of drug content in the particles. Those with 
encapsulation efficiencies higher than 100% may have had some 
unencapsulated drug present or may be due to the loss of fine particles of 
colloidal silica from the spray dryer as reported by others (Xu et al., 2008a). 
 
Figure 4-37: Encapsulation Efficiency and Drug Loading for All DOE Formulations 
(n=3)  
 
4.3.3.6. Suspendability 
 
The recommended dose of quinine salt (being hydrochloride, dihydrochloride 
or sulphate) for children is 10 mg/kg (up to a maximum of 600 mg) every 8 
hours (British Medical Association and the Royal Pharmaceutical Society of 
Great Britain, 2008b). Using a mean weight value of 20 kg to correspond to 
that of a 6 year old (since children may not need liquids after this age) and a 
maximum concentration of 500 mg/5 ml, it can be seen that the volume the 6 
year old would be required to take ranges from 11.9-49.1 ml which at the 
very lower end may be acceptable as it is around 10 ml. 
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Table 4-12: Mass of DOE Formulations and Volumes required for the Lowest and 
Highest Drug Loading DOE Formulations to provide Therapeutic Doses of Quinine 
hydrochloride dihydrate 
 Lowest Drug 
Loading (F3) 
Highest Drug 
Loading (F5) 
Mass of Quinine hydrochloride dihydrate 
(QHD) in 100mg of particles 
4.08mg  16.87mg 
Mass of particles containing 1mg of QHD 24.51mg 5.93mg 
For 20kg child (~6years) requiring 200mg  
- Mass of MP required 
- Dose volume if particle concentration 
of 500mg/5ml 
 
4,902mg 
 
49.1ml! 
 
1,186mg 
 
11.9ml 
  
The suspendability of the particles was determined as reported in Chapter 2. 
Briefly a mass of particles as described below was mixed in 10 ml of 
suspending media using a magnetic stirrer on 60 % for one minute and the 
extent of dispersion of particles/time for particles to sediment assessed 
visually.  The suspending media used was a HPMC 1 % solution (pH value 
of the solution used was determined as 6.4±0.1). HPMC 1 % was used as a 
suspending agent as it had been reported to be acceptable by both taste 
trials. The unflavoured and unsweetened HPMC 1 % was used, as the 
flavoured and sweetened HPMC 1% was found to be too acidic (pH value of 
4.2+0.1) which would be incompatible with the Eudragit E Polymer which 
would be soluble at that pH. The unflavoured and unsweetened HPMC was 
found to be acceptable in the first trial.  
 
All suspendability testing was attempted using a concentration of 1 g of 
particles/10 ml of media but: due to the low density of the spray dried 
particles, this was a large volume of particles and hence it was impossible to 
make a suspension within 10 ml. When this was reduced to 1 g/ 20ml, more 
of a semisolid was made. A more fluid suspension was produced by mixing 
1g particles in 40 ml of vehicle. However as with the Cellets in Chapter 2, it 
was very difficult to disperse the particles due to their poor wettability as 
seen in Figure 4-38. The formulations with smaller particle sizes gave a 
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powder that stuck to the bottom/sides of the vessel and was difficult to 
disperse – what did disperse could be seen as aggregated (as shown to the 
right of Figure 4-38. For the large particle sized formulations, they were 
difficult to uniformly disperse, again a lot like Cellets as shown to the left of 
Figure 4-38. Hence dispersibility was difficult and so a uniform suspension 
was not achieved with any formulation so the homogeneity of content was 
not assessed. It can therefore be seen that the wettability and mixing of 
these particles would need to be improved but a sachet/powder for 
reconstitution is likely to be more achievable given the large size/mass and 
low release retardation as shown to the left of Figure 4-38.  
 
  
Figure 4-38: An assessment of the Suspendability of Larger Particles (<1 mm) of F9 
(left) and Smaller Particles (>25 µm) of F18 (right) at 1g of particles/40 ml of media. 
It can be seen that the larger particles are difficult to suspend and sediment to the 
bottom whereas the lighter particles appear to be compacted by the addition of the 
media and sticks to the bottom/sides of the beaker 
 
 
4.3.3.7. Characterisation 
 
As F16 was one of the formulations which exhibited the highest degree of 
release retardation, e.g. a low percentage of drug released in simulated 
salivary media used to assess for taste masking, had its feed characterised 
retrospectively as shown Table 4-13. This looked at how the viscosity, 
particle size and zeta potential of the F16 differed depending on whether it 
contained drug or not and the effect of standing and homogenisation on 
these characteristics in an attempt to relate this to the spray drying feed 
stability (in terms reducing lumps which formed throughout the process). 
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Table 4-13: Spray Drying Feed Characterisation of F16 formulations (both those 
containing drug and not) on the effect of drug, homogenisation and standing of the 
spray drying suspensions. It can be seen that the addition of drug decreases the pH 
of the feed and reduces the zeta potential also that the particle size and viscosity 
decrease with increasing homogenisation 
 
Sample 
Characteristic 
Mean 
pH (SD 
= 0 for 
all) 
Viscosity 
at 1s-1 
(Mean±S
D) 
Size Zeta 
Potential 
(mV) 
(Mean± 
SD) 
Appearance 
Z-average 
(d.nm) 
(Mean±SD) 
Mean 
Poly-
dispersi
ty index 
F16 (Initial 
Homogenisation) 8.8 2.93±1.44 7708.0±101.8 1 -10.74±2.90 
White 
semisolid 
F16  
(Increased 
Homogenisation, 
before standing) 8.7 0.02±0.01 4894.0±11.3 1 -12.62±4.03 
 
Milky 
white 
liquid 
F16 
(Increased 
Homogenisation, 
after standing) 8.8 0.04±0.01 6020.0±527.0 1 -11.65±5.54 
Placebo 
(before standing) 9.4 0.15±0.05 573.9±12.1 0.54 -57.05±2.34 
Placebo  
(after standing) 9.4 0.14±0.05 517.8±20.1 0.35 -54.48±1.38 
 
The differences between the placebo and drug suspension can be observed 
with the addition of the quinine hydrochloride drug salt decreasing pH and 
reducing the zeta potential (and hence stability). The viscosity of the 
suspensions highlights the importance of the increased homogenization in 
reducing particle size and reducing viscosity as was also confirmed by 
appearance. The large polydispersity index suggests that the particles were 
sedimenting or aggregating and that a Zetasizer with a larger particle size 
range should be used.  The homogeneity of content was unable to be 
assessed on this occasion due to the suspensions blocking the filters used to 
try to filter the feed prior to HPLC analysis and so may need dilution  in 
future. 
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4.3.3.8. Overview 
 
Yield, encapsulation efficiency, drug release in 1 minute in simulated salivary 
fluid, particle size (assessed by percentage of fine particles <25 µm) and 
density were all assessed as separate responses to try to more completely 
understand the particle’s characteristics but the primary response was drug 
release in 1 minute in simulated salivary fluid which we wanted to be as low 
as possible as this will depend whether the bitter drug would be tasted or not. 
 
As there was not prior knowledge about the effect of different levels of the 
five excipients in the spray drying feed on various microparticle 
characteristics a screening experimental design using a fractional factorial 
design was used in an attempt to assess and whittle down the number of 
factors that have any effect.  To have undertaken an initial response surface 
design, i.e. ignoring the screening step, for all five factors would have 
required 47 runs here! A very high-risk version of this design would have 
required 26 runs – but this wasn’t recommended as there was not adequate 
knowledge of the interactions between the factors. The initial plan was run 
the screening design then after analysing the data, append this design with a 
response surface design (a central composite) to would hopefully give an 
idea of the optimum region. However, as the only factor found to have an 
effect on drug release 1 minute in simulated salivary fluid was colloidal silica 
(with decreasing levels causing decreased drug release) also was 
associated with particles <1 mm and hence too large for us to suspend, the 
response surface design was not carried out. 
 
F9 and F16 were seen to have the highest degree of release retardation (e.g. 
the lowest percentages of drug released in 1 minute in simulated salivary 
fluid). The drug was dispersed as seen in Figure 4-39 which shows an 
amorphous nature which may cause problems in stability of the particles. 
Both F9 and F16 had aggregates >1mm as seen in Figure 4-40. Comparing 
the two, F9 had a slightly higher yield and encapsulation efficiency (EE), F16 
was more reproducible in terms of EE (n=3) and had a higher drug loading 
(DL). F16 was hence classed as the “best” formulation and characterised as 
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above in Section 4.3.3.8. Low levels of colloidal silica had a significant effect 
on reducing release. These formulations which did retard release, by being 
larger, were very difficult to disperse/suspend and would require a large 
mass of particles for a therapeutic dose – hence they do not produce uniform 
particles. A lack of feed suspension variability may be present as shown by 
the variability between the repeated midpoints of F1, F2 and F19 throughout 
Chapter 4. 
 
Figure 4-39: DSC Trace of F16 
 
 
 
 
Figure 4-40: SEM images showing aggregates of F9 (top) and F16 (bottom) 
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4.4. Conclusions 
 
The production of taste masked formulations is critically important to 
children’s taking their medicine as covered in Chapter 1; however this work 
did not produce such a taste masked formulation as the particles did not 
adequately retard release so as to have release after 1 minute in simulated 
salivary fluid below the bitterness threshold of quinine. The aqueous spray 
drying process with the excipients and levels chosen did not make for an 
ideal microparticle production method due to a low solids content of the 
spray drying solution requiring high temperatures and spray rates which 
meant the outlet temperature went above the glass transition temperature of 
the polymer and hence sticky, aggregated particles occurred. As a result, low 
yields occurred which made for a process that would not be industrially 
viable.  
 
Drug loading of particles was generally low due to the high levels of 
excipients being used in an attempt to gain release retardation which would 
lead to large particle masses/concentration required. Few formulations 
showed any degree of release retardation or “taste masking”. Formulations 
which produced larger sized particles were more likely to retard release 
which were difficult to disperse and suspend. Low levels of colloidal silica 
were found to reduce drug release; this may be due to increased aggregation 
due to less anti-adherent effect or due to an improved polymeric film or less 
of a hydrophilic excipient. 
 
Quinine hydrochloride is a very soluble drug with a low bitterness threshold 
and mid-level dose so not well suited to the current technique. Others in the 
literature have used less soluble, lower dosed drugs with lower bitterness 
thresholds e.g. medicines such as famotidine: drugs such as this may be 
suited to the current process.  However it is clear that the process would not 
make a platform formulation. Uses for particles produced may include 
compressing them into ODTs or using them as agglomerate or sprinkle. 
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It is possible that taste masked individual particles produced by aqueous 
spray drying of Eudragit E cannot be produced. Particles produced by others 
using aqueous spray drying have suffered in terms of low yields, spray rates 
and aggregation. Within this current work the practical importance of 
suspension properties has been seen with the extensive blockage of spray 
dryers occurring. In future, any formulation should be characterized as a 
minimum in terms of particle size and viscosity prior to the attempted spray 
drying to avoid this. 
 
As different spray drying parameters were tried during the scoping work, this 
method may be difficult to develop further unless a different spray dryer was 
used such as one which could contain a different type of nozzle like a 
rotating disk which cannot block. It is likely that future research will require 
the use of different excipients. Only low colloidal silica was seen to impact 
release with large particles so different anti-adherents should be tried such 
as talc or Glyceryl Monostearate and removing the plasticizer may reduce 
stickiness. The problem of the low glass transition of Eudragit® E is difficult 
to overcome and may need combination with other polymers such as 
alginates or cellulosics or to use an emulsion or organic solvent of minimum 
toxicity such as ethanol. If an alternative method was required, solvent 
evaporation/emulsification has produced taste masked particles but suffers 
from a lack of scale up information. It may also be worth considering a 
method based on pH changes since it may be possible to solubilise the 
Eudragit® polymer at pH below 5 and then reform it as a film by increasing 
the pH above 5.  The industrial practicality of such an approach would need 
to be evaluated. 
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5.  GENERAL DISCUSSION AND FURTHER WORK 
 
5.1. General Discussion 
 
The aims of this project were achieving a multiparticulate-based platform for 
delivering functionalized capability as an oral liquid dosage form. Although 
these very specific aims have not been met, a number of lessons have been 
learnt along the way that can inform future work. 
 
From Chapter 1, the challenges in providing medicines for children were 
identified and it was seen that children have a number of additional needs to 
those of adults which have to be considered, such as swallowability, a lower 
tolerance of poor/taste acceptability, the need for different doses as they 
develop and the difficulties of requiring medicines throughout the school day. 
It was seen that a multiparticulate dosage form would be ideal as particles 
could provide a taste-masked or modified release functionality to meet these 
needs which many currently available medicines cannot. Formulating the 
particles in a suspension provides a way to administer these particles whilst 
keeping their dose adaptability and swallowability unlike compressing them 
into tablets or presenting them in a stickpack.  Developing a platform 
formulation would ensure that time and money is not consumed in bespoke 
pharmaceutical development whilst children wait for much needed 
medicines. 
 
Given that functionalized multiparticulates are, by virtue of containing drug 
and polymer, larger than individual drug particles, it was unknown what the 
limit of particle sizes of these larger particles would be in terms of 
suspendability and grittiness which were explored in Chapter 2 and 3 
respectively. Microcrystalline cellulose starter cores (Cellets®) were used as 
model particles for the suspendability and grittiness studies because they 
come in a range of sizes with narrow size distributions, are inert and 
accepted as safe to be administered orally. Despite all the advantages of the 
Cellets®, they differ in some particle properties compared to those produced 
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by spray drying in Chapter 4 including density, size and morphology. 
Nevertheless the small amount of work undertaken on the suspendability of 
the microparticles described in Chapter 4 suggests that the general 
conclusions drawn from this work with Cellets® are likely to be valid. 
 
As the suspendability of particles and grittiness of a suspension may depend 
upon the properties of the suspending media, some commonly used 
suspending media and soft foods often used for the administration of 
sprinkles were characterized, largely in terms of rheology. As methylcellulose 
and hydroxylpropyl methylcellulose solutions ranging from 0.1, 1 and 3 % w/v 
were seen to “mimic” the range of viscosities from water to commercial 
suspending media and had a largely acceptable pH range so that the 
Eudragit® E polymer to be used to try to produce taste masked particles in 
Chapter 4 would not be soluble, these vehicles are considered worthy of 
further evaluation. However it was found to be difficult to produce a uniform 
and physically stable suspension with any vehicle tested. 
 
Grittiness trials were carried out in young adults due to the logistical 
difficulties with completing the research on children. However children and 
adults can both rank samples in the same order, just the hedonics are 
different. It was seen in the initial grittiness trial looking at the effect of 
particle size, concentration and viscosity on the grittiness of suspensions in 
Chapter 3 that particle size and concentration had a significant effect on 
grittiness whereas viscosity did not. The importance of palatability in all age 
groups was highlighted through complaints received from some participants 
about the “slimy” or mouth coating effect of the HPMC, especially at the 3 % 
w/v concentration. It is thought that this was why viscosity was not seen to 
have a significant effect on grittiness and it was notable that no 3 % w/v 
solutions were rated as the participants “most acceptable” formulations. This 
mouth coating effect may be due to the higher yield stress as covered in 
Chapter 2 of the more concentrated HPMC not being overcome by the 
mouth. The refined (second) grittiness trial in Chapter 3 made 
methodological improvements compared to the initial trial, with an increased 
sample size and narrower particle size/concentration and viscosity ranges. 
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Acting upon this feedback, the unpleasant mouth coating was overcome by 
the formation of a pleasant orange flavoured solution sweetened with 
sucralose. Thereafter viscosity and particle size were seen to have an effect 
but not particle concentration (likely due to the similar scores of the 
microcrystalline cellulose particle (Cellets®) concentrations of 125 mg/5 ml 
and 250 mg/ 5ml. The results from Chapter 3 suggest that viscosity can 
reduce grittiness and that particle sizes should be minimized where possible. 
 
Aqueous spray drying as described in Chapter 4 was desired due to spray 
drying being a multiparticulate production technique which is industrially 
scale-upable and the absence of organic solvents removes risks and 
disadvantages associated with them. Spraying Eudragit® E was difficult with 
much time and product wasted through the continual blockages of both types 
of spray dryer nozzles until the extent of homogenization was increased and 
the solids content of the feed decreased to 4-5% w/v indicating in hindsight 
the criticality of feed properties on this process as assessed in Section 
4.3.3.7. The low solids content along with the high temperature (140 °C) and 
low flow rate of required to successfully evaporate the aqueous solvent were 
not industrially viable and lead to an outlet temperature higher than the (low) 
Tg of Eudragit® E. In turn a low yield was achieved due to loss of product by 
sticking to the sides of the spray dryer. 
 
A screening experimental design was undertaken to assess the effect of 
different levels of excipients. The particles produced by spray drying fell 
largely into two groups: those with particle sizes less than 25 µm or those 
greater than 1mm. The morphology of the particles showed those with larger 
particle sizes to be large aggregates with the largest aggregates showing the 
highest degree of release retardation. The lowest release at 1 minute was 
seen with low levels of colloidal silica seeming to suggest that the release 
retardation was largely due to reduced surface area suggesting that release 
cannot be adequately controlled by this method in forming unaggregated 
particles. Others in the literature who have taste masked with Eudragit® E 
have used microparticles produced to manufacture tablets such as ODTs 
without assessing whether the microparticles can control release 
                                  CHAPTER 5: CONCLUSIONS AND FURTHER WORK 
207 
 
uncompressed (Xu et al., 2008a, Yan et al., 2010). The one paper which 
taste masked as individual particles used organic spray drying (Bora et al., 
2008). Different excipients such as removing the plasticizer, altering the pH 
of the feed or using different anti-adherents may help improve an aqueous 
process in future experiments. 
 
From both the grittiness trials in Chapter 3, it was seen that smallest particles 
(those around ~100 µm) are less gritty and more accepted than the larger 
particles for all viscosities. However in Chapter 4 only the larger particles (>1 
mm) obtained best release retardation but particles produced by spray drying 
had a low density and the larger particles were aggregates which were 
deformable on pressing between fingers (therefore softer than Cellets®). 
Hence it is not known what the mouthfeel of these aggregates breaking down 
or their grittiness would be. From the initial grittiness trial in Chapter 3, it was 
found that low concentration significantly reduces grittiness but this would be 
unlikely in this process due to low drug loading thanks to high levels of 
excipients being required for retardation. High levels of excipients are 
questionable especially those such as Eudragit E as it is non-biodegradable 
and with limited paediatric toxicity data.  
 
The refined grittiness trial in Chapter 3 did not see a significant effect of 
concentration – this is likely to be due the similar grittiness scores for the 
particles around 100 µm at concentrations of both 125 and 250 mg/5 ml. 
With this in mind, the suspendability of the particles produced in Chapter 4 
was assessed at the maximum particle concentration for grittiness of 500 
mg/5 ml in a 10 ml dose (to correspond to the mass of particles required for a 
quinine dose for a 6 year old). The most acceptable sample in both grittiness 
trials in Chapter 3 contained HPMC 1 % w/v along with the lowest particle 
sizes and concentrations in each trial. Hence this media was used to test 
suspendability as in Chapter 2. The unflavoured/sweetened HPMC 1 % was 
used due to the incompatible pH of the orange flavoring agents used in the 
grittiness trial with the Eudragit®. At a concentration of 500 mg/5 ml of spray 
dried particles, a suspension was not formed only a semisolid mush for all 
formulations due to high proportion of solids due to the low density of all 
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spray dried material. At 250 mg/5 ml, dispersibility was difficult and similar to 
that of the Cellets® in Chapter 2 in that smaller particles were more packed 
and stuck to the bottom of the preparation vessel but those that worked free 
were suspended vs. larger particles which dispersed less well throughout. 
With 1 g of particles in 40 ml of vehicle, followed by manual stirring, some 
form of suspensions were produced but these all had levels of creaming, 
aggregation and sedimentation suggesting more work is required on the 
addition of excipients to the suspending media to improve uniformity.  
 
Only some limited degree of release retardation was achieved but this was 
not complete, so these particles would not be stable in a suspension for 30 
minutes. This may require the use of an individual powder for reconstitution 
for the short period of administration time. This would have the advantage of 
requiring less excipients such as preservatives than a suspension 
formulation which are required to ensure stability for a longer period. 
Suspensions would have to be optimized especially for pH, dispersibility and 
taste. However, given the large size but low density and softness of the 
aggregates they may be more effectively administered as a sprinkle onto a 
more viscous food media like those assessed in Chapter 2. However, the 
commonly recommended apple sauce and yoghurt are incompatible due to 
their pH so a different food would have to be assessed such as rice. This 
approach does however suffer due to the large masses of particles required, 
the possibility of chewing and the criticality of drug administration which may 
be compromised if the food is not completely eaten or rejected as 
unacceptable. 
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5.2. Future Work 
 
Functionalised Platform Formation 
 
Since the overall aim of this research was not met, different modifications 
should be looked at as to how a uniform platform could be achieved which 
would be in terms of improving the process (by excipients or other solvents), 
using different polymers or other processes. 
 
A formulation which could be produced by spray drying would still be the aim.  
In terms of spray drying, it may be that using Eudragit® E as a blend with a 
different polymer such as an alginate or a cellulosic derivative or removing 
the “aqueous” criteria and using a lower toxicity solvent such as ethanol may 
also be an option and remove the issue of the low Tg of Eudragit® E. Other 
modifications to a spray drying process which may improve the process 
include modifying the feed by using talc or a hydrophobic colloidal silica as 
an anti-adherent/hydrophobic component, or the pH to ensure the Eudragit® 
is in solution or seeing whether fitting a filter to the process helps. A different 
polymer such as using a blend of HPMC with Eudragit® E, Kollicoat 
Smartseal® 30D or investigating encapsulation in the food industry may offer 
enhanced performance.  Different spray dryer components may be used 
such as a rotating disc atomizer to remove the nozzle which blocks and 
causes problems with increasing solids content or a different spray dryer 
such as that of the Buchi’s nano spray dryer B90. 
 
Although it does not provide a universal platform technology, it may be that 
quinine hydrochloride dihydrate as a soluble salt with a dose of 20 mg/kg of 
quinine base and a low bitterness threshold is not suited to the current 
approach but other less soluble, lower dosed, less bitter drugs would be. 
 
Any future spray drying feeds should be characterized so that time and 
money is not wasted on formulations that do not work. Formulations should 
be assessed at least in terms of pH, viscosity and particle size, with other 
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factors such as zeta potential, surface tension, drug or solids uniformity as 
required. 
 
If spray drying is not possible, small microparticles with controllable release 
have been produced by a variety of methods notably by 
emulsification/solvent evaporation or co-acervation although these suffer 
from poorer scale up potential and often organic components. Other non-
universal approaches may include complexing drugs if charged to IER then 
coat if required. 
 
Suspensions 
 
Poor dispersibility of the Cellets® and spray dried particles of all sizes 
produced suggests that more work is required on additions to HPMC or MC 
to improve dispersibility. This may include the use of surfactant or different 
methods of dispersion such as using mechanical mixers although it is more 
likely, given the short period of taste mask control that a powder for 
reconstitution would need to be used. Having a more uniform dispersion 
would make assessing suspendability easier although assessing the 
uniformity of large particles is still difficult and the methods used were subject 
to interobserver variability. It is likely that the best method of assessing 
uniformity is by dose uniformity in terms of counted drug particles (this may 
also work for placebo particles if a large enough syringe was available and 
particles counted). The use of a Texture Analyser may be an objective way 
to assess the texture/suspendability of suspensions and if so, may also be 
relatable to grittiness to reduce the need for resource intensive sensory trials.  
 
An attempt was made to assess the effect of shaking on suspending media 
to see if this could be linked to a shear rate for different durations of shaking 
of suspensions. It may be that this could be assessed through the population 
effect of having more participants shake suspending media and looking for 
an overall effect. 
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In terms of assessing for thixotropy, it is likely that determining the magnitude 
of hysteresis loop is likely to be more reproducible than the thixotropic step 
test used here. Or if the step test is used in the future, it should have a longer 
initial settling period at a lower shear rate with the time taken for different 
percentages of rebuild evaluated. Along with this, the time for structure 
rebuild could  be related to particle settling by applying a stress to a sample 
e.g. by shaking then allowing different time periods before adding particles 
and timing how long they take to settle. To improve reproducibility a model 
‘particle’ such as a ball bearing of known size and weight could be used.  
This would be analogous to the falling sphere viscometer. Other suspension 
characteristics which could be assessed include the surface tension, specific 
gravity, zeta potential and wettability of particles.  
  
Grittiness: 
 
All of the excipients used in the grittiness trial (HPMC, MCC, sucralose and 
Orange Flavour (Givarome) Permaseal®) are used in the food and Pharma 
industry hence it should be possible to perform a grittiness trial in children. 
The logistics of the trial may be challenging since the grittiness trials 
performed required lots of preparation and were fairly long and laborious. 
With this in mind, fewer samples should be given to ensure that the child 
does not become bored of the trial. As there are no formalized medicine 
acceptability tests for children, depending on the age of the child, the 
assessment of grittiness/acceptability may be based on a caregiver’s 
perspective (e.g. ease of administration) and/or a hedonic scale (“smiley 
faces”), rank order or visual analogue scale as used in this research. A 
grittiness trial undertaken in children could also look at the acceptability in 
terms of the prior medication experience of the children (e.g. comparing 
those acutely unwell to those chronically unwell and those who are healthy 
school pupils). 
  
Given the large size of particles produced, it would be interesting to look at 
the grittiness of softer particles like these deformable aggregates. This is 
likely to have to be as a sprinkle in a semisolid food so this would link with 
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compatibility in food to find a pH appropriate (e.g. not acidic) soft food type 
which may be something like rice or rice/milk pudding. 
 
Gastrointestinal Considerations 
 
In the introduction, it was highlighted how little we know about the paediatric 
gastro-intestinal tract in terms of drug delivery. By virtue of the difficulties of 
research in children, little is known about the characteristics of gastro-
intestinal fluids such as osmolality, viscosity, surface tension and ionic 
composition and how these differ compared to adults. It would therefore be 
interesting to be able to obtain fluid samples to characterise them, although 
this is expected to be difficult as it is invasive so is only likely to be 
achievable in sick children. Even this knowledge may be used to assess 
whether an age appropriate biorevelant dissolution media is needed for the 
assessment of formulations for children. 
 
A non-invasive and simple start to this research could be the assessment of 
the saliva of different aged children to see if/how their saliva differs 
compared to adults. Increased research is also required into how (in terms of 
media volume and composition, equipment and forces applied) taste masked 
particles should be assessed as there are a vast range of methods used in 
the literature. 
 
Whilst the term ‘functionalised’ in this research was used to mean taste 
masking, other forms of functionalized particle such as modified release may 
be impacted by the gastro-intestinal transit of multiparticulates and pH profile 
throughout the length of the gastrointestinal tract of various ages of children. 
Again, very little is known about even healthy children, let alone the effect of 
various disease states. It may be that this data could be obtained through the 
use of models and simulations. 
 
TNO’s TIM is a multi-compartment, computer controlled, gastro-intestinal 
model system designed to simulate digestion in the upper and lower gastro-
intestinal tract through controlling parameters such as flow, composition and 
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temperature. The model is advertised as being able to be used in 
paediatrics. As such, the TNO TIM was identified as a possible method of 
generating data about the transit of multiparticulates in paediatrics e.g. either 
for evaluating the effect of different particle sizes, concentration and 
viscosities of multiparticulates in suspensions on transit, or to compare to 
real pharmacokinetic data by trying to see what combination of settings 
would give comparable data to that of known in vivo performance. However, 
it was determined that no paediatric settings were recommended by the 
company, limited components could be modified to make the system 
“paediatric” and in work which had previously been tried with 
multiparticulates, the particles became stuck in connections and points which 
do not exist physiologically (Naylor, 2011). However it may be possible to 
modify this and such work would be valuable for future research. 
 
In terms of obtaining gastro-intestinal transit data in children to supplement 
formulation decisions in the future, it may be possible to use radiation free 
technologies such as magnetic marker imaging to visualise dosage forms 
and interest was even found from paediatrician’s who are academics and 
clinicians into using radiolabelled Cellets® as a link between the liquid and 
food they currently monitor at different ages, with a low radiation burden. 
However the process of radiolabellling and proving stability, along with 
ethical approval would have been outside the time course of this research. 
 
As a final light hearted thought of how far still has to be travelled in the 
formulation development process for children, when study participants (n=55, 
aged 6-19 years at 2 months to 2 years post study) were asked on their 
views on drug development their answers included (Abdel-Rahman, 2011): 
 
“There would be no more pills to swallow” 
“All medicine would taste good” 
“The study diet should consist of pizza, french fries and chocolate pudding” 
 
Although such an idyllic world is never likely to be realized significant 
improvements in providing age appropriate formulations for children are 
possible and should be pursued.   
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Grittiness Trial Recruiting Poster 
 
 
 
 
 
  
Young Adult Volunteers Wanted!
We are carrying out research to evaluate the grittiness of a variety of placebo suspensions 
and are looking for young adult volunteers to help.
If you are between 18 and 28 years old, it could be you that we are looking for.
The study will involve tasting a range of suspensions and evaluating their grittiness over two 
sessions of 1 hour, commencing as soon as possible
,
Department of Pharmaceutics, The School of Pharmacy, University of London 
to receive a participant information sheet
This study has been approved by The School of Pharmacy ethics committee
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Information Sheet for Participants in Research Studies 
 
You will be given a copy of this information sheet. 
Title of Project:   
Influence of Viscosity, Particle Size and Particle Concentration of 
Placebo Suspensions on Oral Grittiness 
This study has been approved by The School of Pharmacy Research 
Ethics Committee [ REC/A/09/01]  
Name, Address and Contact 
Details of Investigators: 
Shivani Manghani, Alexandra Bowles & Dr Catherine Tuleu, 
Department of Pharmaceutics,  
The School of Pharmacy, University of London 
29/39 Brunswick square,  
London WC1N 1AX  
 
     
We would like to invite you to participate in this research project. You should only participate if you 
want to; choosing not to take part will not disadvantage you in any way. Before you decide whether you 
want to take part, it is important for you to read the following information carefully and discuss it with 
others if you wish. Ask us if there is anything that is not clear or you would like more information.  
 
Details of Study.The main research objective is to investigate the influence of viscosity, particle size 
and particle concentration on the grittiness sensation of suspensions in order to try to eventually 
help to make more acceptable liquid medicines for children.  
 
Your role in the study will be to taste but not to swallow various formulations and to rank them 
according to a given scale, with regards to their grittiness as well as pick the two samples that you 
find the most acceptable each day. The suspending media and particles you will be in contact with 
are well known (hydroxypropyl methycellulose and microcrystalline cellulose respectively). The 
study will take place over 2 sessions on 2 different days and will involve tasting a total number of 34 
samples. During the 1st day, you will be asked to taste 17 formulations of varying grittiness, which 
will last a maximum of an hour. On day two, you will taste another 17 formulations over a maximum 
of an hour. 
 
If the suspensions you taste are very gritty, there is a potential to suffer from temporary oral 
discomfort.  Some, sensitive, participants, may gag in response to the suspensions and vomit. 
Nevertheless, the time of rinsing has been minimised to 15 seconds which minimizes the potential 
for adverse effects, risks or hazards and a delay of 1 minute will be respected between each tested 
solution. Subjects have to rinse their mouth with water before and after each test. 
  
We will make sure that you know the outcomes of the study. If the study is published or presented to 
a wider audience, your anonymity will be respected through anonymisation procedures. All data will 
be collected and stored in accordance with the Data Protection Act 1998. 
No payment for time or such as travel expenses, child-care expenses, demonstrable loss of earnings 
etc will be reimbursed. 
 
It is up to you to decide whether or not to take part. If you decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part you are still 
free to withdraw at any time and without giving a reason and without any penalty at any stage. 
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Informed Consent Form for Participants in Research Studies 
(This form is to be completed independently by the participant after reading the Information 
Sheet and/or having listened to an explanation about the research.) 
 
Title of 
Project:   
Influence of Viscosity, Particle size and Particle Concentration of 
Placebo Suspensions on Oral Grittiness 
This study has been approved by The School of Pharmacy Research Ethics Committee 
[REC/A/09/01] 
 
Participant’s Statement 
I  …………………………………………................................................... agree that I have: 
 
 Read the information sheet and/or the project has been explained to me orally;  
 Had the opportunity to ask questions and discuss the study;  
 Received satisfactory answers to all my questions about the research and my rights as 
a participant and whom to contact in the event of a research-related injury  
 Understood that I must not take part if I have any sensory disorders affecting my 
mouth or have had local anaesthetics (pain-killing injections) into my mouth within 24 
hours of the study  
 Understood that the data produced will be published but that confidentiality and 
anonymity will be maintained and it will not be possible to identify me from any 
publications. 
 
I understand that I am free to withdraw from the study without penalty if I so wish and I 
consent to the processing of my personal information for the purposes of this study only 
and that it will not be used for any other purpose. I understand that such in formation will 
be treated as strictly confidential and handled in accordance with the provisions of the 
Data Protection Act 1998.  
 
 Signed: Date: 
 
Investigator’s Statement 
I  ……………………………………………………………………..  
confirm that I have carefully explained the purpose of the study to the participant and 
outlined any reasonably foreseeable risks or benefits (where applicable).  
 
 Signed: Date: 
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Randomised Order: Refined Trial 
Sample Composition 
Sample  
Code 
 
Internal 
Code 
 
Sample Composition 
 [HPMC] 
(%) 
Particle Size 
(µm) 
[Particle] 
(mg/5ml) 
 6394 1 0.5 90 125 
 3353 2 0.5 90 250 
 6530 3 0.5 90 500 
 9306 4 1 90 125 
 8062 5 1 90 250 
 3161 6 1 90 500 
 1444 7 2 90 125 
 6690 8 2 90 250 
 7918 9 2 90 500 
 8580 10 0.5 127 125 
 
3446 11 0.5 127 250 
 7040 12 0.5 127 500 
 6790 13 1 127 125 
 3416 14 1 127 250 
 4146 15 1 127 500 
 8416 16 2 127 125 
 3435 17 2 127 250 
 4857 18 2 127 500 
 9722 19 0.5 263 125 
 5219 20 0.5 263 250 
 9621 21 0.5 263 500 
 9207 22 1 263 125 
 2230 23 1 263 250 
 2430 24 1 263 500 
 1437 25 2 263 125 
 1547 26 2 263 250 
 2337 27 2 263 500 
 2576 28 0.5 500 500 Blinded +ve control 
6906 29 0.5 0 0 Blinded -ve control 
8754 30a 0.5 500 500 Blinded +ve control 
1463 30b 0.5 0 0 Blinded -ve control 
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First 15 Volunteers Randomisation 
 
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
1 12 27 13 17 14 2 6 26 24 16 1 26 9 20 8 
 
28 21 26 9 28 27 9 3 30a 13 3 16 8 8 7 
  8 4 11 4 24 1 30a 30a 8 22 27 20 22 9 4 
  6 8 7 15 23 8 24 16 2 26 7 10 25 2 28 
  22 10 20 18 3 22 11 8 27 3 15 5 24 15 5 
  1 25 22 14 17 3 8 20 18 28 2 27 10 30b 24 
  17 14 30b 21 8 25 4 15 12 20 25 30a 2 14 26 
  11 28 24 26 6 9 17 18 15 10 6 24 12 18 11 
  19 12 3 3 19 15 23 7 11 27 14 22 28 3 16 
  21 26 28 19 7 26 14 19 6 18 9 8 1 23 6 
  23 3 23 22 13 12 15 1 3 6 22 15 20 27 10 
  27 13 18 13 1 28 1 10 10 1 30b 25 27 28 20 
  13 23 17 5 29 14 18 29 14 8 20 29 21 7 12 
  26 29 12 16 26 30b 29 21 22 17 11 7 29 13 9 
  15 6 15 30b 21 21 2 13 13 23 4 11 14 4 1 
2  9 16 19 25 2 19 7 24 4 5 13 21 6 19 14 
 
3 17 2 24 22 23 27 9 21 15 18 2 18 26 15 
  18 24 16 1 18 6 22 28 23 12 21 23 11 29 2 
  4 9 10 23 25 29 26 22 5 11 24 13 3 24 19 
  7 19 27 2 12 4 13 14 7 24 28 4 30b 11 30a 
  2 5 25 8 16 5 3 17 20 25 5 12 19 22 18 
  30a 30a 8 11 5 18 5 11 25 29 16 28 17 17 23 
  5 2 29 12 11 17 20 2 28 19 19 9 23 5 21 
  24 1 9 7 9 11 21 12 29 14 17 17 13 25 27 
  16 15 14 20 30a 20 19 23 17 21 23 18 26 1 25 
  10 20 6 29 20 10 25 5 9 4 8 3 7 10 3 
  25 7 5 6 4 13 28 25 1 30a 29 1 16 12 22 
  29 22 1 28 27 16 10 27 26 2 26 14 4 21 13 
  14 18 4 10 15 7 16 6 19 7 12 19 5 16 29 
  20 11 21 27 10 24 12 4 16 9 10 6 15 6 17 
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Second 15 Volunteers Randomisation 
Day 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
1 22 11 14 7 12 2 7 17 23 14 22 16 6 21 13 
  10 10 24 21 1 23 3 12 26 12 23 9 4 3 30b 
  24 14 18 15 10 5 5 22 27 18 27 7 26 24 18 
  2 27 29 27 8 14 27 15 10 22 15 1 22 8 28 
  3 24 15 18 20 7 16 23 17 13 28 25 27 14 16 
  27 9 5 1 14 9 18 9 25 28 24 10 17 6 21 
  12 8 27 12 15 15 21 30b 21 23 14 15 19 25 6 
  25 12 10 23 23 10 2 8 6 24 26 26 18 23 15 
  19 19 6 16 16 18 12 6 29 4 12 28 29 17 9 
  8 17 23 30b 4 6 15 10 12 10 13 29 2 20 19 
  13 2 12 6 19 12 25 19 9 27 19 13 12 9 17 
  7 25 25 28 29 27 4 7 15 3 10 17 16 12 20 
  16 30b 20 14 11 3 10 28 14 15 25 21 3 7 22 
  28 5 1 10 25 8 17 3 3 21 29 11 20 5 27 
  14 22 17 24 2 28 28 18 30a 7 2 14 21 29 26 
2 26 21 22 17 18 20 20 20 18 8 20 23 1 16 4 
  15 23 3 20 30b 30a 13 29 19 25 8 18 25 2 1 
  30a 29 19 19 21 25 9 26 24 20 30b 24 15 26 29 
  5 13 2 2 26 29 19 11 22 9 18 30a 9 19 25 
  18 16 26 26 13 11 8 14 4 6 16 6 23 4 11 
  20 7 28 25 24 13 30a 27 28 1 11 27 30b 27 12 
  1 1 9 4 5 17 1 4 8 19 7 12 28 28 10 
  11 15 7 22 6 21 29 5 20 16 5 5 5 11 5 
  6 6 8 5 28 19 6 16 11 5 17 8 24 13 7 
  21 18 4 8 17 1 14 13 2 17 6 3 10 1 14 
  4 28 13 29 27 16 23 25 5 2 9 19 8 22 2 
  17 20 21 3 7 26 11 21 13 30a 3 20 11 30b 8 
  29 3 11 13 3 4 22 24 1 26 21 4 7 18 24 
  9 4 30b 9 9 24 24 1 7 29 1 2 13 10 3 
  23 26 16 11 22 22 26 2 16 11 4 22 14 15 23 
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SPSS Output of the Initial Trial (Significant differences in Bold) 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Concentration Greenhouse-
Geisser 
227246.103 1.986 114415.642 124.66 0.000 
Huynh-Feldt 227246.103 2 113623.051 124.66 0.000 
Error 
(Concentration) 
Greenhouse-
Geisser 
34635.675 37.737 917.823 
    
Huynh-Feldt 34635.675 38 911.465     
Viscosity Greenhouse-
Geisser 
2750.108 1.474 1865.704 1.055 0.342 
Huynh-Feldt 2750.108 1.568 1753.9 1.055 0.345 
Error (Viscosity) Greenhouse-
Geisser 
49538.392 28.007 1768.81     
Huynh-Feldt 49538.392 29.792 1662.812     
Size Greenhouse-
Geisser 
28134.633 1.881 14960.26 27.878 0.000 
Huynh-Feldt 28134.633 2 14067.317 27.878 0.000 
Error(Size) Greenhouse-
Geisser 
19174.756 35.732 536.629 
    
Huynh-Feldt 19174.756 38 504.599     
Size * Viscosity Greenhouse-
Geisser 
15656.031 2.807 5577.159 10.551 0.000 
Huynh-Feldt 15656.031 3.344 4682.297 10.551 0.000 
Error 
(Size*Viscosity) 
Greenhouse-
Geisser 
28192.247 53.336 528.576 
    
Huynh-Feldt 28192.247 63.53 443.765 
    
Concentration * 
viscosity 
Greenhouse-
Geisser 
7419.306 3.474 2135.922 4.274 0.006 
Huynh-Feldt 7419.306 4 1854.826 4.274 0.004 
Error 
(Concentration*
Viscosity) 
Greenhouse-
Geisser 
32986.083 65.998 499.804 
    
Huynh-Feldt 32986.083 76 434.027     
Size * 
Concentration 
Greenhouse-
Geisser 
4745.267 3.375 1405.802 3.959 0.009 
Huynh-Feldt 4745.267 4 1186.317 3.959 0.006 
Error (Size* 
Concentration) 
Greenhouse-
Geisser 
22774.9 64.134 355.113 
    
Huynh-Feldt 22774.9 76 299.67     
Size* 
Concentration * 
Viscosity 
Greenhouse-
Geisser 
3238.436 4.93 656.831 1.138 0.346 
Huynh-Feldt 3238.436 6.866 471.633 1.138 0.344 
Error (Size* 
Concentration 
*Viscosity) 
Greenhouse-
Geisser 
54090.953 93.678 577.417 
    
Huynh-Feldt 54090.953 130.46
2 
414.61 
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SPSS Output of the Refined Trial (Significant differences in Bold) 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Size Greenhouse-
Geisser 
39418.749 1.629 24199.421 39.736 .000 
Huynh-Feldt 39418.749 1.712 23020.998 39.736 .000 
Error(Size) Greenhouse-
Geisser 
28768.802 47.238 609.012 
    
Huynh-Feldt 28768.802 49.657 579.355     
Concentration Greenhouse-
Geisser 
6769.766 1.351 5010.446 3.200 .069 
Huynh-Feldt 6769.766 1.394 4857.445 3.200 .068 
Error 
(Concentration) 
Greenhouse-
Geisser 
61354.059 39.183 1565.842 
    
Huynh-Feldt 61354.059 40.417 1518.027     
Viscosity Greenhouse-
Geisser 
58479.679 1.584 36916.236 68.743 .000 
Huynh-Feldt 58479.679 1.660 35218.523 68.743 .000 
Error (Viscosity) Greenhouse-
Geisser 
24670.243 45.939 537.017 
    
Huynh-Feldt 24670.243 48.154 512.320     
Size * 
Concentration 
Greenhouse-
Geisser 
1252.322 3.343 374.592 1.092 .360 
Huynh-Feldt 1252.322 3.831 326.879 1.092 .363 
Error (Size* 
Concentration) 
Greenhouse-
Geisser 
33247.961 96.952 342.933 
    
Huynh-Feldt 33247.961 111.10
3 
299.253 
    
Size * Viscosity Greenhouse-
Geisser 
4813.773 2.975 1617.824 4.726 .004 
Huynh-Feldt 4813.773 3.353 1435.603 4.726 .003 
Error 
(Size*Viscosity) 
Greenhouse-
Geisser 
29536.705 86.288 342.302 
    
Huynh-Feldt 29536.705 97.241 303.748     
Concentration * 
viscosity 
Greenhouse-
Geisser 
1825.763 3.454 528.608 1.562 .197 
Huynh-Feldt 1825.763 3.978 458.988 1.562 .189 
Error 
(Concentration*
Viscosity) 
Greenhouse-
Geisser 
33894.088 100.16
3 
338.388 
    
Huynh-Feldt 33894.088 115.35
6 
293.821 
    
Size* 
Concentration * 
Viscosity 
Greenhouse-
Geisser 
2204.177 5.586 394.567 1.326 .251 
Huynh-Feldt 2204.177 7.072 311.662 1.326 .239 
Error (Size* 
Concentration 
*Viscosity) 
Greenhouse-
Geisser 
48199.766 162.00
3 
297.523 
    
Huynh-Feldt 48199.766 205.09
8 
235.009 
    
 
